



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C12N 15/00, 15/11, 15/62 C12N 15/67, 15/70, C07H 21/04 C08G 69/02		A1	(11) International Publication Number: WO 94/11496 (43) International Publication Date: 26 May 1994 (26.05.94)
(21) International Application Number: PCT/US93/10850 (22) International Filing Date: 9 November 1993 (09.11.93) (30) Priority data: 07/978,893 10 November 1992 (10.11.92) US		(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant: IXSYS, INC. [US/US]; 3550 General Atomics Court, Suite L-103, San Diego, CA 92121 (US). (72) Inventor: HUSE, William, D. ; 471 Avenida Primavera, Del Mar, CA 92014 (US). (74) Agents: KONSKI, Antoinette, F. et al.; Campbell & Flores, 4370 La Jolla Village Drive, Suite 700, San Diego, CA 92122 (US).			
(54) Title: SOLUBLE PEPTIDES HAVING CONSTRAINED, SECONDARY CONFORMATION IN SOLUTION AND METHOD OF MAKING SAME			
(57) Abstract A method of synthesizing isolated, soluble peptides having constrained secondary structure in solution is described herein. The peptides are encoded by expressible oligonucleotides having a desirable bias of random codon sequences.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TC	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

1

SOLUBLE PEPTIDES HAVING
CONSTRAINED, SECONDARY CONFORMATION IN
SOLUTION AND METHOD OF MAKING SAME

BACKGROUND OF THE INVENTION

5 The biological function of a peptide depends upon its direct, physical interaction with another molecule. The peptide or protein is termed the ligand.

Peptides are distinguishable by their specificity for certain ligand-binding proteins. The specificity of 10 binding, i.e., the discrimination between closely related ligands, is determined by a peptide's binding affinity. Peptides having useful binding properties are invaluable for chemotherapy and drug design. Therefore, a need exists for the generation of peptides having biologically useful 15 binding affinities and being soluble in solution.

Secondary structure of a peptide is critical for determining its binding affinity. For example, a highly flexible peptide is able to interact with many distinct molecules; however, the peptide-ligand interaction is 20 easily disrupted, or in other words, the binding affinity of the peptide is low. Thus, a peptide having a specific secondary structure is able to bind tightly with only a few or one ligand.

However, if secondary structure of the ligand 25 results from non-covalent interactions, the peptide inevitably is insoluble. Intra-peptide covalent bonds can solve this problem resulting in constrained peptides, i.e., peptides having a stable secondary structure in a solution, that are soluble.

30 This invention provides a method to synthesize soluble peptides having constrained, secondary conformation in solution, as well as the peptides produced by this method.

This invention also relates generally to methods for synthesizing and expressing oligonucleotides and, more particularly, to methods for expressing oligonucleotides having biased, but random codon sequences.

5 Oligonucleotide synthesis proceeds via linear coupling of individual monomers in a stepwise reaction. The reactions are generally performed on a solid phase support by first coupling the 3' end of the first monomer to the support. The second monomer is added to the 5' end
10 of the first monomer in a condensation reaction to yield a dinucleotide coupled to the solid support. At the end of each coupling reaction, the by-products and unreacted, free monomers are washed away so that the starting material for the next round of synthesis is the pure oligonucleotide
15 attached to the support. In this reaction scheme, the stepwise addition of individual monomers to a single, growing end of a oligonucleotide ensures accurate synthesis of the desired sequence. Moreover, unwanted side reactions are eliminated, such as the condensation of two
20 oligonucleotides, resulting in high product yields.

In some instances, it is desired that synthetic oligonucleotides have random nucleotide sequences. This result can be accomplished by adding equal proportions of all four nucleotides in the monomer coupling reactions,
25 leading to the random incorporation of all nucleotides and yielding a population of oligonucleotides with random sequences. Since all possible combinations of nucleotide sequences are represented within the population, all possible codon triplets will also be represented. If the
30 objective is ultimately to generate random peptide products, this approach has a severe limitation because the random codons synthesized will bias the amino acids incorporated during translation of the DNA by the cell into polypeptides.

The bias is due to the redundancy of the genetic code. There are four nucleotide monomers which leads to sixty-four possible triplet codons. With only twenty amino acids to specify, many of the amino acids are encoded by 5 multiple codons. Therefore, a population of oligonucleotides synthesized by sequential addition of monomers from a random population will not encode peptides whose amino acid sequence represents all possible combinations of the twenty different amino acids in equal 10 proportions. That is, the frequency of amino acids incorporated into polypeptides will be biased toward those amino acids which are specified by multiple codons.

To alleviate amino acid bias due to the redundancy of the genetic code, the oligonucleotides can be 15 synthesized from nucleotide triplets. Here, a triplet coding for each of the twenty amino acids is synthesized from individual monomers. Once synthesized, the triplets are used in the coupling reactions instead of individual monomers. By mixing equal proportions of the triplets, 20 synthesis of oligonucleotides with random codons can be accomplished. However, this is not possible because of the inefficiency of the coupling, which is less than 3% and the high cost of synthesis.

Amino acid bias can be reduced, however, by 25 synthesizing the degenerate codon sequence NNK where N is a mixture of all four nucleotides and K is a mixture of guanine and thymine nucleotides. Each position within an oligonucleotide having this codon sequence will contain a total of 32 codons (12 encoding amino acids being 30 represented once, 5 represented twice, 3 represented three times and one codon being a stop codon). Oligonucleotides expressed with such degenerate codon sequences will produce peptide products whose sequences are biased toward those amino acids being represented more than once. Thus, 35 populations of peptides whose sequences are completely

random cannot be obtained from oligonucleotides synthesized from d generate sequences.

There thus exists a need for a method to express oligonucleotides having a fully random or desirably biased sequence which alleviates genetic redundancy. The present 5 invention satisfies these needs and provides additional advantages as well.

SUMMARY OF THE INVENTION

This invention provides a peptide having 10 constrained, secondary structure in solution as well as methods of synthesizing these peptides.

The invention provides a plurality of procaryotic cells containing a diverse population of expressible oligonucleotides encoding soluble peptides having 15 constrained secondary structure or conformation in solution, the expressible oligonucleotide being operationally linked to expression elements, the expressible oligonucleotides further characterized as having a desirable bias of random codon sequences.

20

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic drawing for synthesizing oligonucleotides from nucleotide monomers with random triplets at each position using twenty reaction vessels.

Figure 2 is a schematic drawing for synthesizing 25 oligonucleotides from nucleotide monomers with random triplets at each position using ten reaction vessels.

Figure 3 is a schematic diagram of the two vectors used for sublibrary and library production from precursor oligonucleotide portions. M13IX22 (Figure 3A) is

the vector used to clone the anti-sense precursor portions (hatched box). The single-headed arrow r presents the Lac p/o expression sequences and the double-headed arrow represents the portion of M13IX22 which is to be combined 5 with M13IX42. The amber stop codon for biological selection and relevant restriction sites are also shown. M13IX42 (Figure 3B) is the vector used to clone the sense precursor portions (open box). Thick lines represent the pseudo-wild type (ϕ gVIII) and wild type (gVIII) gene VIII 10 sequences. The double-headed arrow represents the portion of M13IX42 which is to be combined with M13IX22. The two amber stop codons and relevant restriction sites are also shown. Figure 3C shows the joining of vector population from sublibraries to form the functional surface expression 15 vector M13IX. Figure 3D shows the generation of a surface expression library in a non-suppressor strain and the production of phage. The phage are used to infect a suppressor strain (Figure 3E) for surface expression and screening of the library.

20 Figure 4 is a schematic diagram of the vector used for generation of surface expression libraries from random oligonucleotide populations (M13IX30). The symbols are as described for Figure 3.

25 Figure 5 is the nucleotide sequence of M13IX42 (SEQ ID NO: 1).

Figure 6 is the nucleotide sequence of M13IX22 (SEQ ID NO: 2).

Figure 7 is the nucleotide sequence of M13IX30 (SEQ ID NO: 3).

30 Figure 8 is the nucleotide sequence of M13ED03 (SEQ ID NO: 4).

Figure 9 is the nucleotide sequence of M13IX421 (SEQ ID NO: 5).

Figure 10 is the nucleotide sequence of M13ED04 (SEQ ID NO: 6).

5

DETAILED DESCRIPTION OF THE INVENTION

This invention is directed to a simple and inexpensive method for synthesizing and expressing oligonucleotides having a desirable bias of random codons using individual monomers. The oligonucleotides produced 10 by this method encode soluble peptides having constrained secondary structure in solution. The method is advantageous in that individual monomers are used instead of triplets and by synthesizing only a non-degenerate subset of all triplets, codon redundancy is alleviated. 15 Thus, the oligonucleotides synthesized represent a large proportion of possible random triplet sequences which can be obtained. The oligonucleotides can be expressed, for example, on the surface of filamentous bacteriophage in a form which does not alter phage viability or impose 20 biological selections against certain peptide sequences. The oligonucleotides produced are therefore useful for generating an unlimited number of pharmacological and research products.

This invention entails the sequential coupling of 25 monomers to produce oligonucleotides with a desirable bias of random codons. The coupling reactions for the randomization of twenty codons which specify the amino acids of the genetic code are performed in ten different reaction vessels. Each reaction vessel contains a support 30 on which the monomers for two different codons are coupled in three sequential reactions. One of the reactions couples an equal mixture of two monomers such that the final product has two different codon sequences. The

codons are randomized by removing the supports from the reaction vessels and mixing them to produce a single batch of supports containing all twenty codons at a particular position. Synthesis at the next codon position proceeds by 5 equally dividing the mixed batch of supports into ten reaction vessels as before and sequentially coupling the monomers for each pair of codons. The supports are again mixed to randomize the codons at the position just synthesized. The cycle of coupling, mixing and dividing 10 continues until the desired number of codon positions have been randomized. After the last position has been randomized, the oligonucleotides with random codons are cleaved from the support. The random oligonucleotides can then be expressed, for example, on the surface of 15 filamentous bacteriophage as gene VIII-peptide fusion proteins. Alternative genes can be used as well. Using this method, one can randomize oligonucleotides at certain positions and select for specific oligonucleotides at others.

20 This invention provides a diverse population of synthetic biased oligonucleotides contained in vectors so as to be expressible in cells. In the preferred embodiment of this invention, the oligonucleotides are fully defined in that at least two codons encode amino acids capable of 25 forming a covalent bond. The populations of oligonucleotides can be expressed as fusion products in combination with surface proteins of filamentous bacteriophage, such as M13, as with gene VIII. The vectors can be transfected into a plurality of cells, such as the 30 procaryote E. coli.

In one embodiment, the diverse population of oligonucleotides can be formed by randomly combining first and second precursor populations, each or either precursor population having a desirable bias of random codon 35 sequences. Methods of synthesizing and expressing the

diverse population of expressible oligonucleotides are also provided.

Two precursor populations of random precursor oligonucleotides are synthesized in one embodiment. The 5 oligonucleotides within each population encode a portion of the final oligonucleotide that is expressed. Oligonucleotides within one precursor population encode the carboxy terminal portion of the expressed oligonucleotides. In one embodiment, these oligonucleotides are cloned in 10 frame with a gene VIII (gVIII) sequence so that translation of the sequence produces peptide fusion proteins. The second population of precursor oligonucleotides are cloned into a separate vector. Each precursor oligonucleotide within this population encodes the anti-sense of the amino 15 terminal portion of the expressed oligonucleotides. This vector also contains the elements necessary for expression. The two vectors containing the random oligonucleotides are combined such that the two precursor oligonucleotide portions are joined together at random to form a population 20 of larger oligonucleotides derived from two smaller portions. The vectors contain selectable markers to ensure maximum efficiency in joining together the two oligonucleotide populations. A mechanism also exists to control the expression of gVIII-peptide fusion proteins 25 during library construction and screening.

As used herein, the term "monomer" or "nucleotide monomer" refers to individual nucleotides used in the chemical synthesis of oligonucleotides. Monomers that can be used include both the ribo- and deoxyribo- forms of each 30 of the five standard nucleotides (derived from the bases adenine (A or dA, respectively), guanine (G or dG), cytosine (C or dC), thymine (T) and uracil (U)). Derivatives and precursors of bases such as inosine which are capable of supporting polypeptide biosynthesis are also 35 included as monomers. Also included are chemically

modified nucleotides, for example, one having a reversible blocking agent attached to any of the positions on the purine or pyrimidine bases, the ribose or deoxyribose sugar or the phosphate or hydroxyl moieties of the monomer. Such 5 blocking groups include, for example, dimethoxytrityl, benzoyl, isobutyryl, beta-cyanoethyl and diisopropylamine groups, and are used to protect hydroxyls, exocyclic amines and phosphate moieties. Other blocking agents can also be used and are known to one skilled in the art.

10 As used herein, the term "tuple" refers to a group of elements of a definable size. The elements of a tuple as used herein are nucleotide monomers. For example, a tuple can be a dinucleotide, a trinucleotide or can also be four or more nucleotides.

15 As used herein, the term "codon" or "triplet" refers to a tuple consisting of three adjacent nucleotide monomers which specify one of the twenty naturally occurring amino acids found in polypeptide biosynthesis. The term also includes nonsense, or stop, codons which do 20 not specify any amino acid.

"Random codons" or "randomized codons," as used herein, refers to more than one codon at a position within a collection of oligonucleotides. The number of different codons can be from two to twenty at any particular 25 position. "Randomized oligonucleotides," as used herein, refers to a collection of oligonucleotides with random codons at one or more positions. "Random codon sequences" as used herein means that more than one codon position within a randomized oligonucleotide contains random codons. 30 For example, if randomized oligonucleotides are six nucleotides in length (i.e., two codons) and both the first and second codon positions are randomized to encode all twenty amino acids, then a population of oligonucleotides having random codon sequences with every possible

combination of the twenty triplets in the first and second position makes up the above population of randomized oligonucleotides. The number of possible codon combinations is 20^2 . Likewise, if randomized 5 oligonucleotides of fifteen nucleotides in length are synthesized which have random codon sequences at all positions encoding all twenty amino acids, then all triplets coding for each of the twenty amino acids will be found in equal proportions at every position. The 10 population constituting the randomized oligonucleotides will contain 20^{15} different possible species of oligonucleotides. "Random triplets," or "randomized triplets" are defined analogously.

As used herein, the term "bias" refers to a 15 preference. It is understood that there can be degrees of preference or bias toward codon sequences which encode particular amino acids. For example, an oligonucleotide whose codon sequences do not preferably encode particular amino acids is unbiased and therefore completely random. 20 The oligonucleotide codon sequences can also be biased toward predetermined codon sequences or codon frequencies and while still diverse and random, will exhibit codon sequences biased toward a defined, or preferred, sequence. "A desirable bias of random codon sequences" as used 25 herein, refers to the predetermined degree of bias which can be selected from totally random to essentially, but not totally, defined (or preferred). There must be at least one codon position which is variable, however.

As used herein, the term "support" refers to a 30 solid phase material for attaching monomers for chemical synthesis. Such support is usually composed of materials such as beads of control pore glass but can be other materials known to one skilled in the art. The term is also meant to include one or more monomers coupled to the 35 support for additional oligonucleotide synthesis reactions.

As used herein, the terms "coupling" or "condensing" refers to the chemical reactions for attaching one monomer to a second monomer or to a solid support. Such reactions are known to one skilled in the art and are 5 typically performed on an automated DNA synthesizer such as a MilliGen/Biosearch Cyclone Plus Synthesizer using procedures recommended by the manufacturer. "Sequentially coupling" as used herein, refers to the stepwise addition of monomers.

10 The term "soluble peptide" means a peptide that is soluble at a concentration equivalent to its affinity to a receptor. The peptide can then be used in aqueous solution without being attached to a cell or phage.

15 The term "constrained secondary structure in solution" means a peptide having a covalent bond that is not the backbone peptide bond.

20 A method of synthesizing oligonucleotides having biased random triplets using individual monomers is described. The method consists of several steps, the first being synthesis of a nucleotide triplet for each triplet to be randomized. As described here and below, a nucleotide triplet (i.e., a codon) will be used as a specific example of a triplet. Any size triplet will work using the methods disclosed herein, and one skilled in the art would know how 25 to use the methods to randomize triplets of any size.

30 If the randomization of codons specifying all twenty amino acids is desired at a position, then twenty different codons are synthesized. Likewise, if randomization of only ten codons at a particular position is desired then those ten codons are synthesized. Randomization of codons from two to sixty-four can be accomplished by synthesizing each desired triplet. Preferably, randomization of from two to twenty codons is

used for any one position because of the redundancy of the genetic code. The codons selected at one position do not have to be the same codons selected at the next position. Additionally, the sense or anti-sense sequence 5 oligonucleotide can be synthesized. The process therefore provides for randomization of any desired codon position with any number of codons. In addition, it also allows one to preselect a specified codon to be present at a particular position within a randomized sequence.

10 Codons to be randomized are synthesized sequentially by coupling the first monomer of each codon to separate supports. The supports for the synthesis of each codon can, for example, be contained in different reaction vessels such that one reaction vessel corresponds to the 15 monomer coupling reactions for one codon. As will be used here and below, if twenty codons are to be randomized, then twenty reaction vessels can be used in independent coupling reactions for the first twenty monomers of each codon. Synthesis proceeds by sequentially coupling the second 20 monomer of each codon to the first monomer to produce a dimer, followed by coupling the third monomer for each codon to each of the above-synthesized dimers to produce a trimer (Figure 1, step 1, where M_1 , M_2 and M_3 represent the first, second and third monomer, respectively, for each 25 codon to be randomized).

Following synthesis of the first codons from individual monomers, the randomization is achieved by mixing the supports from all twenty reaction vessels which contain the individual codons to be randomized. The solid 30 phase support can be removed from its vessel and mixed to achieve a random distribution of all codon species within the population (Figure 1, step 2). The mixed population of supports, constituting all codon species, are then redistributed into twenty independent reaction vessels 35 (Figure 1, step 3). The resultant vessels are all

identical and contain equal portions of all twenty codons coupled to a solid phase support.

For randomization of the second position codon, synthesis of twenty additional codons is performed in each 5 of the twenty reaction vessels produced in step 3 as the condensing substrates of step 1 (Figure 1, step 4). Steps 1 and 4 are therefore equivalent except that step 4 uses the supports produced by the previous synthesis cycle (steps 1 through 3) for codon synthesis whereas step 1 is 10 the initial synthesis of the first codon in the oligonucleotide. The supports resulting from step 4 will each have two codons attached to them (i.e., a hexanucleotide) with the codon at the first position being any one of twenty possible codons (i.e., random) and the 15 codon at the second position being one of the twenty possible codons.

For randomization of the codon at the second position and synthesis of the third position codon, steps 2 through 4 are again repeated. This process yields in 20 each vessel a three codon oligonucleotide (i.e., 9 nucleotides) with codon positions 1 and 2 randomized and position three containing one of the twenty possible codons. Steps 2 through 4 are repeated to randomize the third position codon and synthesize the codon at the next 25 position. The process is continued until an oligonucleotide of the desired length is achieved. After the final randomization step, the oligonucleotide can be cleaved from the supports and isolated by methods known to one skilled in the art. Alternatively, the 30 oligonucleotides can remain on the supports for use in methods employing probe hybridization.

The diversity of codon sequences, i.e., the number of different possible oligonucleotides, that can be obtained using the methods of the present invention, is

extremely large and only limited by the physical characteristics of available materials. For example, a support composed of beads of about 100 μm in diameter will be limited to about 10,000 beads/reaction vessel using a 1 μM reaction vessel containing 25 mg of beads. This size bead can support about 1×10^7 oligonucleotides per bead. Synthesis using separate reaction vessels for each of the twenty amino acids will produce beads in which all the oligonucleotides attached to an individual bead are identical. The diversity which can be obtained under these conditions is approximately 10^7 copies of $10,000 \times 20$ or 200,000 different random oligonucleotides. The diversity can be increased, however, in several ways without departing from the basic methods disclosed herein. For example, the number of possible sequences can be increased by decreasing the size of the individual beads which make up the support. A bead of about 30 μm in diameter will increase the number of beads per reaction vessel and therefore the number of oligonucleotides synthesized. Another way to increase the diversity of oligonucleotides with random codons is to increase the volume of the reaction vessel. For example, using the same size bead, a larger volume can contain a greater number of beads than a smaller vessel and therefore support the synthesis of a greater number of oligonucleotides. Increasing the number of codons coupled to a support in a single reaction vessel also increases the diversity of the random oligonucleotides. The total diversity will be the number of codons coupled per vessel raised to the number of codon positions synthesized. For example, using ten reaction vessels, each synthesizing two codons to randomize a total of twenty codons, the number of different oligonucleotides of ten codons in length per 100 μm bead can be increased where each bead will contain about 2^{10} or 1×10^3 different sequences instead of one. One skilled in the art will know how to modify such parameters to increase the diversity of oligonucleotides with random codons.

A method of synthesizing oligonucleotides having random codons at each position using individual monomers wherein the number of reaction vessels is less than the number of codons to be randomized is also described. For 5 example, if twenty codons are to be randomized at each position within an oligonucleotide population, then ten reaction vessels can be used. The use of a smaller number of reaction vessels than the number of codons to be randomized at each position is preferred because the 10 smaller number of reaction vessels is easier to manipulate and results in a greater number of possible oligonucleotides synthesized.

The use of a smaller number of reaction vessels for random synthesis of twenty codons at a desired position 15 within an oligonucleotide is similar to that described above using twenty reaction vessels except that each reaction vessel can contain the synthesis products of more than one codon. For example, step one synthesis using ten reaction vessels proceeds by coupling about two different 20 codons on supports contained in each of ten reaction vessels. This is shown in Figure 2 where each of the two codons coupled to a different support can consist of the following sequences: (1) (T/G)TT for Phe and Val; (2) (T/C)CT for Ser and Pro; (3) (T/C)AT for Tyr and His; (4) 25 (T/C)GT for Cys and Arg; (5) (C/A)TG for Leu and Met; (6) (C/G)AG for Gln and Glu; (7) (A/G)CT for Thr and Ala; (8) (A/G)AT for Asn and Asp; (9) (T/G)GG for Trp and Gly and (10) A(T/A)A for Ile and Cys. The slash (/) signifies that a mixture of the monomers indicated on each side of the 30 slash are used as if they were a single monomer in the indicated coupling step. The antisense sequence for each of the above codons can be generated by synthesizing the complementary sequence. For example, the antisense for Phe and Val can be AA(C/A). The amino acids encoded by each of 35 the above pairs of sequences are given as the standard three letter nomenclature.

Coupling of the monomers in this fashion will yield codons specifying all twenty of the naturally occurring amino acids attached to supports in ten reaction vessels. However, the number of individual reaction vessels to be used will depend on the number of codons to be randomized at the desired position and can be determined by one skilled in the art. For example, if ten codons are to be randomized, then five reaction vessels can be used for coupling. The codon sequences given above can be used for this synthesis as well. The sequences of the codons can also be changed to incorporate or be replaced by any of the additional forty-four codons which constitutes the genetic code.

The remaining steps of synthesis of oligonucleotides with random codons using a smaller number of reaction vessels are as outlined above for synthesis with twenty reaction vessels except that the mixing and dividing steps are performed with supports from about half the number of reaction vessels. These remaining steps are shown in Figure 2 (steps 2 through 4).

Oligonucleotides having at least one specified triplet at a predetermined position and the remaining positions having random triplets are synthesized using the methods described herein. The synthesis steps are similar to those outlined above using twenty or less reaction vessels except that prior to synthesis of the specified codon position, the dividing of the supports into separate reaction vessels for synthesis of different codons is omitted. For example, if the codon at the second position of the oligonucleotide is to be specified, then following synthesis of random codons at the first position and mixing of the supports, the mixed supports are not divided into new reaction vessels but, instead, are contained in a single reaction vessel to synthesize the specified codon. The specified codon is synthesized sequentially from

individual monomers as described above. Thus, the number of reaction vessels is increased or decreased at each step to allow for the synthesis of a specified codon or a desired number of random codons. In the most preferred 5 embodiment of this invention, the specified codons are codons capable of forming covalent bonds, e.g., cysteine, glutamic acid, lysine, leucine and tyrosine.

Following codon synthesis, the mixed supports are divided into individual reaction vessels for synthesis of 10 the next codon to be randomized (Figure 1, step 3) or can be used without separation for synthesis of a consecutive specified codon. The rounds of synthesis can be repeated for each codon to be added until the desired number of positions with predetermined or randomized codons are 15 obtained.

Synthesis of oligonucleotides with the first position codon being specified can also be synthesized using the above method. In this case, the first position codon is synthesized from the appropriate monomers. The 20 supports are divided into the required number of reaction vessels needed for synthesis of random codons at the second position and the rounds of synthesis, mixing and dividing are performed as described above.

A method of synthesizing oligonucleotides having 25 tuples which are diverse but biased toward a predetermined sequence is also described herein. This method employs two reaction vessels, one vessel for the synthesis of a predetermined sequence and the second vessel for the synthesis of a random sequence. This method is 30 advantageous to use when a significant number of codon positions, for example, are to be of a specified sequence since it alleviates the use of multiple reaction vessels. Instead, a mixture of four different monomers such as adenine, guanine, cytosine and thymine nucleotides are used

for the first and second monomers in the codon. The codon is completed by coupling a mixture of a pair of monomers of either guanine and thymine or cytosine and adenine nucleotides at the third monomer position. In the second 5 vessel, nucleotide monomers are coupled sequentially to yield the predetermined codon sequence. Mixing of the two supports yields a population of oligonucleotides containing both the predetermined codon and the random codons at the desired position. Synthesis can proceed by using this 10 mixture of supports in a single reaction vessel, for example, for coupling additional predetermined codons or, further dividing the mixture into two reaction vessels for synthesis of additional random codons.

The two reaction vessel method can be used for 15 codon synthesis within an oligonucleotide with a predetermined triplet sequence by dividing the support mixture into two portions at the desired codon position to be randomized. Additionally, this method allows for the extent of randomization to be adjusted. For example, 20 unequal mixing or dividing of the two supports will change the fraction of codons with predetermined sequences compared to those with random codons at the desired position. Unequal mixing and dividing of supports can be useful when there is a need to synthesize random codons at 25 a significant number of positions within an oligonucleotide of a longer or shorter length.

The extent of randomization can also be adjusted by using unequal mixtures of monomers in the first, second and third monomer coupling steps of the random codon 30 position. The unequal mixtures can be in any or all of the coupling steps to yield a population of codons enriched in sequences reflective of the monomer proportions.

Synthesis of randomized oligonucleotides is performed using methods well known to one skilled in the

art. Linear coupling of monomers can, for example, be accomplished using phosphoramidite chemistry with a MilliGen/Bioscience Cyclone Plus automated synthesizer as described by the manufacturer (Millipore, Burlington, MA).

5 Other chemistries and automated synthesizers can be employed as well and are known to one skilled in the art.

Synthesis of multiple codons can be performed without modification to the synthesizer by separately synthesizing the codons in individual sets of reactions.

10 Alternatively, modification of an automated DNA synthesizer can be performed for the simultaneous synthesis of codons in multiple reaction vessels.

In one embodiment, the invention provides a plurality of prokaryotic cells containing a diverse population of expressible oligonucleotides operationally linked to expression elements, the expressible oligonucleotides having a desirable bias of random codon sequences. These oligonucleotides can, in one embodiment, be produced from diverse combinations of first and second 20 precursor oligonucleotides having a desirable bias of random sequences. The invention provides for a method for constructing such a plurality of prokaryotic cells as well.

The oligonucleotides synthesized by the above methods can be used to express a plurality of random 25 soluble peptides having constrained secondary structure in solution, diverse but biased toward a predetermined sequence or which contain at least one specified codon at a predetermined position. The need will determine which type of oligonucleotide is to be expressed to give the 30 resultant population of random peptides and is known to one skilled in the art. Expression can be performed in any compatible vector/host system. Such systems include, for example, plasmids or phagemids in prokaryotes such as E. coli, yeast systems, and other eucaryotic systems such as

mammalian cells, but will be described herein in context with its presently preferred embodiment, i.e. expression on the surface of filamentous bacteriophage. Filamentous bacteriophage can be, for example, M13, f1 and fd. Such 5 phage have circular single-stranded genomes and double strand replicative DNA forms. Additionally, the peptides can also be expressed in soluble or secreted form depending on the need and the vector/host system employed. Furthermore, this invention provides host cells containing 10 the expressible oligonucleotides, the vectors and the isolated soluble, stable peptides produced by growing a host cell described above under conditions favoring expression of the oligonucleotide, and isolating the peptide so produced.

15 For the purpose of illustration only, expression of random peptides on the surface of M13 can be accomplished, for example, using the vector system shown in Figure 3. Construction of the vectors enabling one of ordinary skill to make them are explicitly set out in 20 Examples I and II. The complete nucleotide sequences are given in Figures 5, 6 and 7 (SEQ ID NOS: 1, 2 and 3, respectively). This system produces random oligonucleotides functionally linked to expression elements and to gVIII by combining two smaller oligonucleotide 25 portions contained in separate vectors into a single vector. The diversity of oligonucleotide species obtained by this system or others described herein can be 5×10^7 or greater. Diversity of less than 5×10^7 can also be obtained and will be determined by the need and type of 30 random peptides to be expressed. The random combination of two precursor portions into a larger oligonucleotide increases the diversity of the population several fold and has the added advantage of producing oligonucleotides larger than what can be synthesized by standard methods. 35 Additionally, although the correlation is not known, when the number of possible paths an oligonucleotide can take

during synthesis such as described herein is greater than the number of beads, then there will be a correlation between the synthesis path and the sequences obtained. By combining oligonucleotide populations which are synthesized 5 separately, this correlation will be destroyed. Therefore, any bias which may be inherent in the synthesis procedures will be alleviated by joining two precursor portions into a contiguous random oligonucleotide.

Populations of precursor oligonucleotides to be 10 combined into an expressible form are each cloned into separate vectors. The two precursor portions which make up the combined oligonucleotide corresponds to the carboxy and amino terminal portions of the expressed peptide. Each precursor oligonucleotide can encode either the sense or 15 anti-sense and will depend on the orientation of the expression elements and the gene encoding the fusion portion of the protein as well as the mechanism used to join the two precursor oligonucleotides. For the vectors shown in Figure 3, precursor oligonucleotides corresponding 20 to the carboxy terminal portion of the peptide encode the sense strand. Those corresponding to the amino terminal portion encode the anti-sense strand. Oligonucleotide populations are inserted between the Eco RI and Sac I restriction enzyme sites in M13IX22 and M13IX42 (Figure 3A 25 and B). M13IX42 (SEQ ID NO: 1) is the vector used for sense strand precursor oligonucleotide portions and M13IX22 (SEQ ID NO: 2) is used for anti-sense precursor portions.

The populations of randomized oligonucleotides inserted into the vectors are synthesized with Eco RI and 30 Sac I recognition sequences flanking opposite ends of the random codon sequences. The sites allow annealing and ligation of these single strand oligonucleotides into a double stranded vector restricted with Eco RI and Sac I. Alternatively, the oligonucleotides can be inserted into 35 the vector by standard mutagenesis methods. In this latter

method, single stranded vector DNA is isolated from the phage and annealed with random oligonucleotides having known sequences complementary to vector sequences. The oligonucleotides are extended with DNA polymerase to 5 produce double stranded vectors containing the randomized oligonucleotides.

A vector useful for sense strand oligonucleotide portions, M13IX42 (Figure 3B) contains down-stream and in frame with the Eco RI and Sac I restriction sites a 10 sequence encoding the pseudo-wild type gVIII product. This gene encodes the wild type M13 gVIII amino acid sequence but has been changed at the nucleotide level to reduce homologous recombination with the wild type gVIII contained on the same vector. The wild type gVIII is present to 15 ensure that at least some functional, non-fusion coat protein will be produced. The inclusion of a wild type gVIII therefore reduces the possibility of non-viable phage production and biological selection against certain peptide fusion proteins. Differential regulation of the two gen's 20 can also be used to control the relative ratio of the pseudo and wild type proteins.

Also contained downstream and in frame with the Eco RI and Sac I restriction sites is an amber stop codon. The mutation is located six codons downstream from Sac I 25 and therefore lies between the inserted oligonucleotides and the gVIII sequence. As was the function of the wild type gVIII, the amber stop codon also reduces biological selection when combining precursor portions to produce expressible oligonucleotides. This is accomplished by 30 using a non-suppressor (sup O) host strain because non-suppressor strains will terminate expression after the oligonucleotide sequences but before the pseudo gVIII sequences. Therefore, the pseudo gVIII will never be expressed on the phage surface under these circumstances. 35 Instead, only soluble peptides will be produced.

Expression in a non-suppressor strain can be advantageously utilized when one wishes to produce large populations of soluble peptides. Stop codons other than amber, such as opal and ochre, or molecular switches, such as inducible 5 repressor elements, can also be used to unlink peptide expression from surface expression. Additional controls exist as well and are described below.

A vector useful for anti-sense strand oligonucleotide portions, M13IX22, (Figure 3A), contains 10 the expression elements for the peptide fusion proteins. Upstream and in frame with the Sac I and Eco RI sites in this vector is a leader sequence for surface expression. A ribosome binding site and Lac Z promoter/operator elements are present for transcription and translation of 15 the peptide fusion proteins.

Both vectors contain a pair of Fok I restriction enzyme sites (Figure 3 A and B) for joining together two precursor oligonucleotide portions and their vector sequences. One site is located at the ends of each 20 precursor oligonucleotide which is to be joined. The second Fok I site within the vectors is located at the end of the vector sequences which are to be joined. The 5' overhang of this second Fok I site has been altered to encode a sequence which is not found in the overhangs 25 produced at the first Fok I site within the oligonucleotide portions. The two sites allow the cleavage of each circular vector into two portions and subsequent ligation of essential components within each vector into a single circular vector where the two oligonucleotide precursor 30 portions form a contiguous sequence (Figure 3C). Non-compatible overhangs produced at the two Fok I sites allows optimal conditions to be selected for performing concatemerization or circularization reactions for joining 35 the two vector portions. Such selection of conditions can be used to govern the reaction order and therefore increase

the efficiency of joining.

Fok I is a restriction enzyme whose recognition sequence is distal to the point of cleavage. Distal placement of the recognition sequence in its location to the cleavage point is important since if the two were superimposed within the oligonucleotide portions to be combined, it would lead to an invariant codon sequence at the juncture. To alleviate the formation of invariant codons at the juncture, Fok I recognition sequences can be placed outside of the random codon sequence and still be used to restrict within the random sequence. Subsequent annealing of the single-strand overhangs produced by Fok I and ligation of the two oligonucleotide precursor portions allows the juncture to be formed. A variety of restriction enzymes restrict DNA by this mechanism and can be used instead of Fok I to join precursor oligonucleotides without creating invariant codon sequences. Such enzymes include, for example, Alw I, Bbu I, Bsp MI, Hga I, Hph I, Mbo II, Mnl I, Ple I and Sfa NI. One skilled in the art knows how to substitute Fok I recognition sequences for alternative enzyme recognition sequences such as those above, and use the appropriate enzyme for joining precursor oligonucleotide portions.

Although the sequences of the precursor oligonucleotides are random and will invariably have oligonucleotides within the two precursor populations whose sequences are sufficiently complementary to anneal after cleavage, the efficiency of annealing can be increased by insuring that the single-strand overhangs within one precursor population will have a complementary sequence within the second precursor population. This can be accomplished by synthesizing a non-degenerate series of known sequences at the Fok I cleavage site coding for each of the twenty amino acids. Since the Fok I cleavage site contains a four base overhang, forty different sequences

are needed to randomly encode all twenty amino acids. For example, if two precursor populations of ten codons in length are to be combined, then after the ninth codon position is synthesized, the mixed population of supports 5 are divided into forty reaction vessels for each of the populations and complementary sequences for each of the corresponding reaction vessels between populations are independently synthesized. The sequences are shown in Tables III and VI of Example I where the oligonucleotides 10 on columns 1R through 40R form complementary overhangs with the oligonucleotides on the corresponding columns 1L through 40L once cleaved. The degenerate X positions in Table VI are necessary to maintain the reading frame once the precursor oligonucleotide portions are joined. 15 However, use of restriction enzymes which produce a blunt end, such as Mnl I can be alternatively used in place of Fok I to alleviate the degeneracy introduced in maintaining the reading frame.

The last feature exhibited by each of the vectors 20 is an amber stop codon located in an essential coding sequence within the vector portion lost during combining (Figure 3C). The amber stop codon is present to select for viable phage produced from only the proper combination of precursor oligonucleotides and their vector sequences into 25 a single vector species. Other non-sense mutations or selectable markers can work as well.

The combining step randomly brings together different precursor oligonucleotides within the two populations into a single vector (Figure 3C; M13IX). For 30 example, the vector sequences donated from each independent vector described above, M13IX22 and M13IX42, are necessary for production of viable phage. Also, since the expression elements are contained in M13IX22 and the gVIII sequences are contained in M13IX42, expression of functional gVIII- 35 peptide fusion proteins cannot be accomplished until the

sequences are linked as shown in M13IX.

The combining step is performed by restricting each population of vectors containing randomized oligonucleotides with Fok I, mixing and ligating (Figure 5 3C). Any vectors generated which contain an amber stop codon will not produce viable phage when introduced into a non-suppressor strain (Figure 3D). Therefore, only the sequences which do not contain an amber stop codon will make up the final population of vectors contained in the 10 library. These vector sequences are the sequences required for surface expression of randomized peptides. By analogous methodology, more than two vector portions can be combined into a single vector which expresses random peptides.

15 Surface expression of the random peptide library is performed in an amber suppressor strain. As described above, the amber stop codon between the random codon sequence and the gVIII sequence unlinks the two components in a non-suppressor strain. Isolating the phage produced 20 from the non-suppressor strain and infecting a suppressor strain will link the random codon sequences to the gVIII sequence during expression (Figure 3E). Culturing the suppressor strain after infection allows the expression of all peptide species within the library as gVIII-peptide 25 fusion proteins. Alternatively, the DNA can be isolated from the non-suppressor strain and then introduced into a suppressor strain to accomplish the same effect.

The level of expression of gVIII-peptide fusion proteins can additionally be controlled at the 30 transcriptional level. The gVIII-peptide fusion proteins are under the inducible control of the Lac Z promoter/operator system. Other inducible promoters can work as well and are known by one skilled in the art. For high levels of surface expression, the suppressor library

is cultured in an inducer of the Lac Z promoter such as isopropylthio- β -galactoside (IPTG). Inducible control is beneficial because biological selection against non-functional gVIII-peptide fusion proteins can be minimized 5 by culturing the library under non-expressing conditions. Expression can then be induced only at the time of screening to ensure that the entire population of oligonucleotides within the library are accurately represented on the phage surface. Also this can be used to 10 control the valency of the peptide on the phage surface.

The surface expression library is screened for specific peptides which bind ligand binding proteins by standard affinity isolation procedures. Such methods include, for example, panning, affinity chromatography and 15 solid phase blotting procedures. Panning as described by Parmley and Smith, Gene 73:305-318 (1988), which is incorporated herein by reference, is preferred because high titers of phage can be screened easily, quickly and in small volumes. Furthermore, this procedure can select 20 minor peptide species within the population, which otherwise would have been undetectable, and amplified to substantially homogenous populations. The selected peptide sequences can be determined by sequencing the nucleic acid encoding such peptides after amplification of the phage 25 population.

The invention provides a plurality of prokaryotic cells containing a diverse population of oligonucleotides encoding soluble peptides having constrained secondary structure in solution, the oligonucleotides being 30 operationally linked to expression sequences. The invention provides for methods of constructing such populations of cells as well.

Random oligonucleotides synthesized by any of the methods described previously can also be expressed on the

surface of filamentous bacteriophage, such as M13, for example, without the joining together of precursor oligonucleotides. A vector such as that shown in Figure 4, M13IX30, can be used. This vector exhibits all the 5 functional features of the combined vector shown in Figure 3C for surface expression of gVIII-peptide fusion proteins. The complete nucleotide sequence for M13IX30 (SEQ ID NO: 3) is shown in Figure 7.

For example, M13IX30 contains a wild type gVIII 10 for phage viability and a pseudo gVIII sequence for peptide fusions. The vector also contains in frame restriction sites for cloning random peptides. The cloning sites in this vector are Xho I, Stu I and Spe I. Oligonucleotides should therefore be synthesized with the appropriate 15 complementary ends for annealing and ligation or insertional mutagenesis. Alternatively, the appropriate termini can be generated by PCR technology. Between the restriction sites and the pseudo gVIII sequence is an in-frame amber stop codon, again, ensuring complete viability 20 of phage in constructing and manipulating the library. Expression and screening is performed as described above for the surface expression library of oligonucleotides generated from precursor portions.

Thus, peptides can be selected that are capable 25 of being bound by a ligand binding protein from a population of random peptides by (a) operationally linking a diverse population of oligonucleotides having a desirable bias of random codon sequences to expression elements; (b) introducing said population of vectors into a compatible 30 host under conditions sufficient for expressing said population of random peptides; and (c) determining the peptides which bind to said binding protein. Also provided is a method for determining the encoding nucleic acid sequence of such selected peptides.

The following examples are intended to illustrate, but not limit the invention.

EXAMPLE I

5 Isolation and Characterization of Peptide Ligands Generated From Right and Left Half Random Oligonucleotides

This example shows the synthesis of random oligonucleotides and the construction and expression of surface expression libraries of the encoded randomized peptides. The random peptides of this example derive from the mixing and joining together of two random oligonucleotides. Also demonstrated is the isolation and characterization of peptide ligands and their corresponding nucleotide sequence for specific binding proteins.

15 Synthesis of Random Oligonucleotides

The synthesis of two randomized oligonucleotides which correspond to smaller portions of a larger randomized oligonucleotide is shown below. Each of the two smaller portions make up one-half of the larger oligonucleotide. The population of randomized oligonucleotides constituting each half are designated the right and left half. Each population of right and left halves are ten codons in length with twenty random codons at each position. The right half corresponds to the sense sequence of the randomized oligonucleotides and encode the carboxy terminal half of the expressed peptides. The left half corresponds to the anti-sense sequence of the randomized oligonucleotides and encode the amino terminal half of the expressed peptides. The right and left halves of the randomized oligonucleotide populations are cloned into separate vector species and then mixed and joined so that the right and left halves come together in random combination to produce a single expression vector species

which contains a population of randomized oligonucleotides twenty codons in length. Electroporation of the vector population into an appropriate host produces filamentous phage which express the random peptides on their surface.

5 The reaction vessels for oligonucleotide synthesis were obtained from the manufacturer of the automated synthesizer (Millipore, Burlington, MA; supplier of MilliGen/Biosearch Cyclone Plus Synthesizer). The vessels were supplied as packages containing empty reaction 10 columns (1 μ mole), frits, crimps and plugs (MilliGen/Biosearch catalog # GEN 860458). Derivatized and underivatized control pore glass, phosphoramidite nucleotides, and synthesis reagents were also obtained from MilliGen/Biosearch. Crimper and decrimper tools were 15 obtained from Fisher Scientific Co., Pittsburgh, PA (Catalog numbers 06-406-20 and 06-406-25A, respectively).

20 Ten reaction columns were used for right half synthesis of random oligonucleotides ten codons in length. The oligonucleotides have 5 monomers at their 3' end of the sequence 5'GAGCT3' and 8 monomers at their 5' end of the sequence 5'AATTCCAT3'. The synthesizer was fitted with a column derivatized with a thymine nucleotide (T-column, MilliGen/Biosearch # 0615.50) and was programmed to 25 synthesize the sequences shown in Table I for each of ten columns in independent reaction sets. The sequence of the last three monomers (from right to left since synthesis proceeds 3' to 5') encode the indicated amino acids:

Table I

30	<u>Column</u>	<u>Sequence (5' to 3')</u>	<u>Amino Acids</u>
	column 1R	(T/G)TTGAGCT	Phe and Val
	column 2R	(T/C)CTGAGCT	Ser and Pro
	column 3R	(T/C)ATGAGCT	Tyr and His

	column 4R	(T/C)GTGAGCT	Cys and Arg
	column 5R	(C/A)TGGAGCT	Leu and Met
	column 6R	(C/G)AGGAGCT	Gln and Glu
	column 7R	(A/G)CTGAGCT	Thr and Ala
5	column 8R	(A/G)ATGAGCT	Asn and Asp
	column 9R	(T/G)GGGAGCT	Trp and Gly
	column 1R	A(T/A)AGAGCT	Ile and Cys

where the two monomers in parentheses denote a single monomer position within the codon and indicate that an 10 equal mixture of each monomer was added to the reaction for coupling. The monomer coupling reactions for each of the 10 columns were performed as recommended by the manufacturer (amidite version S1.06, # 8400-050990, scale 1 μ M). After the last coupling reaction, the columns were 15 washed with acetonitrile and lyophilized to dryness.

Following synthesis, the plugs were removed from each column using a decrimper and the reaction products were poured into a single weigh boat. Initially the bead mass increases, due to the weight of the monomers, however, 20 at later rounds of synthesis material is lost. In either case, the material was equalized with underivatized control pore glass and mixed thoroughly to obtain a random distribution of all twenty codon species. The reaction products were then aliquotted into 10 new reaction columns 25 by removing 25 mg of material at a time and placing it into separate reaction columns. Alternatively, the reaction products can be aliquotted by suspending the beads in a liquid that is dense enough for the beads to remain dispersed, preferably a liquid that is equal in density to 30 the beads, and then aliquoting equal volumes of the suspension into separate reaction columns. The lip on the inside of the columns where the frits rest was cleared of material using vacuum suction with a syringe and 25 G needle. New frits were placed onto the lips, the plugs 35 were fitted into the columns and were crimped into place

using a crimper.

Synthesis of the second codon position was achieved using the above 10 columns containing the random mixture of reaction products from the first codon 5 synthesis. The monomer coupling reactions for the second codon position are shown in Table II. An A in the first position means that any monomer can be programmed into the synthesizer. At that position, the first monomer position is not coupled by the synthesizer since the software 10 assumes that the monomer is already attached to the column. An A also denotes that the columns from the previous codon synthesis should be placed on the synthesizer for use in the present synthesis round. Reactions were again sequentially repeated for each column as shown in Table II 15 and the reaction products washed and dried as described above.

Table II

	<u>Column</u>	<u>Sequence (5' to 3')</u>	<u>Amino Acids</u>
5	column 1R	(T/G)TT <u>A</u>	Phe and Val
	column 2R	(T/C)CT <u>A</u>	Ser and Pro
	column 3R	(T/C)AT <u>A</u>	Tyr and His
	column 4R	(T/C)GT <u>A</u>	Cys and Arg
	column 5R	(C/A)TG <u>A</u>	Leu and Met
10	column 6R	(C/G)AG <u>A</u>	Gln and Glu
	column 7R	(A/G)CT <u>A</u>	Thr and Ala
	column 8R	(A/G)AT <u>A</u>	Asn and Asp
	column 9R	(T/G)GG <u>A</u>	Trp and Gly
	column 10R	A(T/A)AA	Ile and Cys

Randomization of the second codon position was
 15 achieved by removing the reaction products from each of the
 columns and thoroughly mixing the material. The material
 was again divided into new reaction columns and prepared
 for monomer coupling reactions as described above.

Random synthesis of the next seven codons
 20 (positions 3 through 9) proceeded identically to the cycle
 described above for the second codon position and again
 used the monomer sequences of Table II. Each of the newly
 repacked columns containing the random mixture of reaction
 products from synthesis of the previous codon position was
 25 used for the synthesis of the subsequent codon position.
 After synthesis of the codon at position nine and mixing of
 the reaction products, the material was divided and
 repacked into 40 different columns and the monomer
 sequences shown in Table III were coupled to each of the 40
 30 columns in independent reactions. The oligonucleotides
 from each of the 40 columns were mixed once more and
 cleaned from the control pore glass as recommended by the
 manufacturer.

Table III

	<u>Column</u>	<u>Sequence (5' to 3')</u>
5	column 1R	AATTCTTTA <u>A</u>
	column 2R	AATTCTGTTA <u>A</u>
	column 3R	AATTCGTTA <u>A</u>
	column 4R	AATTCCGGTTA <u>A</u>
	column 5R	AATTCTTCTA <u>A</u>
	column 6R	AATTCTCCTA <u>A</u>
10	column 7R	AATTCGTCTA <u>A</u>
	column 8R	AATTCCGCCTA <u>A</u>
	column 9R	AATTCTTATA <u>A</u>
	column 10R	AATTCTCATA <u>A</u>
	column 11R	AATTCGTATA <u>A</u>
	column 12R	AATTCCGCATA <u>A</u>
15	column 13R	AATTCTTGTA <u>A</u>
	column 14R	AATTCTCGTA <u>A</u>
	column 15R	AATTCGTGT <u>A</u>
	column 16R	AATTCCGCGTA <u>A</u>
	column 17R	AATTCTCTGA <u>A</u>
	column 18R	AATTCTATGA <u>A</u>
20	column 19R	AATTCCGCTGA <u>A</u>
	column 20R	AATTCCGATGA <u>A</u>
	column 21R	AATTCTCAGA <u>A</u>
	column 22R	AATTCTGAGA <u>A</u>
	column 23R	AATTCCGCAGA <u>A</u>
	column 24R	AATTCCGGAGA <u>A</u>
25	column 25R	AATTCTACTA <u>A</u>
	column 26R	AATTCTGCTA <u>A</u>
	column 27R	AATTCGACTA <u>A</u>
	column 28R	AATTCCGGCTA <u>A</u>
	column 29R	AATTCTAATA <u>A</u>
	column 30R	AATTCTGATA <u>A</u>
30	column 31R	AATTCGAATA <u>A</u>
	column 32R	AATTCCGGATA <u>A</u>
	column 33R	AATTCTTGGA <u>A</u>
	column 34R	AATTCTGGGA <u>A</u>

	column 35R	<u>AATTCGTGGA</u>
	column 36R	<u>AATTCGGGGA</u>
	column 37R	<u>AATTCTATAA</u>
	column 38R	<u>AATTCTAAAA</u>
5	column 39R	<u>AATTCGATAA</u>
	column 40R	<u>AATTCGAAAA</u>

Left half synthesis of random oligonucleotides proceeded similarly to the right half synthesis. This half of the oligonucleotide corresponds to the anti-sense sequence of the encoded randomized peptides. Thus, the complementary sequence of the codons in Tables I through III are synthesized. The left half oligonucleotides also have 5 monomers at their 3' end of the sequence 5'GAGCT3' and 8 monomers at their 5' end of the sequence 10 15 5'AATTCCAT3'. The rounds of synthesis, washing, drying, mixing, and dividing are as described above.

For the first codon position, the synthesizer was fitted with a T-column and programmed to synthesize the sequences shown in Table IV for each of ten columns in 20 independent reaction sets. As with right half synthesis, the sequence of the last three monomers (from right to left) encode the indicated amino acids:

Table IV

	<u>Column</u>	<u>Sequence (5' to 3')</u>	<u>Amino Acids</u>
5	column 1L	AA(A/C)GAGCT	Phe and Val
	column 2L	AG(A/G)GAGCT	Ser and Pro
	column 3L	AT(A/G)GAGCT	Tyr and His
	column 4L	AC(A/G)GAGCT	Cys and Arg
	column 5L	CA(G/T)GAGCT	Leu and Met
	column 6L	CT(G/C)GAGCT	Gln and Glu
10	column 7L	AG(T/C)GAGCT	Thr and Ala
	column 8L	AT(T/C)GAGCT	Asn and Asp
	column 9L	CC(A/C)GAGCT	Trp and Gly
	column 10L	T(A/T)TGAGCT	Ile and Cys

Following washing and drying, the plugs for each column were removed, mixed and aliquotted into ten new reaction columns as described above. Synthesis of the second codon position was achieved using these ten columns containing the random mixture of reaction products from the first codon synthesis. The monomer coupling reactions for the second codon position are shown in Table V.

Table V

	<u>Column</u>	<u>Sequence (5' to 3')</u>	<u>Amino Acids</u>
25	column 1L	AA(A/C) <u>A</u>	Phe and Val
	column 2L	AG(A/G) <u>A</u>	Ser and Pro
	column 3L	AT(A/G) <u>A</u>	Tyr and His
	column 4L	AC(A/G) <u>A</u>	Cys and Arg
	column 5L	CA(G/T) <u>A</u>	Leu and Met
	column 6L	CT(G/C) <u>A</u>	Gln and Glu
30	column 7L	AG(T/C) <u>A</u>	Thr and Ala
	column 8L	AT(T/C) <u>A</u>	Asn and Asp
	column 9L	CC(A/C) <u>A</u>	Trp and Gly
	column 10L	T(A/T) <u>TA</u>	Ile and Cys

Again, randomization of the second codon position was achieved by removing the reaction products from each of the columns and thoroughly mixing the beads. The beads were repacked into ten new reaction columns.

5 Random synthesis of the next seven codon positions proceeded identically to the cycle described above for the second codon position and again used the monomer sequences of Table V. After synthesis of the codon at position nine and mixing of the reaction products, the 10 material was divided and repacked into 40 different columns and the monomer sequences shown in Table VI were coupled to each of the 40 columns in independent reactions.

Table VI

	<u>Column</u>	<u>Sequence (5' to 3')</u>
15	column 1L	AATTCCATAAAAXXA
	column 2L	AATTCCATAAACXXA
	column 3L	AATTCCATAACAXXA
	column 4L	AATTCCATAACCXXA
	column 5L	AATTCCATAGAAXXA
20	column 6L	AATTCCATAGACXXA
	column 7L	AATTCCATAGGAXXA
	column 8L	AATTCCATAGGCXXA
	column 9L	AATTCCATATAAXXA
	column 10L	AATTCCATATACXXA
25	column 11L	AATTCCATATGAXXA
	column 12L	AATTCCATATGCXXA
	column 13L	AATTCCATACAAAXXA
	column 14L	AATTCCATACACXXA
	column 15L	AATTCCATACGAXXA
30	column 16L	AATTCCATACGCXXA
	column 17L	AATTCCATCAGAXXA
	column 18L	AATTCCATCAGCXXA
	column 19L	AATTCCATCATAAXXA
	column 20L	AATTCCATCATCXXA

	column 21L	AATTCCATCTGAXXA
	column 22L	AATTCCATCTGCXXA
	column 23L	AATTCCATCTCAXXA
	column 24L	AATTCCATCTCCXXA
5	column 25L	AATTCCATAGTAXXA
	column 26L	AATTCCATAGTCXXA
	column 27L	AATTCCATAGCAXXA
	column 28L	AATTCCATAGCCXXA
	column 29L	AATTCCATATTAXXA
10	column 30L	AATTCCATATTCXXA
	column 31L	AATTCCATATCAXXA
	column 32L	AATTCCATATCCXXA
	column 33L	AATTCCATCCAAXXA
	column 34L	AATTCCATCCACXXA
15	column 35L	AATTCCATCCCAXXA
	column 36L	AATTCCATCCCCXXA
	column 37L	AATTCCATTATAAXXA
	column 38L	AATTCCATTATCXXA
	column 39L	AATTCCATTTTAXXA
20	column 40L	AATTCCATTTCXXA

The first two monomers denoted by an "X" represent an equal mixture of all four nucleotides at that position. This is necessary to retain a relatively unbiased codon sequence at the junction between right and left half oligonucleotides.

25 The above right and left half random oligonucleotides were cleaved and purified from the supports and used in constructing the surface expression libraries below.

Vector Construction

Two M13-based vectors, M13IX42 (SEQ ID NO: 1) and 30 M13IX22 (SEQ ID NO: 2), were constructed for the cloning and propagation of right and left half populations of random oligonucleotides, respectively. The vectors were specially constructed to facilitate the random joining and subsequent expression of right and left half

oligonucleotide populations. Each vector within the population contains one right and one left half oligonucleotide from the population joined together to form a single contiguous oligonucleotide with random codons 5 which is twenty-two codons in length. The resultant population of vectors are used to construct a surface expression library.

M13IX42, or the right-half vector, was constructed to harbor the right half populations of 10 randomized oligonucleotides. M13mp18 (Pharmacia, Piscataway, NJ) was the starting vector. This vector was genetically modified to contain, in addition to the encoded wild type M13 gene VIII already present in the vector: (1) a pseudo-wild type M13 gene VIII sequence with a stop codon 15 (amber) placed between it and an Eco RI-Sac I cloning site for randomized oligonucleotides; (2) a pair of Fok I sites to be used for joining with M13IX22, the left-half vector; (3) a second amber stop codon placed on the opposite side of the vector than the portion being combined with the 20 left-half vector; and (4) various other mutations to remove redundant restriction sites and the amino terminal portion of Lac Z.

The pseudo-wild type M13 gene VIII was used for surface expression of random peptides. The pseudo-wild 25 type gene encodes the identical amino acid sequence as that of the wild type gene; however, the nucleotide sequence has been altered so that only 63% identity exists between this gene and the encoded wild type gene VIII. Modification of the gene VIII nucleotide sequence used for surface 30 expression reduces the possibility of homologous recombination with the wild type gene VIII contained on the same vector. Additionally, the wild type M13 gene VIII was retained in the vector system to ensure that at least some functional, non-fusion coat protein would be produced. The 35 inclusion of wild type gene VIII therefore reduces the

possibility of non-viable phage production from the random peptide fusion genes.

The pseudo-wild type gene VIII was constructed by chemically synthesizing a series of oligonucleotides which 5 encode both strands of the gene. The oligonucleotides are presented in Table VII (SEQ ID NOS: 7 through 16).

TABLE VII

Pseudo-Wild Type Gene VIII Oligonucleotide Series

	<u>Top Strand Oligonucleotides</u>	<u>Sequence (5' to 3')</u>
10	VIII 03	GATCC TAG GCT GAA GGC GAT GAC CCT GCT AAG GCT GC
	VIII 04	A TTC AAT AGT TTA CAG GCA AGT GCT ACT GAG TAC A
15	VIII 05	TT GGC TAC GCT TGG GCT ATG GTA GTA GTT ATA GTT
	VIII 06	GGT GCT ACC ATA GGG ATT AAA TTA TTC AAA AAG TT
	VIII 07	T ACG AGC AAG GCT TCT TA
20	<u>Bottom Strand Oligonucleotides</u>	
	VIII 08	AGC TTA AGA AGC CTT GCT CGT AAA CTT TTT GAA TAA TTT
25	VIII 09	AAT CCC TAT GGT AGC ACC AAC TAT AAC TAC TAC CAT
	VIII 10	AGC CCA AGC GTA GCC AAT GTA CTC AGT AGC ACT TG
	VIII 11	C CTG TAA ACT ATT GAA TGC AGC CTT AGC AGG GTC
30	VIII 12	ATC GCC TTC AGC CTA G

Except for the terminal oligonucleotides VIII 03 (SEQ ID NO: 7) and VIII 08 (SEQ ID NO: 12), the above oligonucleotides (oligonucleotides VIII 04-VIII 07 and 09-12 (SEQ ID NOS: 8 through 11 and 13 through 16)) were mixed 5 at 200 ng each in 10 μ l final volume and phosphorylated with T4 polynucleotide Kinase (Pharmacia, Piscataway, NJ) with 1 mM ATP at 37°C for 1 hour. The reaction was stopped at 65°C for 5 minutes. Terminal oligonucleotides were added to the mixture and annealed into double-stranded form 10 by heating to 65°C for 5 minutes, followed by cooling to room temperature over a period of 30 minutes. The annealed oligonucleotides were ligated together with 1.0 U of T4 DNA ligase (BRL). The annealed and ligated oligonucleotides yield a double-stranded DNA flanked by a Bam HI site at its 15 5' end and by a Hind III site at its 3' end. A translational stop codon (amber) immediately follows the Bam HI site. The gene VIII sequence begins with the codon GAA (Glu) two codons 3' to the stop codon. The double-stranded insert was phosphorylated using T4 DNA Kinase 20 (Pharmacia, Piscataway, NJ) and ATP (10 mM Tris-HCl, pH 7.5, 10 mM MgCl₂) and cloned in frame with the Eco RI and Sac I sites within the M13 polylinker. To do so, M13mp18 was digested with Bam HI (New England Biolabs, Beverley, MA) and Hind III (New England Biolabs) and combined at a 25 molar ratio of 1:10 with the double-stranded insert. The ligations were performed at 16°C overnight in 1X ligase buffer (50 mM Tris-HCl, pH 7.8, 10 mM MgCl₂, 20 mM DTT, 1 mM ATP, 50 μ g/ml BSA) containing 1.0 U of T4 DNA ligase (New England Biolabs). The ligation mixture was transformed 30 into a host and screened for positive clones using standard procedures in the art.

Several mutations were generated within the right-half vector to yield functional M13IX42. The mutations were generated using the method of Kunkel et al., 35 Meth. Enzymol. 154:367-382 (1987), which is incorporated herein by reference, for site-directed mutagenesis. The

reagents, strains and protocols were obtained from a Bio Rad Mutagenesis kit (Bio Rad, Richmond, CA) and mutagenesis was performed as recommended by the manufacturer.

A Fok I site used for joining the right and left halves was generated 8 nucleotides 5' to the unique Eco RI site using the oligonucleotide 5'-CTCGAATTCTGACATCCTGGTCATAGC-3' (SEQ ID NO: 17). The second Fok I site retained in the vector is naturally encoded at position 3547; however, the sequence within the overhang was changed to encode CTTC. Two Fok I sites were removed from the vector at positions 239 and 7244 of M13mp18 as well as the Hind III site at the end of the pseudo gene VIII sequence using the mutant oligonucleotides 5'-CATTTTGAGATGGCTTAGA-3' (SEQ ID NO: 18) and 5'-TAGCATTAAACGTCCAATA-3' (SEQ ID NO: 19), respectively. New Hind III and Mlu I sites were also introduced at position 3919 and 3951 of M13IX42. The oligonucleotides used for this mutagenesis had the sequences 5'-ATATATTTAGTAAGCTTCATCTTCT-3' (SEQ ID NO: 20) and 5'-GACAAAGAACGCGTAAAAACTT-3' (SEQ ID NO: 21), respectively. The amino terminal portion of Lac Z was deleted by oligonucleotide-directed mutagenesis using the mutant oligonucleotide 5' - GCGGGCCTCTCGCTATTGCTTAAGAAGCCTTGCT-3' (SEQ ID NO: 22). This deletion also removed a third M13mp18 derived Fok I site. The distance between the Eco RI and Sac I sites was increased to ensure complete double digestion by inserting a spacer sequence. The spacer sequence was inserted using the oligonucleotide 5' - TTCAGCCTAGGATCCGCCGAGCTCTCCTACCTGCGAATTCTGACATCC-3' (SEQ ID NO: 23). Finally, an amber stop codon was placed at position 4492 using the mutant oligonucleotide 5' - TGGATTATACTTCTAAATAATGGA-3' (SEQ ID NO: 24). The amber stop codon is used as a biological selection to ensure the proper recombination of vector sequences to bring together right and left halves of the randomized oligonucleotides. In constructing the above mutations, all changes made in a

M13 coding region were performed such that the amino acid sequence remained unaltered. It should be noted that several mutations within M13mp18 were found which differed from the published sequence. Where known, these sequence 5 differences are recorded herein as found and therefore may not correspond exactly to the published sequence of M13mp18.

The sequence of the resultant vector, M13IX42, is shown in Figure 5 (SEQ ID NO: 1). Figure 3A also shows 10 M13IX42 where each of the elements necessary for producing a surface expression library between right and left half randomized oligonucleotides is marked. The sequence between the two Fok I sites shown by the arrow is the portion of M13IX42 which is to be combined with a portion 15 of the left-half vector to produce random oligonucleotides as fusion proteins of gene VIII.

M13IX22, or the left-half vector, was constructed to harbor the left half populations of randomized oligonucleotides. This vector was constructed from M13mp19 20 (Pharmacia, Piscataway, NJ) and contains: (1) Two Fok I sites for mixing with M13IX42 to bring together the left and right halves of the randomized oligonucleotides; (2) sequences necessary for expression such as a promoter and signal sequence and translation initiation signals; (3) an 25 Eco RI-Sac I cloning site for the randomized oligonucleotides; and (4) an amber stop codon for biological selection in bringing together right and left half oligonucleotides.

Of the two Fok I sites used for mixing M13IX22 30 with M13IX42, one is naturally encoded in M13mp18 and M13mp19 (at position 3547). As with M13IX42, the overhang within this naturally occurring Fok I site was changed to CTTC. The other Fok I site was introduced after construction of the translation initiation signals by site-

directed mutagenesis using the oligonucleotide 5'-TAACACTCATTCCGGATGGAATTCTGGAGTCTGGGT-3' (SEQ ID NO: 25).

The translation initiation signals were constructed by annealing of overlapping oligonucleotides as 5 described above to produce a double-stranded insert containing a 5' Eco RI site and a 3' Hind III site. The overlapping oligonucleotides are shown in Table VIII (SEQ ID NOS: 26 through 34) and were ligated as a double-stranded insert between the Eco RI and Hind III sites of 10 M13mp18 as described for the pseudo gene VIII insert. The ribosome binding site (AGGAGAC) is located in oligonucleotide 015 (SEQ ID NO: 26) and the translation initiation codon (ATG) is the first three nucleotides of oligonucleotide 016 (SEQ ID NO: 27).

15

TABLE VIII

Oligonucleotide Series for Construction of
Translation Signals in M13IX22

	<u>Oligonucleotide</u>	<u>Sequence (5' to 3')</u>
20	015	AATT C GCC AAG GAG ACA GTC AT
	016	AATG AAA TAC CTA TTG CCT ACG GCA
	017	GCC GCT GGA TTG TT
	018	ATTA CTC GCT GCC CAA CCA GCC ATG
25		GCC GAG CTC GTG AT
		GACC CAG ACT CCA GATATC CAA CAG
		GAA TGA GTG TTA AT
	019	TCT AGA ACG CGT C
30	020	ACGT G ACG CGT TCT AGA AT TAA
		CACTCA TTC CTG T
	021	TG GAT ATC TGG AGT CTG GGT CAT
		CAC GAG CTC GGC CAT G
	022	GC TGG TTG GGC AGC GAG TAA TAA
		CAA TCC AGC GGC TGC C

023

GT AGG CAA TAG GTA TTT CAT TAT
GAC TGT CCT TGG CG

Oligonucleotide 017 (SEQ ID NO: 27) contained a Sac I restriction site 67 nucleotides downstream from the 5 ATG codon. The naturally occurring Eco RI site was removed and a new site introduced 25 nucleotides downstream from the Sac I. Oligonucleotides 5'-TGACTGTCTCCTGGCGTGTGAAATTGTTA-3' (SEQ ID NO: 35) and 5'-TAACACTCATTCCGGATGGAATTCTGGAGTCT 10 GGGT-3' (SEQ ID NO: 36) were used to generate each of the mutations, respectively. An amber stop codon was also introduced at position 3263 of M13mp18 using the oligonucleotide 5'-CAATTATCCTAAATCTTACCAAC-3' (SEQ ID NO: 37).

15 In addition to the above mutations, a variety of other modifications were made to remove certain sequences and redundant restriction sites. The LAC Z ribosome binding site was removed when the original Eco RI site in M13mp18 was mutated. Also, the Fok I sites at positions 20 239, 6361 and 7244 of M13mp18 were likewise removed with mutant oligonucleotides 5'-CATTTTGAGATGGCTTAGA-3' (SEQ ID NO: 38), 5'-CGAAAGGGGGTGTGCTGCAA-3' (SEQ ID NO: 39) and 5'-TAGCATTAAACGTCCAATA-3' (SEQ ID NO: 40), respectively. Again, mutations within the coding region did not alter the 25 amino acid sequence.

The resultant vector, M13IX22, is 7320 base pairs in length, the sequence of which is shown in Figure 6 (SEQ ID NO: 2). The Sac I and Eco RI cloning sites are at positions 6290 and 6314, respectively. Figure 3A also 30 shows M13IX22 where each of the elements necessary for producing a surface expression library between right and left half randomized oligonucleotides is marked.

Library Construction

Each population of right and left half randomized oligonucleotides from columns 1R through 40R and columns 1L through 40L are cloned separately into M13IX42 and M13IX22, respectively, to create sublibraries of right and left half 5 randomized oligonucleotides. Therefore, a total of eighty sublibraries are generated. Separately maintaining each population of randomized oligonucleotides until the final screening step is performed to ensure maximum efficiency of annealing of right and left half oligonucleotides. The 10 greater efficiency increases the total number of randomized oligonucleotides which can be obtained. Alternatively, one can combine all forty populations of right half oligonucleotides (columns 1R-40R) into one population and of left half oligonucleotides (columns 1L-40L) into a 15 second population to generate just one sublibrary for each.

For the generation of sublibraries, each of the above populations of randomized oligonucleotides are cloned separately into the appropriate vector. The right half oligonucleotides are cloned into M13IX42 to generate 20 sublibraries M13IX42.1R through M13IX42.40R. The left half oligonucleotides are similarly cloned into M13IX22 to generate sublibraries M13IX22.1L through M13IX22.40L. Each vector contains unique Eco RI and Sac I restriction enzyme sites which produce 5' and 3' single-stranded overhangs, 25 respectively, when digested. The single strand overhangs are used for the annealing and ligation of the complementary single-stranded random oligonucleotides.

The randomized oligonucleotide populations are cloned between the Eco RI and Sac I sites by sequential 30 digestion and ligation steps. Each vector is treated with an excess of Eco RI (New England Biolabs) at 37°C for 2 hours followed by addition of 4-24 units of calf intestinal alkaline phosphatase (Boehringer Mannheim, Indianapolis, IN). Reactions are stopped by ph nol/chloroform extraction 35 and ethanol precipitation. The pellets are resuspended in

an appropriate amount of distilled or deionized water (dH₂O). About 10 pmol of vector is mixed with a 5000-fold molar excess of each population of randomized oligonucleotides in 10 μ l of 1X ligase buffer (50 mM Tris-5 HCl, pH 7.8, 10 mM MgCl₂, 20 mM DTT, 1 mM ATP, 50 μ g/ml BSA) containing 1.0 U of T4 DNA ligase (BRL, Gaithersburg, MD). The ligation is incubated at 16°C for 16 hours. Reactions are stopped by heating at 75°C for 15 minutes and the DNA is digested with an excess of Sac I (New England Biolabs) 10 for 2 hours. Sac I is inactivated by heating at 75°C for 15 minutes and the volume of the reaction mixture is adjusted to 300 μ l with an appropriate amount of 10X ligase buffer and dH₂O. One unit of T4 DNA ligase (BRL) is added and the mixture is incubated overnight at 16°C. The DNA is 15 ethanol precipitated and resuspended in TE (10 mM Tris-HCl, pH 8.0, 1 mM EDTA). DNA from each ligation is electroporated into XL1 Blue™ cells (Stratagene, La Jolla, CA), as described below, to generate the sublibraries.

E. coli XL1 Blue™ is electroporated as described 20 by Smith et al., Focus 12:38-40 (1990) which is incorporated herein by reference. The cells are prepared by inoculating a fresh colony of XL1s into 5 mls of SOB without magnesium (20 g bacto-tryptone, 5 g bacto-yeast extract, 0.584 g NaCl, 0.186 g KC1, dH₂O to 1,000 mls) and 25 grown with vigorous aeration overnight at 37°C. SOB without magnesium (500 ml) is inoculated at 1:1000 with the overnight culture and grown with vigorous aeration at 37°C until the OD₅₅₀ is 0.8 (about 2 to 3 h). The cells are harvested by centrifugation at 5,000 rpm (2,600 x g) in a 30 GS3 rotor (Sorvall, Newtown, CT) at 4°C for 10 minutes, resuspended in 500 ml of ice-cold 10% (v/v) sterile glycerol and centrifuged and resuspended a second time in the same manner. After a third centrifugation, the cells are resuspended in 10% sterile glycerol at a final volume 35 of about 2 ml, such that the OD₅₅₀ of the suspension is 200 to 300. Usually, resuspension is achieved in the 10%

glycerol that remains in the bottle after pouring off the supernate. Cells are frozen in 40 μ l aliquots in microcentrifuge tubes using a dry ice-ethanol bath and stored frozen at -70°C.

5 Frozen cells are electroporated by thawing slowly on ice before use and mixing with about 10 pg to 500 ng of vector per 40 μ l of cell suspension. A 40 μ l aliquot is placed in an 0.1 cm electroporation chamber (Bio-Rad, Richmond, CA) and pulsed once at 0°C using 200 Ω parallel 10 resistor, 25 μ F, 1.88 kV, which gives a pulse length (τ) of ~4 ms. A 10 μ l aliquot of the pulsed cells are diluted into 1 ml SOC (98 mls SOB plus 1 ml of 2 M MgCl₂, and 1 ml of 2 M glucose) in a 12- x 75-mm culture tube, and the culture is shaken at 37°C for 1 hour prior to culturing in 15 selective media, (see below).

Each of the eighty sublibraries are cultured using methods known to one skilled in the art. Such methods can be found in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold 20 Spring Harbor, 1989, and in Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, New York, 1989, both of which are incorporated herein by reference. Briefly, the above 1 ml sublibrary cultures were grown up by diluting 50-fold into 2XYT media (16 g 25 tryptone, 10 g yeast extract, 5 g NaCl) and culturing at 37°C for 5-8 hours. The bacteria were pelleted by centrifugation at 10,000 xg. The supernatant containing phage was transferred to a sterile tube and stored at 4°C.

Double strand vector DNA containing right and 30 left half randomized oligonucleotide inserts is isolated from the cell pellet of each sublibrary. Briefly, the pellet is washed in TE (10 mM Tris, pH 8.0, 1 mM EDTA) and recollected by centrifugation at 7,000 rpm for 5' in a Sorval centrifuge (Newtown, CT). Pellets are resuspended

in 6 mls of 10% Sucrose, 50 mM Tris, pH 8.0. 3.0 ml of 10 mg/ μ l lysozyme is added and incubated on ice for 20 minutes. 12 mls of 0.2 M NaOH, 1% SDS is added followed by 10 minutes on ice. The suspensions are then incubated on 5 ice for 20 minutes after addition of 7.5 mls of 3 M NaOAc, pH 4.6. The samples are centrifuged at 15,000 rpm for 15 minutes at 4°C, RNased and extracted with phenol/chloroform, followed by ethanol precipitation. The pellets are resuspended, weighed and an equal weight of 10 CsCl₂ is dissolved into each tube until a density of 1.60 g/ml is achieved. EtBr is added to 600 μ g/ml and the double-stranded DNA is isolated by equilibrium centrifugation in a TV-1665 rotor (Sorval) at 50,000 rpm for 6 hours. These DNAs from each right and left half 15 sublibrary are used to generate forty libraries in which the right and left halves of the randomized oligonucleotides have been randomly joined together.

Each of the forty libraries are produced by joining together one right half and one left half 20 sublibrary. The two sublibraries joined together corresponded to the same column number for right and left half random oligonucleotide synthesis. For example, sublibrary M13IX42.1R is joined with M13IX22.1L to produce the surface expression library M13IX.1RL. In the 25 alternative situation where only two sublibraries are generated from the combined populations of all right half synthesis and all left half synthesis, only one surface expression library would be produced.

For the random joining of each right and 1 ft 30 half oligonucleotide populations into a single surface expression vector species, the DNAs isolated from each sublibrary are digested an excess of Fok I (New England Biolabs). The reactions are stopped by phenol/chloroform extraction, followed by ethanol precipitation. Pellets are 35 resuspended in dH₂O. Each surface expression library is

generated by ligating equal molar amounts (5-10 pmol) of Fok I digested DNA isolated from corresponding right and left half sublibraries in 10 μ l of 1X ligase buffer containing 1.0 U of T4 DNA ligase (Bethesda Research Laboratories, Gaithersburg, MD). The ligations proceeded overnight at 16°C and are electroporated into the sup O strain MK30-3 (Boehringer Mannheim Biochemical, (BMB), Indianapolis, IN) as previously described for XL1 cells. Because MK30-3 is sup O, only the vector portions encoding the randomized oligonucleotides which come together will produce viable phage.

Screening of Surface Expression Libraries

Purified phage are prepared from 50 ml liquid cultures of XL1 Blue™ cells (Stratagene) which are infected at a m.o.i. of 10 from the phage stocks stored at 4°C. The cultures are induced with 2 mM IPTG. Supernatants from all cultures are combined and cleared by two centrifugations, and the phage are precipitated by adding 1/7.5 volumes of PEG solution (25% PEG-8000, 2.5 M NaCl), followed by incubation at 4°C overnight. The precipitate is recovered by centrifugation for 90 minutes at 10,000 x g. Phage pellets are resuspended in 25 ml of 0.01 M Tris-HCl, pH 7.6, 1.0 mM EDTA, and 0.1% Sarkosyl and then shaken slowly at room temperature for 30 minutes. The solutions are adjusted to 0.5 M NaCl and to a final concentration of 5% polyethylene glycol. After 2 hours at 4°C, the precipitates containing the phage are recovered by centrifugation for 1 hour at 15,000 x g. The precipitates are resuspended in 10 ml of NET buffer (0.1 M NaCl, 1.0 mM EDTA, and 0.01 M Tris-HCl, pH 7.6), mixed well, and the phage repelleted by centrifugation at 170,000 x g for 3 hours. The phage pellets are subsequently resuspended overnight in 2 ml of NET buffer and subjected to cesium chloride centrifugation for 18 hours at 110,000 x g (3.86 g of cesium chloride in 10 ml of buffer). Phage bands are

collect d, diluted 7-fold with NET buffer, re-centrifuged at 170,000 X g for 3 hours, resuspended, and stored at 4°C in 0.3 ml of NET buffer containing 0.1 mM sodium azide.

Ligand binding proteins used for panning on streptavidin coated dishes are first biotinylated and then absorbed against UV-inactivated blocking phage (see below). The biotinylating reagents are dissolved in dimethylformamide at a ratio of 2.4 mg solid NHS-SS-Biotin (sulfosuccinimidyl 2-(biotinamido)ethyl-1,3'-dithiopropionate; Pierce, Rockford, IL) to 1 ml solvent and used as recommended by the manufacturer. Small-scale reactions are accomplished by mixing 1 μ l dissolved reagent with 43 μ l of 1 mg/ml ligand binding protein diluted in sterile bicarbonate buffer (0.1 M NaHCO₃, pH 8.6). After 2 hours at 25°C, residual biotinylating reagent is reacted with 500 μ l 1 M ethanolamine (pH adjusted to 9 with HCl) for an additional 2 hours. The entire sample is diluted with 1 ml TBS containing 1 mg/ml BSA, concentrated to about 50 μ l on a Centricon 30 ultra-filter (Amicon), and washed on the same filter three times with 2 ml TBS and once with 1 ml TBS containing 0.02% NaN₃, and 7 \times 10¹² UV-inactivated blocking phage (see below); the final retentate (60-80 μ l) is stored at 4°C. Ligand binding proteins biotinylated with the NHS-SS-Biotin reagent are linked to biotin via a disulfide-containing chain.

UV-irradiated M13 phage were used for blocking binding proteins which fortuitously bound filamentous phage in general. M13mp8 (Messing and Vieira, Gene 19: 262-276 (1982), which is incorporated herein by reference) was chosen because it carries two amber stop codons, which ensure that the few phage surviving irradiation will not grow in the sup O strains used to titer the surface expression libraries. A 5 ml sample containing 5 \times 10¹³ M13mp8 phage, purified as described above, was placed in a small petri plate and irradiated with a germicidal lamp at

a distance of two feet for 7 minutes (flux 150 $\mu\text{W}/\text{cm}^2$). NaN₃ was added to 0.02% and phage particles concentrated to 10¹⁴ particles/ml on a Centricon 30-kDa ultrafilter (Amicon).

5 For panning, polystyrene petri plates (60 x 15 mm, Falcon; Becton Dickinson, Lincoln Park, NJ) are incubated with 1 ml of 1 mg/ml of streptavidin (BMB) in 0.1 M NaHCO₃, pH 8.6-0.02% NaN₃, in a small, air-tight plastic box overnight in a cold room. The next day streptavidin is
10 removed and replaced with at least 10 ml blocking solution (29 mg/ml of BSA; 3 $\mu\text{g}/\text{ml}$ of streptavidin; 0.1 M NaHCO₃, pH 8.6-0.02% NaN₃) and incubated at least 1 hour at room temperature. The blocking solution is removed and plates are washed rapidly three times with Tris buffered saline
15 containing 0.5% Tween 20 (TBS-0.5% Tween 20).

Selection of phage expressing peptides bound by the ligand binding proteins is performed with 5 μl (2.7 μg ligand binding protein) of blocked biotinylated ligand binding proteins reacted with a 50 μl portion of each
20 library. Each mixture is incubated overnight at 4°C, diluted with 1 ml TBS-0.5% Tween 20, and transferred to a streptavidin-coated petri plate prepared as described above. After rocking 10 minutes at room temperature, unbound phage are removed and plates washed ten times with
25 TBS-0.5% Tween 20 over a period of 30-90 minutes. Bound phage are eluted from plates with 800 μl sterile elution buffer (1 mg/ml BSA, 0.1 M HCl, pH adjusted to 2.2 with glycerol) for 15 minutes and eluates neutralized with 48 μl 2 M Tris (pH unadjusted). A 20 μl portion of each eluate
30 is titered on MK30-3 concentrated cells with dilutions of input phage.

A second round of panning is performed by treating 750 μl of first eluate from each library with 5 mM DTT for 10 minutes to break disulfide bonds linking biotin

groups to residual biotinylated binding proteins. The treated eluate is concentrated on a Centricon 30 ultrafilter (Amicon), washed three times with TBS-0.5% Tween 20, and concentrated to a final volume of about 50 5 μ l. Final retentate is transferred to a tube containing 5.0 μ l (2.7 μ g ligand binding protein) blocked biotinylated ligand binding proteins and incubated overnight. The solution is diluted with 1 ml TBS-0.5% Tween 20, panned, and eluted as described above on fresh streptavidin-coated 10 petri plates. The entire second eluate (800 μ l) is neutralized with 48 μ l 2 M Tris, and 20 μ l is titered simultaneously with the first eluate and dilutions of the input phage.

Individual phage populations are purified through 15 2 to 3 rounds of plaque purification. Briefly, the second eluate titer plates are lifted with nitrocellulose filters (Schleicher & Schuell, Inc., Keene, NH) and processed by washing for 15 minutes in TBS (10 mM Tris-HCl, pH 7.2, 150 mM NaCl), followed by an incubation with shaking for an 20 additional 1 hour at 37°C with TBS containing 5% nonfat dry milk (TBS-5% NDM) at 0.5 ml/cm². The wash is discarded and fresh TBS-5% NDM is added (0.1 ml/cm²) containing the ligand binding protein between 1 nM to 100 mM, preferably between 1 to 100 μ M. All incubations are carried out in heat- 25 sealable pouches (Sears). Incubation with the ligand binding protein proceeds for 12-16 hours at 4°C with shaking. The filters are removed from the bags and washed 3 times for 30 minutes at room temperature with 150 mls of TBS containing 0.1% NDM and 0.2% NP-40 (Sigma, St. Louis, 30 MO). The filters are then incubated for 2 hours at room temperature in antiserum against the ligand binding protein at an appropriate dilution in TBS-0.5% NDM, washed in 3 changes of TBS containing 0.1% NDM and 0.2% NP-40 as described above and incubated in TBS containing 0.1% NDM 35 and 0.2% NP-40 with 1 x 10⁶ cpm of ¹²⁵I-labeled Protein A (specific activity = 2.1 x 10⁷ cpm/ μ g). After a washing

with TBS containing 0.1% NDM and 0.2% NP-40 as described above, the filters are wrapped in Saran Wrap and exposed to Kodak X-Omat x-ray film (Kodak, Rochester, NY) for 1-12 hours at -70°C using Dupont Cronex Lightning Plus

5 **Intensifying Screens (Dupont, Wilmington, DE).**

Positive plaques identified are cored with the large end of a pasteur pipet and placed into 1 ml of SM (5.8 g NaCl, 2 g MgSO₄·7H₂O, 50 ml 1 M Tris-HCl, pH 7.5, 5 mls 2% gelatin, to 1000 mls with dH₂O) plus 1-3 drops of 10 CHCl₃, and incubated at 37°C 2-3 hours or overnight at 4°C. The phage are diluted 1:500 in SM and 2 µl are added to 300 µl of XL1 cells plus 3 mls of soft agar per 100 mm² plate. The XL1 cells are prepared for plating by growing a colony overnight in 10 ml LB (10 g bacto-tryptone, 5 g bacto-yeast 15 extract, 10 g NaCl, 1000 ml dH₂O) containing 100 µl of 20% maltose and 100 µl of 1 M MgSO₄. The bacteria are pelleted by centrifugation at 2000 xg for 10 minutes and the pellet is resuspended gently in 10 mls of 10 mM MgSO₄. The suspension is diluted 4-fold by adding 30 mls of 10 mM MgSO₄ 20 to give an OD₆₀₀ of approximately 0.5. The second and third round screens are identical to that described above except that the plaques are cored with the small end of a pasteur pipet and placed into 0.5 mls SM plus a drop of CHCl₃, and 1-5 µl of the phage following incubation are used for plating 25 without dilution. At the end of the third round of purification, an individual plaque is picked and the templates prepared for sequencing.

Template Preparation and Sequencing

Templates are prepared for sequencing by 30 inoculating a 1 ml culture of 2XYT containing a 1:100 dilution of an overnight culture of XL1 with an individual plaque. The plaques are picked using a sterile toothpick. The culture is incubated at 37°C for 5-6 hours with shaking and then transferred to a 1.5 ml microfuge tube. 200 µl of

PEG solution is added, followed by vortexing and placed on ice for 10 minutes. The phage precipitate is recovered by centrifugation in a microfuge at 12,000 x g for 5 minutes. The supernatant is discarded and the pellet is resuspended 5 in 230 μ l of TE (10 mM Tris-HCl, pH 7.5, 1 mM EDTA) by gently pipeting with a yellow pipet tip. Phenol (200 μ l) is added, followed by a brief vortex and microfuged to separate the phases. The aqueous phase is transferred to a separate tube and extracted with 200 μ l of 10 phenol/chloroform (1:1) as described above for the phenol extraction. A 0.1 volume of 3 M NaOAc is added, followed by addition of 2.5 volumes of ethanol and precipitated at 15 -20°C for 20 minutes. The precipitated templates are recovered by centrifugation in a microfuge at 12,000 x g for 8 minutes. The pellet is washed in 70% ethanol, dried 15 and resuspended in 25 μ l TE. Sequencing was performed using a Sequenase™ sequencing kit following the protocol supplied by the manufacturer (U.S. Biochemical, Cleveland, OH).

20

EXAMPLE IIIsolation and Characterization of Peptide Ligands Generated
From Oligonucleotides Having Random Codons at Two
Predetermined Positions

This example shows the generation of a surface 25 expression library from a population of oligonucleotides having randomized codons. The oligonucleotides are ten codons in length and are cloned into a single vector species for the generation of a M13 gene VIII-based surface expression library. The example also shows the selection 30 of peptides for a ligand binding protein and characterization of their encoded nucleic acid sequences.

Oligonucleotide Synthesis

Oligonucleotides were synthesized as described in Example I. The synthesizer was programmed to synthesize the sequences shown in Table IX. These sequences correspond to the first random codon position synthesized 5 and 3' flanking sequences of the oligonucleotide which hybridizes to the leader sequence in the vector. The complementary sequences are used for insertional mutagenesis of the synthesized population of oligonucleotides.

10

Table IX

	<u>Column</u>	<u>Sequence (5' to 3')</u>
15	column 1	AA(A/C)GGTTGGTCGGTACCGG
	column 2	AG(A/G)GGTTGGTCGGTACCGG
	column 3	AT(A/G)GGTTGGTCGGTACCGG
	column 4	AC(A/G)GGTTGGTCGGTACCGG
	column 5	CA(G/T)GGTTGGTCGGTACCGG
	column 6	CT(G/C)GGTTGGTCGGTACCGG
	column 7	AG(T/C)GGTTGGTCGGTACCGG
	column 8	AT(T/C)GGTTGGTCGGTACCGG
	column 9	CC(A/C)GGTTGGTCGGTACCGG
	column 10	T(A/T)GGTTGGTCGGTACCGG

The next eight random codon positions were synthesized as described for Table V in Example I. Following the ninth position synthesis, the reaction 25 products were once more combined, mixed and redistributed into 10 new reaction columns. Synthesis of the last random codon position and 5' flanking sequences are shown in Table X.

Table X

30	<u>Column</u>	<u>Sequence (5' to 3')</u>
	column 1	AGGATCCGCCGAGCTCAA(A/C)A
	column 2	AGGATCCGCCGAGCTCAG(A/G)A
	column 3	AGGATCCGCCGAGCTCAT(A/G)A

	column 4	AGGATCCGCCGAGCTCAC (A/G) <u>A</u>
	column 5	AGGATCCGCCGAGCTCCA (G/T) <u>A</u>
	column 6	AGGATCCGCCGAGCTCCT (G/C) <u>A</u>
	column 7	AGGATCCGCCGAGCTCAG (T/C) <u>A</u>
5	column 8	AGGATCCGCCGAGCTCAT (T/C) <u>A</u>
	column 9	AGGATCCGCCGAGCTCCC (A/C) <u>A</u>
	column 10	AGGATCCGCCGAGCTCT (A/T) <u>TA</u>

10 The reaction products were mixed once more and the oligonucleotides cleaved and purified as recommended by the manufacturer. The purified population of oligonucleotides were used to generate a surface expression library as described below.

Vector Construction

15 The vector used for generating surface expression libraries from a single oligonucleotide population (i.e., without joining together of right and left half oligonucleotides) is described below. The vector is a M13-based expression vector which directs the synthesis of gene VIII-peptide fusion proteins (Figure 4). This vector 20 exhibits all the functions that the combined right and left half vectors of Example I exhibit.

25 An M13-based vector was constructed for the cloning and surface expression of populations of random oligonucleotides (Figure 4, M13IX30), M13mp19 (Pharmacia) was the starting vector. This vector was modified to contain, in addition to the encoded wild type M13 gene VIII: (1) a pseudo-wild type gene, gene VIII sequence with an amber stop codon placed between it and the restriction sites for cloning oligonucleotides; (2) Stu I, Spe I and 30 Xho I restriction sites in frame with the pseudo-wild type gVIII for cloning oligonucleotides; (3) sequences necessary for expression, such as a promoter, signal sequence and translation initiation signals; (4) various other mutations

to remove redundant restriction sites and the amino terminal portion of Lac Z.

Construction of M13IX30 was performed in four steps. In the first step, a precursor vector containing 5 the pseudo gene VIII and various other mutations was constructed, M13IX01F. The second step involved the construction of a small cloning site in a separate M13mp18 vector to yield M13IX03. In the third step, expression sequences and cloning sites were constructed in M13IX03 to 10 generate the intermediate vector M13IX04B. The fourth step involved the incorporation of the newly constructed sequences from the intermediate vector into M13IX01F to yield M13IX30. Incorporation of these sequences linked them with the pseudo gene VIII.

15 Construction of the precursor vector M13IX01F was similar to that of M13IX42 described in Example I except for the following features: (1) M13mp19 was used as the starting vector; (2) the Fok I site 5' to the unique Eco 20 RI site was not incorporated and the overhang at the naturally occurring Fok I site at position 3547 was not changed to 5'-CTTC-3'; (3) the spacer sequence was not incorporated between the Eco RI and Sac I sites; and (4) the amber codon at position 4492 was not incorporated.

In the second step, M13mp18 was mutated to remove 25 the 5' end of Lac Z up to the Lac i binding site and including the Lac Z ribosome binding site and start codon. Additionally, the polylinker was removed and a Mlu I site was introduced in the coding region of Lac Z. A single oligonucleotide was used for these mutagenesis and had the 30 sequence "5'-AAACGACGCCAGTGCCAAAGTGACGCGTGTGAAATTGTTATCC-3'" (SEQ ID NO: 41). Restriction enzyme sites for Hind III and Eco RI were introduced downstream of the MluI site using the oligonucleotide "5' - GCGAAAGGAATTCTGCAAGGCGATTAAGCTTGGGTAACGCC-3'" (SEQ ID NO:

42). These modifications of M13mp18 yielded the vector M13IX03.

The expression sequences and cloning sites were introduced into M13IX03 by chemically synthesizing a series of oligonucleotides which encode both strands of the desired sequence. The oligonucleotides are presented in Table XI (SEQ ID NOS: 43 through 50).

TABLE XI
M13IX30 Oligonucleotide Series

10 <u>Top Strand Oligonucleotides</u>		<u>Sequence (5' to 3')</u>
	084	GGCGTTACCCAAGCTTGATGGAGAAAATAAAG
	027	TGAAACAAAGCACTATTGCACTGGCACTCTTACCGT TACCGT
15	028	TACTGTTACCCCTGTGACAAAAGCCGCCAGGTCC AGCTGC
	029	TCGAGTCAGGCCTATTGTGCCAGGGATTGTACTAG TGGATCCG
20 <u>Bottom Oligonucleotides</u>		<u>Sequence (5' to 3')</u>
	085	TGGCGAAAGGGATTCTGGATCCACTAGTACAATCCCTG
	031	GGCACAAATAGGCCTGACTCGAGCAGCTGGACCAGGGCG GCTT
25	032	TTGTCACAGGGTAAACAGTAACGGTAACGGTAAGTGT GCCA
	033	GTGCAATAGTGCTTGTTCACTTATTTCTCCATGT ACAA

The above oligonucleotides except for the terminal oligonucleotides 084 (SEQ ID NO: 43) and 085 (SEQ ID NO: 47) of Table XI were mixed, phosphorylated, annealed and ligated to form a double stranded insert as described in Example I. However, instead of cloning directly into

the intermediate vector the insert was first amplified by PCR using the terminal oligonucleotides 084 (SEQ ID NO: 43) and 085 (SEQ ID NO: 47) as primers. The terminal oligonucleotide 084 (SEQ ID NO: 43) contains a Hind III site 10 nucleotides internal to its 5' end. Oligonucleotide 085 (SEQ ID NO: 47) has an Eco RI site at its 5' end. Following amplification, the products were restricted with Hind III and Eco RI and ligated as described in Example I into the polylinker of M13mp18 digested with the same two enzymes. The resultant double stranded insert contained a ribosome binding site, a translation initiation codon followed by a leader sequence and three restriction enzyme sites for cloning random oligonucleotides (Xho I, Stu I, Spe I). The vector was 15 named M13IX04.

During cloning of the double-stranded insert, it was found that one of the GCC codons in oligonucleotides 028 and its complement in 031 was deleted. Since this deletion did not affect function, the final construct is 20 missing one of the two GCC codons. Additionally, oligonucleotide 032 contained a GTG codon where a GAG codon was needed. Mutagenesis was performed using the oligonucleotide 5'-TAACGGTAAGAGTGCCAGTGC-3' (SEQ ID NO: 51) to convert the codon to the desired sequence. The 25 resultant intermediate vector was named M13IX04B.

The fourth step in constructing M13IX30 involved inserting the expression and cloning sequences from M13IX04B upstream of the pseudo-wild type gVIII in M13IX01F. This was accomplished by digesting M13IX04B with 30 Dra III and Bam HI and gel isolating the 700 base pair insert containing the sequences of interest. M13IX01F was likewise digested with Dra III and Bam HI. The insert was combined with the double digested vector at a molar ratio of 3:1 and ligated as described in Example I. It should be 35 noted that all modifications in the vectors described

herein were confirmed by sequence analysis. The sequence of the final construct, M13IX30, is shown in Figure 7 (SEQ ID NO: 3). Figure 4 also shows M13IX30 where each of the elements necessary for surface expression of randomized 5 oligonucleotides is marked.

Library Construction, Screening and Characterization of Encoded Oligonucleotides

Construction of an M13IX30 surface expression library is accomplished identically to that described in 10 Example I for sublibrary construction except the oligonucleotides described above are inserted into M13IX30 by mutagenesis instead of by ligation. The library is constructed and propagated on MK30-3 (BMB) and phage stocks are prepared for infection of XLI cells and screening. The 15 surface expression library is screened and encoding oligonucleotides characterized as described in Example I.

EXAMPLE III

Isolation and Characterization of Peptide Ligands Generated from Right and Left Half 20 Degenerate Oligonucleotides

This example shows the construction and expression of a surface expression library of degenerate oligonucleotides. The encoded peptides of this example derive from the mixing and joining together of two separate 25 oligonucleotide populations. Also demonstrated is the isolation and characterization of peptide ligands and their corresponding nucleotide sequence for specific binding proteins.

Synthesis of Oligonucleotide Populations

30 A population of left half degenerate

oligonucleotides and a population of right half degenerate oligonucleotides was synthesized using standard automated procedures as described in Example I.

The degenerate codon sequences for each 5 population of oligonucleotides were generated by sequentially synthesizing the triplet NNG/T where N is an equal mixture of all four nucleotides. The antisense sequence for each population of oligonucleotides was synthesized and each population contained 5' and 3' 10 flanking sequences complementary to the vector sequence. The complementary termini was used to incorporate each population of oligonucleotides into their respective vectors by standard mutagenesis procedures. Such procedures have been described previously in Example I and 15 in the Detailed Description. Synthesis of the antisense sequence of each population was necessary since the single-stranded form of the vectors are obtained only as the sense strand.

The left half oligonucleotide population was 20 synthesized having the following sequence: 5'-AGCTCCCGGATGCCCTCAGAAGATG(A/CNN),GGCTTTGCCACAGGGG-3' (SEQ ID NO: 52). The right half oligonucleotide population was synthesized having the following sequence: 5'-CAGCCTCGGATCCGCC(A/CNN),ATG(A/C)GAAT-3' (SEQ ID NO. 53). 25 These two oligonucleotide populations when incorporated into their respective vectors and joined together encode a 20 codon oligonucleotide having 19 degenerate positions and an internal predetermined codon sequence.

Vector Construction

30 Modified forms of the previously described vectors were used for the construction of right and left half sublibraries. The construction of left half sublibraries was performed in an M13-based vector termed

M13ED03. This vector is a modified form of the previously described M13IX30 vector and contains all the essential features of both M13IX30 and M13IX22. M13ED03 contains, in addition to a wild type and a pseudo-wild type gene VIII, 5 sequences necessary for expression and two Fok I sites for joining with a right half oligonucleotide sublibrary. Therefore, this vector combines the advantages of both previous vectors in that it can be used for the generation and expression of surface expression libraries from a 10 single oligonucleotide population or it can be joined with a sublibrary to bring together right and left half oligonucleotide populations into a surface expression library.

M13ED03 was constructed in two steps from 15 M13IX30. The first step involved the modification of M13IX30 to remove a redundant sequence and to incorporate a sequence encoding the eight amino-terminal residues of human β -endorphin. The leader sequence was also mutated to increase secretion of the product.

20 During construction of M13IX04 (an intermediate vector to M13IX30 which is described in Example II), a six nucleotide sequence was duplicated in oligonucleotide 027 (SEQ ID NO: 44) and its complement 032 (SEQ ID NO: 49). This sequence, 5'-TTACCG-3', was deleted by mutagenesis in 25 the construction of M13ED01. The oligonucleotide used for the mutagenesis was 5'-GGTAAACAGTAACGGTAAGAGTGCCAG-3' (SEQ ID NO: 54). The mutation in the leader sequence was generated using the oligonucleotide 5'-GGGCTTTGCCACAGGGGT- 3' (SEQ ID NO: 55). This mutagenesis resulted in the A 30 residue at position 6353 of M13IX30 being changed to a G residue. The resultant vector was designated M13IX32.

To generate M13ED01, the nucleotide sequence encoding β -endorphin (8 amino acid residues of β -endorphin plus 3 extra amino acid residues) was incorporated after

the leader sequence by mutagenesis. The oligonucleotide used had the following sequence: 5'-AGGGTCATGCCTTCAGCTCCGGATCCCTCAGAAGTCATAAACCCCCCATAGGC TTTGCCAC-3' (SEQ ID NO: 56). This mutagenesis also 5 removed some of the downstream sequences through the Spe I site.

The second step in the construction of M13ED03 involved vector changes which put the β -endorphin sequence in frame with the downstream pseudo-gene VIII sequence and 10 incorporated a Fok I site for joining with a sublibrary of right half oligonucleotides. This vector was designed to incorporate oligonucleotide populations by mutagenesis using sequences complementary to those flanking or overlapping with the encoded β -endorphin sequence. The 15 absence of β -endorphin expression after mutagenesis can therefore be used to measure the mutagenesis frequency. In addition to the above vector changes, M13ED03 was also modified to contain an amber codon at position 3262 for 20 biological selection during joining of right and left half sublibraries.

The mutations were incorporated using standard mutagenesis procedures as described in Example I. The frame shift changes and Fok I site were generated using the oligonucleotide 5'-TCGCCTTCAGCTCCGGATGCCTCAGAAGCATGAACCCCCCATAGGC-3' (SEQ ID NO: 57). The amber codon was generated using the oligonucleotide 5'-CAATTTATCCTAAATCTTACCAAC-3' (SEQ ID NO: 58). The full sequence of the resultant vector, M13ED03, is provided in Figure 8 (SEQ ID NO: 4).

30 The construction of right half oligonucleotide sublibraries was performed in a modified form of the M13IX42 vector. The new vector, M13IX421, is identical to M13IX42 except that the amber codon between the Eco RI-SacI cloning site and the pseudo-gene VIII sequence was removed.

This change insures that all expression off of the Lac Z promoter produces a peptide-gene VIII fusion protein. Removal of the amber codon was performed by mutagenesis using the following oligonucleotide: 5'-
5 GCCTTCAGCCTCGGATCCGCC-3' (SEQ ID NO: 59). The full sequence of M13IX421 is shown in Figure 9 (SEQ ID NO: 5).

Library Construction, Screening and Characterization of Encoded Oligonucleotides

A sublibrary was constructed for each of the 10 previously described degenerate populations of oligonucleotides. The left half population of oligonucleotides was incorporated into M13ED03 to generate the sublibrary M13ED03.L and the right half population of oligonucleotides was incorporated into M13IX421 to generate 15 the sublibrary M13IX421.R. Each of the oligonucleotide populations were incorporated into their respective vectors using site-directed mutagenesis as described in Example I. Briefly, the nucleotide sequences flanking the degenerate codon sequences were complementary to the vector at the 20 site of incorporation. The populations of nucleotides were hybridized to single-stranded M13ED03 or M13IX421 vectors and extended with T4 DNA polymerase to generate a double-stranded circular vector. Mutant templates were obtained by uridine selection in vivo, as described by Kunkel et 25 al., supra. Each of the vector populations were electroporated into host cells and propagated as described in Example I.

The random joining of right and left half sublibraries into a single surface expression library was 30 accomplished as described in Example I except that prior to digesting each vector population with Fok I they were first digested with an enzyme that cuts in the unwanted portion of each vector. Briefly, M13ED03.L was digested with Bgl II (cuts at 7094) and M13IX421.R was digested with Hind III

(cuts at 3919). Each of the digested populations were further treated with alkaline phosphatase to ensure that the ends would not religate and then digest d with an excess of Fok I. Ligations, electroporation and 5 propagation of the resultant library was performed as described in Example I.

The surface expression library was screened for ligand binding proteins using a modified panning procedure. 10 Briefly, 1 ml of the library, about 10^{12} phage particles, was added to 1-5 μ g of the ligand binding protein. The ligand binding protein was either an antibody or receptor globulin (Rg) molecule, Aruffo et al., Cell 61:1303-1313 (1990), which is incorporated herein by reference. Phage 15 were incubated shaking with affinity ligand at room temperature for 1 to 3 hours followed by the addition of 200 μ l of 1 μ m latex beads (Biosite, San Diego, CA) which were coated with goat-antimouse IgG. This mixture was incubated shaking for an additional 1-2 hours at room 20 temperature. Beads were pelleted for 2 minutes by centrifugation in a microfuge and washed with TBS which can contain 0.1% Tween 20. Three additional washes were performed where the last wash did not contain any Tween 20.

Beads containing bound phage were added to plates at 25 a concentration that produces a suitable density for plaque identification screening and sequencing of positive clones (i.e., plated at confluence for rare clones and 200-500 plaques/plate if pure plaques were needed). Briefly, plaques grown for about 6 hours at 37°C were overlaid with 30 nitrocellulose filters that had been soaked in 2 mM IPTG and briefly dried. The filters remained on the plaques overnight at room temperature, removed and placed in blocking solution for 1-2 hours. Following blocking, the filters were incubated in 1 μ g/ml ligand binding protein in 35 blocking solution for 1-2 hours at room temperature. Goat antimouse Ig-coupled alkaline phosphatase (Fisher) was

added at a 1:1000 dilution and the filters were rapidly washed with 10 mls of TBS or block solution over a glass vacuum filter. Positive plaques were identified after alkaline phosphatase development for detection.

5 Alternatively, the bound phage were eluted from the beads using 200 μ l 0.1 M Glycine-HCl, pH 2.2, for 15 minutes and the beads were removed by centrifugation. The supernatant containing phage (eluate) was removed and phage exhibiting binding to the ligand binding protein were 10 further enriched by one to two more cycles of panning. The eluates were screened by plaque formation, as described above. Typical yields after the first eluate were about 1×10^6 - 5×10^6 pfu. The second and third eluate generally yielded about 5×10^6 - 2×10^7 pfu and 5×10^7 - 1×10^{10} 15 pfu, respectively.

Screening of the degenerate oligonucleotide library with several different ligand binding proteins resulted in the identification of peptide sequences which bound to each of the ligands. For example, screening with 20 an antibody to β -endorphin resulted in the detection of about 30-40 different clones which essentially all had the core amino acid sequence known to interact with the antibody. The sequences flanking the core sequences were different showing that they were independently derived and 25 not duplicates of the same clone. Screening with an antibody known as 57 gave similar results (i.e., a core consensus sequence was identified but the flanking sequences among the clones were different).

EXAMPLE IV

30 Generation of a Left Half Random Oligonucleotide Library

This example shows the synthesis and construction of a left half random oligonucleotide library.

A population of random oligonucleotides nine codons in length was synthesized as described in Example I except that different sequences at their 5' and 3' ends were synthesized so that they could be easily inserted into 5 the vector by mutagenesis. Also, the mixing and dividing steps for generating random distributions of reaction products was performed by the alternative method of dispensing equal volumes of bead suspensions. The liquid chosen that was dense enough for the beads to remain 10 dispersed was 100% acetonitrile.

Briefly, each column was prepared for the first coupling reaction by suspending 22 mg (1 μ mole) of 48 μ mol/g capacity beads (Genta, San Diego, CA) in 0.5 mls of 100% acetonitrile. These beads are smaller than those described 15 in Example I and are derivatized with a guanine nucleotide. They also do not have a controlled pore size. The bead suspension was then transferred to an empty reaction column. Suspensions were kept relatively dispersed by gently pipetting the suspension during transfer. Columns 20 were plugged and monomer coupling reactions were performed as shown in Table XII.

Table XII

	<u>Column</u>	<u>Sequence (5' to 3')</u>
25	column 1L	AA(A/C)GGCTTTGCCACAGG
	column 2L	AG(A/G)GGCTTTGCCACAGG
	column 3L	AT(A/G)GGCTTTGCCACAGG
	column 4L	AC(A/G)GGCTTTGCCACAGG
	column 5L	CA(G/T)GGCTTTGCCACAGG
30	column 6L	CT(G/C)GGCTTTGCCACAGG
	column 7L	AG(T/C)GGCTTTGCCACAGG
	column 8L	AT(T/C)GGCTTTGCCACAGG
	column 9L	CC(A/C)GGCTTTGCCACAGG
	column 10L	T(A/T)GGCTTTGCCACAGG

After coupling of the last monomer, the columns were unplugged as described previously and their contents were poured into a 1.5 ml microfuge tube. The columns were rinsed with 100% acetonitrile to recover any remaining beads. The volume used for rinsing was determined so that the final volume of total bead suspension was about 100 μ l for each new reaction column that the beads would be aliquoted into. The mixture was vortexed gently to produce a uniformly dispersed suspension and then divided, with constant pipetting of the mixture, into equal volumes. Each mixture of beads was then transferred to an empty reaction column. The empty tubes were washed with a small volume of 100% acetonitrile and also transferred to their respective columns. Random codon positions 2 through 9 were then synthesized as described in Example I where the mixing and dividing steps were performed using a suspension in 100% acetonitrile. The coupling reactions for codon positions 2 through 9 are shown in Table XIII.

Table XIII

	<u>Column</u>	<u>Sequence (5' to 3')</u>
20	column 1L	AA(A/C)A
	column 2L	AG(A/G)A
	column 3L	AT(A/G)A
25	column 4L	AC(A/G)A
	column 5L	CA(G/T)A
	column 6L	CT(G/C)A
	column 7L	AG(T/C)A
	column 8L	AT(T/C)A
30	column 9L	CC(A/C)A
	column 10L	T(A/T)TA

After coupling of the last monomer for the ninth codon position, the reaction products were mixed and a portion was transferred to an empty reaction column.

Columns were plugged and the following monomer coupling reactions were performed: 5'-CGGATGCCTCAGAAGCCCCXXA-3' (SEQ ID NO: 60). The resulting population of random oligonucleotides was purified and incorporated by 5 mutagenesis into the left half vector M13ED04.

M13ED04 is a modified version of the M13ED03 vector described in Example III and therefore contains all the features of that vector. The difference between M13ED03 and M13ED04 is that M13ED04 does not contain the 10 five amino acid sequence (Tyr Gly Gly Phe Met) recognized by anti- β -endorphin antibody. This sequence was deleted by mutagenesis using the oligonucleotide 5'-CGGATGCCTCAGAAGGGCTTTGCCACAGG (SEQ ID NO: 61). The entire nucleotide sequence of this vector is shown in Figure 10 15 (SEQ ID NO: 6).

EXAMPLE V

Generation of Soluble, Conformationally-Constrained Random Peptides

This example shows the synthesis and construction 20 of expressible oligonucleotides encoding soluble peptides having a constrained secondary structure in solution.

As noted previously, the binding affinity of a peptide for a ligand-binding protein is a function of the primary and secondary structure of the peptide. The effect 25 of primary structure on affinity may be determined as disclosed in the above examples.

In its broadest form, the disclosed method provides oligonucleotides that are synthesized having a desired bias of predetermined codons such that the 30 oligonucleotides encode peptides having a constrained secondary structure in aqueous solution. In a preferred

mbodiment, oligonucleotides encoding peptides having a constrained secondary structure are synthesized having a desired bias of predetermined codons such that the predetermined codons are separated by at least one random 5 codon.

Oligonucleotides having more than one tuplet encoding an amino acid capable of forming a covalent bond at a predetermined position and the remaining positions having random triplets are synthesized using the methods 10 described herein. The synthesis steps are similar to those outlined above using twenty or less reaction vessels except that prior to synthesis of the specified codon position, the dividing of the supports into separate reaction vessels for synthesis of different codons is omitted. For example, 15 if the codon at the second position of the oligonucleotide is to be specified, then following synthesis of random codons at the first position and mixing of the supports, the mixed supports are not divided into new reaction vessels but, instead, are contained in a single reaction 20 vessel to synthesize the specified codon. The specified codon is synthesized sequentially from individual monomers as described above. Thus, the number of reaction vessels is increased or decreased at each step to allow for the synthesis of a specified codon or a desired number of 25 random codons.

Alternatively, a population of random left and right precursor oligonucleotides are synthesized essentially as described in Example I, except that at least one predetermined codon encoding cysteine, lysine, glutamic 30 acid, leucine or tyrosine is incorporated into each oligonucleotide. Combination of right and left oligonucleotides results in a single oligonucleotide containing at least two predetermined codons. Alternatively, a population of random oligonucleotides is 35 synthesized as described in Example II, except that at

least two predetermined codons encoding cysteine, lysine, glutamic acid, leucine or tyrosine are incorporated into only one of the two precursor oligonucleotide populations.

Following expression of the oligonucleotides, a 5 peptide having a constrained secondary structure is obtained by allowing the formation of at least one intra-peptide covalent bond. One skilled in the art would know the conditions necessary to allow formation of the particular covalent bond. See, for example, Proteins, 10 Structures and Molecular Principles, Creighton, T.E. ed., W.H. Freeman and Co., New York (1984), incorporated herein by reference. Although oligonucleotides can encode peptides capable of forming more than one intra-peptide covalent bond, only one such bond is necessary to form a 15 conformationally-constrained peptide.

The peptide libraries are expressed on the surface of a cell, for example, a bacteriophage. Phage expressing peptide ligands are initially identified by panning, essentially as described in Example I, except that 20 the phage are first incubated in the presence of a ligand-binding protein (in this example, an antibody), then panned in protein A-coated dishes. Individual phage populations are purified through three rounds of plaque purification, essentially as described in Example I.

25 Two phage encoding peptides showing significantly higher ligand binding affinity than the general phage population are isolated, the oligonucleotide sequences are determined and the amino acid sequences deduced. The ligand binds with highest affinity to a twenty-two amino 30 acid peptide having the sequence TQSKCSTDHWLGYIEYFIMCTY (SEQ. ID. NO.: 62). The ligand also binds with high affinity to a peptide having the sequence CDDQYYTDHEQGKCEVALYYTG (SEQ. ID. NO.: 63).

The above-identified peptides are each capable of forming several intra-peptide covalent bonds. For example, a disulfide bond may form between two cysteine residues, a $\epsilon(\gamma\text{-glutamyl})$ -lysine bond may form between lysine and 5 glutamic acid residues, a lysinonorleucine bond may form between lysine and leucine residues or a dityrosine bond can form between two tyrosine residues (Devlin, Textbook of Biochemistry 3d ed. (1992)). In addition, other peptides can be constructed that contain, for example, four lysine 10 residues, which can form the heterocyclic structure of desmosine.

The nature of the covalent bond in the peptide having the sequence TQSKCSTDHWLGYIEYFIMCTY (SEQ. ID. NO.: 62) is determined by examining the effect of amino acid 15 substitutions on the binding affinity of the ligand, by methods known to those skilled in the art, and described herein. Creighton, supra, pp. 335-396, incorporated herein by reference.

The oligonucleotide encoding this peptide is 20 cloned into a vector that allowed secretion of the expressed peptide. The peptide TQSKCSTDHWLGYIEYFIMCTY (SEQ. ID. NO.: 62) is soluble at a concentration of 4 mg/ml. The same peptide, except containing the substitution of alanine for cysteine is insoluble at this 25 concentration.

EXAMPLE VI

Binding Studies Using Conformationally Constrained Peptides

The association constant (K_a), dissociation 30 constant (K_d) and affinity constant (K) were determined for the r action of a monoclonal antibody with the linear or the cyclized form of a peptide, using a BIACore automated biosensor (Pharmacia Biosensor AB, Uppsala, Sweden), as

described by Karlsson et al., J. Immunol. Meth. 145:229-240 (1991). A 24 amino acid peptide, TQSKCSTDHWLGYIEYFIMCTYRR (SEQ. ID. NO.: 64), which is recognized by the J2B9 monoclonal antibody, was used for these experiments. The 5 peptide contains two cysteine residues that form a disulfide bond under oxidizing conditions.

The cyclized form of the peptide was immobilized by its amino terminus to the BIAcore sensor chip and exposed to 0.016, 0.033, 0.066, 0.13 or 2.3 nM solutions of 10 the J2B9 antibody. Changes in refractive index were measured and the formulas described by Karlsson et al., supra, were used to calculate the following rate and affinity constants: $K_a = 3.7 \times 10^5 \text{ M}^{-1}\text{s}^{-1}$; $K_d = 4.5 \times 10^{-4} \text{ sec}^{-1}$ and $K = 8.4 \times 10^8 \text{ M}$.

15 After the above-described measurements were obtained, the disulfide bond was reduced by treating the cyclized peptide with 10 mM dithiothreitol, while the peptide was still attached to the BIAcore sensor chip. The dissociation rate of the linear peptide and the J2B9 20 monoclonal antibody was then determined, as described above.

The dissociation rate of the J2B9 antibody and the linear peptide was calculated to be $1.54 \times 10^{-3} \text{ sec}$. Thus, the antibody dissociated from the linear peptide 25 three times faster than it dissociated from the cyclized peptide. Reoxidation of the linearized peptide to reform the cyclized peptide resulted in the dissociation rate again decreasing to the 10^{-4} range. These results show that a conformationally constrained peptide binds a specific 30 receptor with greater affinity than a peptide with a less stable secondary structure.

EXAMPLE VIISoluble, Conformationally-Constrained Random Peptides Having High Affinity to An Anti-Tetanus Toxin Antibody

This example shows the synthesis and construction of
5 expressible random oligonucleotides encoding soluble
peptides with constrained secondary structures and the
selection of high affinity binders to an anti-tetanus
toxin antibody.

Oligonucleotide Synthesis

10 Random oligonucleotides of ten codons in length were
synthesized as right and left half precursors essentially
as described in Example I. When combined, they yield an
oligonucleotide coding for twenty amino acid long random
peptides. Codons for cysteine were used to produce
15 peptides with a potential for forming covalent bonds for
secondary structure constraints. In contrast to that
described in Example V where the amino acids used for
cyclization of the peptides were placed at predetermined
positions, the cysteine codons were introduced at all
20 positions with a predetermined bias compared to the other
nineteen random codons.

Briefly, ten reaction vessels were used for the
synthesis of twenty random codons at each codon position
essentially as described in Example I. In addition to
25 the normal ten reaction vessels used for synthesis, an
extra two reaction vessels were used for the synthesis of
the two cysteine codons, TGC and TGT. Thus, the
synthesis procedure used a total of twelve reaction
vessels for the synthesis of each codon position where
30 the frequency of cysteine codons at each position is
twenty percent. The 5' and 3' flanking sequences for the
right and left half oligonucleotides were those described

in Example I. The use of the extra two vessels encoding cysteine residues results in the increased frequency of cysteine being incorporated at each codon position. This increased frequency insures the presence of residues 5 capable of forming covalent bonds for constraining the peptide's secondary structure. Moreover, the random incorporation of cysteines at each of the codon positions, instead of incorporation at predetermined positions, increases the probability of obtaining 10 peptides with a constrained conformation and, thus, a high affinity toward a binding protein since a greater number of peptides are available to screen.

Library Construction and Screening

15 Library construction from right and left half oligonucleotides were generated as described in Example I. The libraries were screened for peptides that bind to an anti-tetanus toxin antibody essentially as described in Example III. After two rounds of panning, eight phage clones were selected that showed high affinity binding to 20 the antibody. Sequencing of the encoding nucleic acids revealed seven peptides having cysteines spaced at ten residues apart and one peptide having cysteines were seven residues apart. The sequences are shown in Table XIV and are listed in the sequencing listing as SEQ ID 25 NOS: 65 through 72.

Table XIV

Conformationally Constrained Peptides Having High Affinity for Anti-Tetanus Toxin Antibody

Although the invention has been described with reference to the presently preferred embodiment, it should be understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: IXSYS, INC.

(ii) TITLE OF INVENTION: Soluble Peptides Having Constrained, Secondary Conformation in Solution and Method of Making Same.

(iii) NUMBER OF SEQUENCES: 72

(iv) CORRESPONDENCE ADDRESS:

- (A) ADDRESSEE: Campbell and Flores
- (B) STREET: 4370 La Jolla Village Drive, Suite 700
- (C) CITY: San Diego
- (D) STATE: California
- (E) COUNTRY: USA
- (F) ZIP: 92122

(v) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:

- (A) APPLICATION NUMBER:
- (B) FILING DATE: 10-NOV-1993
- (C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

- (A) APPLICATION NUMBER: US 07/978,893
- (B) FILING DATE: 10-NOV-1992

(viii) ATTORNEY/AGENT INFORMATION:

- (A) NAME: Konski, Antoinette F.
- (B) REGISTRATION NUMBER: 34,202
- (C) REFERENCE/DOCKET NUMBER: FP-IX 9769

(ix) TELECOMMUNICATION INFORMATION:

- (A) TELEPHONE: (619) 535-9001
- (B) TELEFAX: (619) 535-8949

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7294 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: both
- (D) TOPOLOGY: circular

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

AATGCTACTA CTATTAGTAG AATTGATGCC ACCTTTTCAG CTCGGCGCC	60
ATAGCTAAC AGGTTATTGA CCATTTGCGA AATGTATCTA ATGGTCAAAC TAAATCTACT	120
CGTCGCAGA ATTGGGAATC AACTGTTACA TGGAATGAAA CTTCCAGACA CCGTACTTTA	180
GTTGCATATT TAAAACATGT TGAGCTACAG CACCAAGATTC AGCAATTAAG CTCTAAGCCA	240
TCTGCAAAA TGACCTCTTA TCAAAAGGAG CAATTAAGG TACTCTCTAA TCCTGACCTG	300

TTGGAGTTTG	CTTCGGTCT	GGTCGCTTT	GAAGCTCGAA	TTAAAACGCG	ATATTGAAAG	360
TCTTCGGGC	TTCCTCTAA	TCTTTTGAT	GCAATCCGCT	TTGCTTCTGA	CTATAATAGT	420
CAGGGTAAAG	ACCTGATTT	TGATTTATGG	TCATTCTCGT	TTTCTGAAC	GTTAAAGCA	480
TTTGAGGGGG	ATTCAATGAA	TATTTATGAC	GATTCCGCAG	TATTGGACGC	TATCCAGTCT	540
AAACATTTA	CTATTACCCC	CTCTGGCAAA	ACTTCTTTG	CAAAGGCCTC	TCGCTATTT	600
GGTTTTATC	GTCGTCTGGT	AAACGAGGGT	TATGATAGTG	TTGCTCTTAC	TATGCCTCGT	660
AATTCCCTTT	GGCGTTATGT	ATCTGCATTA	GTTGAATGTG	GTATTCCCTAA	ATCTCAACTG	720
ATGAATCTTT	CTACCTGTAA	TAATGTTGTT	CCGTTAGTTC	TTTTTATTAA	CGTAGATTT	780
TCTTCCCAAC	GTCCTGACTG	GTATAATGAG	CCAGTTCTTA	AAATCGCATA	AGGTAATTCA	840
CAATGATTAA	AGTTGAAATT	AAACCATCTC	AAGCCCAATT	TACTACTCGT	TCTGGTGT	900
CTCGTCAGGG	CAAGCCTTAT	TCACTGAATG	AGCAGCTTG	TTACGTTGAT	TTGGGTAATG	960
AATATCCGGT	TCTTGTCAAG	ATTACTCTTG	ATGAAGGTCA	GCCAGCCTAT	GCGCCTGGTC	1020
TGTACACCGT	TCATCTGTCC	TCTTCAAAG	TTGGTCAGTT	CGGTTCCCTT	ATGATTGACC	1080
GTCTGCGCCT	CGTTCCGGCT	AAAGTAACATG	GAGCAGGTG	CGGATTTCGA	CACAATTTAT	1140
CAGGCGATGA	TACAAATCTC	CGTTGTACTT	TGTTTCCGCG	TTGGTATAAT	CGCTGGGGGT	1200
CAAAGATGAG	TGTTTAGTG	TATTCTTCG	CCTCTTCGT	TTAGGGTTGG	TGCCTTCGTA	1260
GTGGCATTAC	GTATTTACC	CGTTTAATGG	AAACTCCCTC	ATGAAAAAGT	CTTTAGTCCT	1320
CAAAGCCTCT	GTAGCCGTTG	CTACCCCTCGT	TCCGATGCTG	TCTTTCGCTG	CTGAGGGTGA	1380
CGATCCCGCA	AAAGCGGCCT	TTAACTCCCT	GCAAGCCTCA	GCGACCGAAT	ATATCGGTTA	1440
TGCGTGGCG	ATGGTTGTTG	TCATTGTCGG	CGCAACTATC	GGTATCAAGC	TGTTAAGAA	1500
ATTCACCTCG	AAAGCAAGCT	GATAAACCGA	TACAATTAAA	GGCTCCTTTT	GGAGCCTTTT	1560
TTTTTGGAGA	TTTCAACGT	GAAAAAATTA	TTATTGCAA	TTCTTTAGT	TGTTCTTTTC	1620
TATTCTCACT	CCGCTGAAAC	TGTTGAAAGT	TGTTAGCAA	AAACCCATAC	AGAAAATTCA	1680
TTTACTAACG	TCTGGAAAGA	CGACAAAAC	TTAGATCGTT	ACGCTAACTA	TGAGGGTTGT	1740
CTGTGGAATG	CTACAGGCGT	TGTTAGTTGT	ACTGGTACG	AAACTCAGTG	TTACGGTACA	1800
TGGGTTCTA	TTGGGCTTGC	TATCCCTGAA	AATGAGGGTG	GTGGCTCTGA	GGGTGGCGGT	1860
TCTGAGGGTG	GCGGTTCTGA	GGGTGGCGGT	ACTAAACCTC	CTGAGTACGG	TGATACACCT	1920
ATTCCGGGCT	ATACTTATAT	CAACCCCTCTC	GACGGCACTT	ATCCGCTGG	TACTGAGCAA	1980
AAACCCCGCTA	ATCCTAATCC	TTCTCTTGAG	GAGTCTCAGC	CTCTTAATAC	TTTCATGTTT	2040
CAGAATAATA	GGTTCCGAAA	TAGGCAGGGG	GCATTAAC	TTTATACGGG	CACTGTTACT	2100
CAAGGCACTG	ACCCCGTTAA	AACTTATTAC	CAGTACACTC	CTGTATCCTC	AAAAGCCATG	2160
TATGACGCTT	ACTGGAACGG	TAAATTCAAGA	GAATGCGCTT	TCCATTCTGG	CTTTAATGAA	2220
GATCCATTG	TTTGTGAATA	TCAAGGCCAA	TCGTCTGACC	TGCCTCAACC	TCCTGTCAAT	2280
GCTGGCGGCG	GCTCTGGTGG	TGGTTCTGGT	GGCGGCTCTG	AGGGTGGTGG	CTCTGAGGGT	2340

GGCGGTTCTG	AGGGTGGCGG	CTCTGAGGGA	GGCGGTTCCG	GTGGTGGCTC	TGGTTCCGGT	2400
GATTTTGATT	ATGAAAAGAT	GGCAAACGCT	AATAAGGGGG	CTATGACCGA	AAATGCCGAT	2460
GAAAACGCGC	TACAGTCTGA	CGCTAAAGGC	AAACTTGATT	CTGTCGCTAC	TGATTACGGT	2520
GCTGCTATCG	ATGGTTTCAT	TGGTGACGTT	TCCGGCCTTG	CTAATGGTAA	TGGTGCTACT	2580
GGTGATTTG	CTGGCTCTAA	TTCCCAAATG	GCTCAAGTCG	GTGACGGTGA	TAATTCACCT	2640
TTAATGAATA	ATTTCCGTCA	ATATTTACCT	TCCCTCCCTC	AATCGGTTGA	ATGTCGCCCT	2700
TTTGTCTTTA	GCGCTGGTAA	ACCATATGAA	TTTTCTATTG	ATTGTGACAA	AATAAACTTA	2760
TTCCCGTGGTG	TCTTTGCGTT	TCTTTTATAT	GTTGCCACCT	TTATGTATGT	ATTTTCTACG	2820
TTTGCTAACAA	TACTGCGTAA	TAAGGAGTCT	TAATCATGCC	AGTTCTTTG	GGTATTCCGT	2880
TATTATTGCG	TTTCCTCGGT	TTCCCTCTGG	TAACTTGTT	CGGCTATCTG	CTTACTTTTC	2940
TTAAAAAGGG	CTTCGGTAAG	ATAGCTATTG	CTATTCATT	GTTTCTTGCT	CTTATTATTG	3000
GGCTTAACTC	AATTCTTGTG	GGTTATCTCT	CTGATATTAG	CGCTCAATTA	CCCTCTGACT	3060
TTGTTCAAGGG	TGTTCAGTTA	ATTCTCCCGT	CTAATGCGCT	TCCCTGTTT	TATGTTATTC	3120
TCTCTGTAAA	GGCTGCTATT	TTCATTTTG	ACGTTAAACA	AAAAATCGTT	TCTTATTG	3180
ATTGGGATAA	ATAATATGGC	TGTTTATTTT	GTAACTGGCA	AATTAGGCTC	TGGAAAGACG	3240
CTCGTTAGCG	TTGGTAAGAT	TCAGGATAAA	ATTGTAGCTG	GGTGCAAAAT	AGCAACTAAT	3300
CTTGATTTAA	GGCTTCAAAA	CCTCCCGCAA	GTCGGGAGGT	TCGCTAAAC	GCCTCGCGTT	3360
CTTAGAATAC	CGGATAAGCC	TTCTATATCT	GATTTGCTTG	CTATTGGCG	CGGTAATGAT	3420
TCCTACGATG	AAAATAAAA	CGGCTTGCTT	GTTCTCGATG	AGTGCAGTAC	TTGGTTAAT	3480
ACCCGTTCTT	GGAATGATAA	GGAAAGACAG	CCGATTATTG	ATTGGTTCT	ACATGCTCGT	3540
AAATTAGGAT	GGGATATTAT	CTTCCTGTT	CAGGACTTAT	CTATTGTTGA	AAAACAGGCG	3600
CGTTCTGCAT	TAGCTGAACA	TGTTGTTAT	TGTCGTCGTC	TGGACAGAAT	TACTTACCT	3660
TTTGTGGTA	CTTTATATTC	TCTTATTACT	GGCTGAAAAA	TGCCCTGCCC	AAAATTACAT	3720
GTTGGCGTTG	TTAAATATGG	CGATTCTCAA	TTAAGCCCTA	CTGTTGAGCG	TTGGTTTAT	3780
ACTGGTAAGA	ATTTGTATAA	CGCATATGAT	ACTAAACAGG	CTTTTCTAG	TAATTATGAT	3840
TCCGGTGT	ATTCTTATTT	AACGCCCTAT	TTATCACACG	GTCGGTATTT	CAAACCATTA	3900
AATTAGGTC	AGAAGATGAA	GCTTACTAAA	ATATATTGAA	AAAAGTTTC	ACGCGTTCTT	3960
TGTCTTGC	TTGGATTTC	ATCAGCATT	ACATATAGTT	ATATAACCCA	ACCTAACGCCG	4020
GAGGTTAAAA	AGGTAGTCTC	TCAGACCTAT	GATTTGATA	AATTCACTAT	TGACTCTTCT	4080
CAGCGTCTTA	ATCTAACGCTA	TCGCTATGTT	TTCAAGGATT	CTAAGGGAAA	ATTAATTAAT	4140
AGCGACGATT	TACAGAACCA	AGGTTATTCA	CTCACATATA	TTGATTTATG	TACTGTTCC	4200
ATTAAGGAGG	TAATTCAAAT	GAAATTGTTA	AATGTAATT	ATTTGTTTT	CTTGATGTTT	4260
GTTCATCAT	CTTCTTTGC	TCAGGTAATT	GAAATGAATA	ATTGCGCTCT	GCGCGATTTT	4320
GTAACCTGGT	ATTCAAAGCA	ATCAGGCGAA	TCCGTTATTG	TTTCTCCCGA	TGTAAAAGGT	4380

ACTGTTACTG TATATTCA	TGACGTTAAA CCTGAAAATC TACGCAATT	TTTATTCT	4440		
GT	TTTACGTG CTAATAATT	TGATATGGTT GGTTCAATT	CTTCCATT	TTAGAAGTAT	4500
AATCCAAACA ATCAGGATTA	TATTGATGAA TTGCCATCAT CTGATAATCA GGAATATGAT	4560			
GATAATTCCG CTCCTTCTGG	TGGTTCTTT GTTCCGAAA ATGATAATGT TACTCAA	4620			
TTTAAAATTA ATAACGTTG	GGCAAAGGAT TTAATACGAG TTGTCGAATT GTTGTAAAG	4680			
TCTAATAC	TT CTAATCCTC AAATGTATTA TCTATTGACG GCTCTAATCT ATTAGTTGTT	4740			
AGTGCACCTA AAGATATTT	AGATAACCTT CCTCAATTCC TTTCTACTGT TGATTGCA	4800			
ACTGACCAGA TATTGATTGA	GGGTTGATA TTTGAGGTT AGCAAGGTGA TGCTTAGAT	4860			
TTTTCATTG CTGCTGGCTC	TCAGCGTGGC ACTGTTGCAG GCGGTGTTAA TACTGACC	4920			
CTCACCTCTG	TTTATCTTC TGCTGGTGGT TCGTTCGGTA TTTTAATGG CGATGTTTA	4980			
GGGCTATCAG TTGCGCATT	AAAGACTAAT AGCCATTCAA AAATATTGTC TGTGCCACGT	5040			
ATTCTTACGC	TTTCAGGTCA GAAGGGTTCT ATCTCTGTTG GCCAGAATGT CCCTTTATT	5100			
ACTGGTCGTG	TGACTGGTGA ATCTGCCAAT GTAAATAATC CATTTCAGAC GATTGAGCGT	5160			
CAAAATGTAG	GTATTCAT GAGCGTTTT CCTGTTGCAA TGGCTGGCGG TAATATTGTT	5220			
CTGGATATTA	CCAGCAAGGC CGATAGTTG AGTTCTCTA CTCAGGCAAG TGATGTTATT	5280			
ACTAATCAA	GAAGTATTGC TACAACGGTT AATTGCGTG ATGGACAGAC TCTTTACTC	5340			
GGTGGCCTCA	CTGATTATAA AAACACTTCT CAAGATTCTG GCGTACCGTT CCTGCTAAA	5400			
ATCCCCTTAA	TCGGCCTCCT GTTAGCTCC CGCTCTGATT CCAACGAGGA AAGCACGTTA	5460			
TACGTGCTCG	TCAAAGCAAC CATACTACGC GCCCTGTAGC GGCGCATTAA GCGCGGCGGG	5520			
TGTGGTGGTT	ACGCGCAGCG TGACCGCTAC ACTTGCCAGC GCCCTAGCGC CCGCTCCTTT	5580			
CGCTTCTTC	CCTTCCTTTC TCGCCACGTT CGCCGGCTTT CCCCCTCAAG CTCTAAATCG	5640			
GGGGCTCCCT	TTAGGGTTCC GATTTAGTGC TTTACGGCAC CTCGACCCCCA AAAAATTGA	5700			
TTTGGGTGAT	GGTCACGTA GTGGGCCATC GCCCTGATAG ACGGTTTTTC GCCCTTGAC	5760			
GTTGGAGTCC	ACGTTCTTA ATAGTGGACT CTTGTTCAA ACTGGAACAA CACTCAACCC	5820			
TATCTCGGGC	TATTCTTTG ATTATAAGG GATTTGCCG ATTTCGGAAC CACCATCAA	5880			
CAGGATTTTC	GCCTGCTGGG GCAAACCAAGC GTGGACCGCT TGCTGCAACT CTCTCAGGGC	5940			
CAGGGGGTGA	AGGGCAATCA GCTGTTGCCG GTCTCGCTGG TGAAAAGAAA AACCAACCTG	6000			
GCGCCCAATA	CGCAAACCGC CTCTCCCGC GCGTTGGCCG ATTCAATTAT GCAGCTGGCA	6060			
CGACAGGTTT	CCCGACTGGA AAGCGGGCAG TGAGCGAAC GCAATTAAAT TGAGTTAGCT	6120			
CACTCATTAG	GCACCCCCAGG CTTTACACTT TATGCTTCCG GCTCGTATGT TGTGTGGAAT	6180			
TGTGAGCGGA	TAACAATTTC ACACAGGAAA CAGCTATGAC CAGGATGTAC GAATTGCGAG	6240			
GTAGGAGAGC	TCGGCGGATC CTAGGCTGAA GGCGATGACC CTGCTAAGGC TGCATTCAAT	6300			
AGTTTACAGG	CAAGTGCTAC TGAGTACATT GGCTACGCTT GGGCTATGGT AGTAGTTATA	6360			
GTTGGTGCTA	CCATAGGGAT TAAATTATTC AAAAGTTTA CGAGCAAGGC TTCTTAACCA	6420			

GCTGGCGTAA TAGCGAAGAG GCCCCCACCG ATCGCCCTTC CCAACAGTTG CGCAGCCTGA	6480
ATGGCGAATG GCGCTTGCCTGG CACCAAGAAGC GGTGCCGGAA AGCTGGCTGG	6540
AGTGGATCT TCCTGAGGCC GATACTGGTCG TCGTCCCTC AAACCTGGCAG ATGCACGGTT	6600
ACGATGCGCC CATCTACACC AACGTAACCT ATCCCATTAC GGTCAATCCG CCGTTGTTTC	6660
CCACGGAGAA TCCGACGGGT TGTTACTCGC TCACATTAA TGTTGATGAA AGCTGGCTAC	6720
AGGAAGGCCA GACGCGAATT ATTTTGATG GCGTTCTAT TGTTAAAAAA ATGAGCTGAT	6780
TTAACAAAAA TTTAACGCGA ATTTAACAA AATATTAACG TTACAAATT AAATATTTGC	6840
TTATACAAATC TTCTGTTTT TGGGGCTTTT CTGATTATCA ACCGGGGTAC ATATGATTGA	6900
CATGCTAGTT TTACGATTAC CGTTCATCGA TTCTCTGTT TGCTCCAGAC TCTCAGGCAA	6960
TGACCTGATA GCCTTTGTAG ATCTCTAAA AATAGCTACC CTCTCCGGCA TTAATTATC	7020
AGCTAGAACG GTTGAATATC ATATTGATGG TGATTTGACT GTCTCCGGCC TTTCTCACCC	7080
TTTTGAATCT TTACCTACAC ATTACTCAGG CATTGCATTT AAAATATATG AGGGTTCTAA	7140
AAATTTTAT CCTTGCCTTG AAATAAAGGC TTCTCCCGCA AAAGTATTAC AGGGTCATAA	7200
TGTTTTGGT ACAACCGATT TAGCTTATG CTCTGAGGCT TTATTGCTTA ATTTGCTAA	7260
TTCTTGCCT TGCCTGTATG ATTTATTGGA CGTT	7294

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7320 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: both
- (D) TOPOLOGY: circular

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

AATGCTACTA CTATTAGTAG AATTGATGCC ACCTTTCAAG CTCGCGCCCC AAATGAAAAT	60
ATAGCTAAAC AGGTTATTGA CCATTGCGA AATGTATCTA ATGGTCAAAC TAAATCTACT	120
CGTTCGCAGA ATTGGGAATC AACTGTTACA TGGAATGAAA CTTCCAGACA CCGTACTTTA	180
GTTGCATATT TAAAACATGT TGAGCTACAG CACCAAGATTG AGCAATTAAG CTCTAAGCCA	240
TCTGCAAAAA TGACCTCTTA TCAAAAGGAG CAATTAAAGG TACTCTCTAA TCCTGACCTG	300
TTGGAGTTTG CTTCCGGTCT GGTCGCTTT GAAGCTCGAA TTAACACGG ATATTGAAAG	360
TCTTCGGGC TTCCTCTAA TCTTTTGAT GCAATCCGCT TTGCTTCTGA CTATAATAGT	420
CAGGGTAAAG ACCTGATTT TGATTTATGG TCATTCTCGT TTTCTGAACG GTTTAAAGCA	480
TTTGAGGGGG ATTCAATGAA TATTATGAC GATTCCGCAG TATTGGACGC TATCCAGTCT	540
AAACATTTA CTATTACCCC CTCTGGCAAA ACTTCTTTG CAAAAGCCTC TCGCTATTAA	600
GGTTTTATC GTCGTCTGGT AAACGAGGGT TATGATAGTG TTGCTCTTAC TATGCCCTCGT	660
AATTCCCTTT GGCGTTATGT ATCTGCATTA GTTGAATGTG GTATTCCCTAA ATCTCAACTG	720
ATGAATCTT CTACCTGTAA TAATGTTGTT CCGTTAGTTC GTTTATTAA CGTAGATTAA	780

TCTTCCTAAC	GTCCTGACTG	GTATAATGAG	CCAGTTCTTA	AAATCGCATA	AGGTAATTCA	840
CAATGATTAA	AGTTGAAATT	AAACCATCTC	AAGCCCAATT	TACTACTCGT	TCTGGTGT	900
CTCGTCAGGG	CAAGCCTTAT	TCACTGAATG	AGCAGCTTG	TTACGTTGAT	TTGGGTAATG	960
AAATATCCGGT	TCTTGTCAAG	ATTACTCTTG	ATGAAGGTCA	GCCAGCCTAT	GCGCCTGGTC	1020
TGTACACCGT	TCATCTGTCC	TCTTCAAAG	TTGGTCAGTT	CGGTTCCCTT	ATGATTGACC	1080
GTCTGCGCCT	CGTTCCGGCT	AAGTAACATG	GAGCAGGTG	CGGATTTCGA	CACAATTAT	1140
CAGGGATGA	TACAAATCTC	CGTTGTACTT	TGTTTCCGCG	TTGGTATAAT	CGCTGGGGGT	1200
CAAAGATGAG	TGTTTTAGTG	TATTCTTCG	CCTCTTCGT	TTAGGTTGG	TGCCTTCGTA	1260
GTGGCATTAC	GTATTTTACC	CGTTTAATGG	AAACTTCCTC	ATGAAAAAGT	CTTTAGTCCT	1320
CAAAGCCTCT	GTAGCCGTTG	CTACCCCTCGT	TCCGATGCTG	TCTTCGCTG	CTGAGGGTGA	1380
CGATCCCGCA	AAAGCGGCCT	TTAACTCCCT	GCAAGCCTCA	GCGACCGAAT	ATATCGGTTA	1440
TGCGTGGGCG	ATGGTTGTTG	TCATTGTCGG	CGCAACTATC	GGTATCAAGC	TGTTAAGAA	1500
ATTCACCTCG	AAAGCAAGCT	GATAAACCGA	TACAATTAAA	GGCTCCTTTT	GGAGCCTTTT	1560
TTTTTGGAGA	TTTCAACGT	GAAAAAATTA	TTATTCGAA	TTCTTTAGT	TGTTCTTTTC	1620
TATTCTCACT	CCGCTGAAAC	TGTTGAAAGT	TGTTTAGCAA	AACCCCATAAC	AGAAAATTCA	1680
TTTACTAACG	TCTGGAAAAGA	CGACAAAAC	TTAGATCGTT	ACGCTAACTA	TGAGGGTTGT	1740
CTGTGGAATG	CTACAGGCCT	TGTAGTTGT	ACTGGTGACG	AAACTCAGTG	TTACGGTACA	1800
TGGGTTCCCTA	TTGGGCTTGC	TATCCCTGAA	AATGAGGGTG	GTGGCTCTGA	GGGTGGCGGT	1860
TCTGAGGGTG	GCGGTTCTGA	GGGTGGCGGT	ACTAAACCTC	CTGAGTACGG	TGATACACCT	1920
ATTCCGGGCT	ATACTTATAT	CAACCCCTCTC	GACGGCACTT	ATCCGCCTGG	TACTGAGCAA	1980
AACCCCGCTA	ATCCTAATCC	TTCTCTTGAG	GAGTCTCAGC	CTCTTAATAC	TTTCATGTTT	2040
CAGAATAATA	GGTTCCGAAA	TAGGCAGGGG	GCATTAACTG	TTTATACGGG	CACTGTTACT	2100
CAAGGCACTG	ACCCCCGTTAA	AACTTATTAC	CACTACACTC	CTGTATCCTC	AAAAGCCATG	2160
TATGACGCTT	ACTGGAACGG	AAATTTCAGA	GAUTGCGCTT	TCCATTCTGG	CTTTAATGAA	2220
GATCCATTG	TTTGTGAATA	TCAAGGCCAA	TCGTCTGACC	TGCGCTAAC	TCCTGTCAAT	2280
GCTGGCGGCG	GCTCTGGTGG	TGGTTCTGGT	GGCGGCTCTG	AGGGTGGTGG	CTCTGAGGGT	2340
GGCGGTTCTG	AGGGTGGCGG	CTCTGAGGGG	GGCGGTTCCG	GTGGTGGCTC	TGGTCCGGT	2400
GATTTGATT	ATGAAAAGAT	GGCAAACGCT	AAATAAGGGGG	CTATGACCGA	AAATGCCGAT	2460
GAAAACGCGC	TACAGTCTGA	CGCTAAAGGC	AAACTTGATT	CTGTCGCTAC	TGATTACGGT	2520
GCTGCTATCG	ATGGTTTCAT	TGGTGACGTT	TCCGGCCTTG	CTAATGGTAA	TGGTGCTACT	2580
GGTGATTTG	CTGGCTCTAA	TTCCCAAATG	GCTCAAGTCG	GTGACGGTGA	TAATTCACCT	2640
TTAATGAATA	ATTTCCGTCA	ATATTTACCT	TCCCTCCCTC	AATCGGTTGA	ATGTCGCCCT	2700
TTTGTCTTTA	GCGCTGGTAA	ACCATATGAA	TTTTCTATTG	ATTGTGACAA	AATAAACTTA	2760
TTCCGTGGTG	TCTTTGCGTT	TCTTTATAT	GTTGCCACCT	TTATGTATGT	ATTTTCTACG	2820

TTTGCTAAC A TACTGCGTAA TAAGGAGTCT TAATCATGCC AGTTCTTTG GGTATTCCGT	2880
TATTATTGCG T TCCCTCGGT TCCCTCTGG TAACTTGTT CGGCTATCTG CTTACTTTTC	2940
TTAAAAAGGG CTTCGGTAAG ATAGCTATTG CTATTCATT GTTTCTGCT CTTATTATTG	3000
GGCTTAACTC AATTCTTGTG GGTTATCTCT CTGATATTAG CGCTCAATTA CCCTCTGACT	3060
TTGTTCAGGG TGTTCAGTTA ATTCTCCCGT CTAATGCGCT TCCCTGTTT TATGTTATTC	3120
TCTCTGTAAA GGCTGCTATT TTCATTTTG ACGTTAAACA AAAAATCGTT TCTTATTTGG	3180
ATTGGGATAA ATAATATGGC TGTTTATTTT GTAACTGGCA AATTAGGCTC TGGAAAGACG	3240
CTCGTTAGCG TTGGTAAGAT TTAGGATAAA ATTGTAGCTG GGTGCAAAAT AGCAACTAAT	3300
CTTGATTAA GGCTTCAAAA CCTCCCGCAA GTCGGGAGGT TCGCTAAAC GCCTCGCGTT	3360
CTTAGAATAC CGGATAAGCC TTCTATATCT GATTGCTTG CTATTGGGCG CGGTAATGAT	3420
TCCTACGATG AAAATAAAA CGGCTTGCTT GTTCTCGATG AGTGCAGTAC TTGGTTAAT	3480
ACCCGTTCTT GGAATGATAA GGAAAGACAG CCGATTATTG ATTGGTTCT ACATGCTCGT	3540
AAATTAGGAT GGGATATTAT CTTCTTGTT CAGGACTTAT CTATTGTTGA TAAACAGGCG	3600
CGTTCTGCAT TAGCTGAACA TGTGTTTAT TGTCGTCGTC TGGACAGAAT TACTTTACCT	3660
TTTGTGGTA CTTTATATTC TCTTATTACT GGCTCGAAAA TGCCCTGCCC TAAATTACAT	3720
GTTGGCGTTG TAAATATGG CGATTCTCAA TTAAGCCCTA CTGTTGAGCG TTGGCTTTAT	3780
ACTGGTAAGA ATTTGTATAA CGCATATGAT ACTAACACAG CTTTTCTAG TAATTATGAT	3840
TCCGGTGTGTT ATTCTTATTT AACGCCTTAT TTATCACACG GTCGGTATT CAAACCATT	3900
AATTTAGGTC AGAAGATGAA ATTAACAAA ATATATTGA AAAAGTTTC TCGCGTTCTT	3960
TGTCTTGCAG TTGGATTTCG ATCAGCATT ACATATAGTT ATATAACCCA ACCTAAGCCG	4020
GAGGTTAAA AGGTAGTCTC TCAGACCTAT GATTTGATA AATTCACTAT TGACTCTCT	4080
CAGCGTCTTA ATCTAACGCTA TCGCTATGTT TTCAAGGATT CTAAGGGAAA ATTAATTAAT	4140
AGCGACGATT TACAGAACCA AGGTTATTCA CTCACATATA TTGATTATG TACTGTTCC	4200
ATTAAAAAG GTAATTCAA TGAAATTGTT AAATGTAATT AATTTGTTT TCTTGATGTT	4260
TGTTTCATCA TCTTCTTTG CTCAGGTAAT TGAAATGAAT AATTCGCTC TGCGCGATTT	4320
TGTAACCTGG TATTCAAAGC AATCAGGCAG ATCCGTTATT GTTTCTCCCG ATGAAAAGG	4380
TACTGTTACT GTATATTCACT CTGACGTTAA ACCTGAAAAT CTACGCAATT TCTTATTT	4440
TGTTTACGT GCTAATAATT TTGATATGGT TGTTCAATT CCTTCCATAA TTCAGAACGA	4500
TAATCCAAAC AATCAGGATT ATATTGATGA ATTGCCATCA TCTGATAATC AGGAATATGA	4560
TGATAATTCC GCTCCTCTG GTGGTTCTT TGTTCCGCAA AATGATAATG TTACTCAAAC	4620
TTTTAAAATT AATAACGTTG GGGCAAAGGA TTTAATACGA GTTGTGAAAT TGTTGTAAA	4680
GTCTAATAC TCTAAATCCT CAAATGTATT ATCTATTGAC GGCTCTAAC TATTAGTTGT	4740
TAGTGCACCT AAAGATATTT TAGATAACCT TCCTCAATT CTTTCTACTG TTGATTTGCC	4800
AACTGACCAAG ATATTGATTG AGGGTTTGAT ATTTGAGGTT CAGCAAGGTG ATGCTTTAGA	4860

TTTTTCATTT	GCTGCTGGCT	CTCAGCGTGG	CACTGTTGCA	GGCGGTGTTA	ATACTGACCG	4920
CCTCACCTCT	GTTTTATCTT	CTGCTGGTGG	TTCGTTCGGT	ATTTTTAATG	GCGATGTTTT	4980
AGGGCTATCA	GTTCGCGCAT	TAAAGACTAA	TAGCCATTCA	AAAATATTGT	CTGTGCCACG	5040
TATTCTTACG	CTTTCAGGTC	AGAAGGGTTC	TATCTCTGTT	GGCCAGAATG	TCCCTTTAT	5100
TACTGGTCGT	GTGACTGGTG	AATCTGCCAA	TGTAAATAAT	CCATTTCAGA	CGATTGAGCG	5160
TCAAAATGTA	GGTATTTCCA	TGAGCGTTTT	TCCTGTTGCA	ATGGCTGGCG	GTAATATTGT	5220
TCTGGATATT	ACCAGCAAGG	CCGATAGTTT	GAGTTCTTCT	ACTCAGGCAA	GTGATGTTAT	5280
TACTAATCAA	AGAAGTATTG	CTACAACGGT	TAATTTGCGT	GATGGACAGA	CTCTTTACT	5340
CGGTGGCCTC	ACTGATTATA	AAAACACTTC	TCAAGATTCT	GGCGTACCGT	TCCTGTCTAA	5400
AATCCCTTTA	ATCGGCCTCC	TGTTTAGCTC	CCGCTCTGAT	TCCAACGAGG	AAAGCACGTT	5460
ATACGTGCTC	GTCAAAGCAA	CCATAGTACG	CGCCCTGTAG	CGGCGCATT	AGCGCGGCGG	5520
GTGTGGTGGT	TACGCGCAGC	GTGACCGCTA	CACTTGCCAG	CGCCCTAGCG	CCCGCTCCTT	5580
TCGCTTCTT	CCCTTCCTT	CTCGCCACGT	TCGCCGGCTT	TCCCCGTCAA	GCTCTAAATC	5640
GGGGGCTCCC	TTTAGGGTTC	CGATTTAGTG	CTTTACGGCA	CCTCGACCCC	AAAAAACTTG	5700
ATTTGGGTGA	TGGTTCACGT	AGTGGGCCAT	CGCCCTGATA	GACGGTTTTT	CGCCCTTTGA	5760
CGTTGGAGTC	CACGTTCTTT	AATAGTGGAC	TCTTGTCCA	AACTGGAAACA	ACACTCAACC	5820
CTATCTCGGG	CTATTCTTTT	GATTTATAAG	GGATTTGCC	GATTTCGGAA	CCACCATCAA	5880
ACAGGATTTT	CGCCTGCTGG	GGCAAACCG	CGTGGACCGC	TTGCTGCAAC	TCTCTCAGGG	5940
CCAGGCGGTG	AAGGGCAATC	AGCTGTTGCC	CGTCTCGCTG	GTGAAAAGAA	AAACCACCC	6000
GGCGCCCAAT	ACGCAAACCG	CCTCTCCCCG	CGCGTTGGCC	GATTCAATTAA	TGCAGCTGGC	6060
ACGACAGGTT	TCCCAGCTGG	AAAGCGGGCA	GTGAGCGCAA	CGCAATTAAAT	GTGAGTTAGC	6120
TCACTCATTA	GGCACCCCCAG	GCTTTACACT	TTATGCTTCC	GGCTCGTATG	TTGTGTGGAA	6180
TTGTGAGCGG	ATAACAATT	CACACGCCAA	GGAGACAGTC	ATAATGAAAT	ACCTATTGCC	6240
TACGGCAGCC	GCTGGATTGT	TATTACTCGC	TGCCCAACCA	GCCATGGCCG	AGCTCGTGAT	6300
GACCCAGACT	CCAGAATTCC	ATCCGGAATG	AGTGTAAATT	CTAGAACCGG	TAAGCTTGGC	6360
ACTGGCCGTC	GTCCCCAAC	GTCTGACTG	GGAAAACCT	GGCGTTACCC	AACTTAATCG	6420
CCTTGCAGCA	CACCCCCCTT	TCGCCAGCTG	CGTAAATAGC	GAAGAGGCC	GCACCGATCG	6480
CCCTTCCCAA	CAGTTGCGCA	GCCTGAATGG	CGAATGGCGC	TTTGCCTGGT	TTCCGGCACC	6540
AGAAGCGGTG	CCGGAAAGCT	GGCTGGAGTG	CGATCTTCCT	GAGGCCGATA	CGGTCGTCGT	6600
CCCCTCAAAC	TGGCAGATGC	ACGGTTACGA	TGCGCCCAC	TACACCAACG	TAACCTATCC	6660
CATTACGGTC	AATCCGCCGT	TTGTTCCCAC	GGAGAATCCG	ACGGGTTGTT	ACTCGCTCAC	6720
ATTTAATGTT	GATGAAAGCT	GGCTACAGGA	AGGCCAGACG	CGAATTATT	TTGATGGCGT	6780
TCCTATTGGT	AAAAAAATGA	GCTGATTTAA	CAAAATTTA	ACCGGAATT	TAACAAAATA	6840
TTAACGTTTA	CAATTAAAT	ATTGCTTAT	ACAATCTTCC	TGTTTTGGG	GCTTTCTGA	6900

TTATCAACCG GGGTACATAT GATTGACATG CTAGTTTAC GATTACCGTT CATCGATTCT	6960
CTTGTGCT CCAGACTCTC AGGCAATGAC CTGATAGCCT TTGTAGATCT CTCAAAAATA	7020
GCTACCCCTCT CCGGCATTA TTTATCAGCT AGAACGGTTG AATATCATAT TGATGGTGAT	7080
TTGACTGTCT CCGGCCTTTC TCACCCCTTT GAATCTTAC CTACACATTA CTCAGGCATT	7140
GCATTTAAA TATATGAGGG TTCTAAAAAT TTTTATCCTT GCGTTGAAAT AAAGGCTTCT	7200
CCCGCAAAAG TATTACAGGG TCATAATGTT TTTGGTACAA CCGATTTAGC TTTATGCTCT	7269
GAGGCTTTAT TGCTTAATTT TGCTAATTCT TTGCCCTTGCC TGTATGATT ATTGGACGTT	7320

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7445 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: both
- (D) TOPOLOGY: circular

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

AATGCTACTA CTATTAGTAG AATTGATGCC ACCTTTCAAG CTCGCGCCCC AAATGAAAAT	60
ATAGCTAAAC AGGTTATTGA CCATTTGCGA AATGTATCTA ATGGTCAAAC TAAATCTACT	120
CGTCGCAGA ATTGGGAATC AACTGTTACA TGGAATGAAA CTTCCAGACA CCGTACTTTA	180
GTTGCATATT TAAAACATGT TGAGCTACAG CACCAAGATT AGCAATTAAG CTCTAAGCCA	240
TCTGCAAAA TGACCTCTTA TCAAAAGGAG CAATTAAGG TACTCTCTAA TCCTGACCTG	300
TTGGAGTTTG CTTCCGGTCT GGTTCGCTTT GAAGCTCGAA TTAAAACGCG ATATTGAAAG	360
TCTTTCGGGC TTCCCTTTAA TCTTTTGAT GCAATCCGCT TTGCTTCTGA CTATAATAGT	420
CAGGGTAAAG ACCTGATTT TGATTTATGG TCATTCTCGT TTTCTGAACG GTTTAAAGCA	480
TTTGAGGGGG ATTCAATGAA TATTTATGAC GATTCCGCAG TATTGGACGC TATCCAGTCT	540
AAACATTTTA CTATTACCCC CTCTGGCAAA ACTTCCTTTG CAAAAGCCTC TCGCTATTTT	600
GGTTTTATC GTCGTCTGGT AAACGAGGGT TATGATAGTG TTGCTCTTAC TATGCCTCGT	660
AATTCCCTTT GGCGTTATGT ATCTGCATTA GTTGAATGTG GTATTCTAA ATCTCAACTG	720
ATGAATCTTT CTACCTGTAA TAATGTTGTT CCGTTAGTTC GTTTTATTAA CGTAGATTTT	780
TCTTCCCAAC GTCCTGACTG GTATAATGAG CCAGTTCTTA AAATCGCATA AGGTAATTCA	840
CAATGATTAA AGTTGAAATT AAACCATCTC AAGCCCAATT TACTACTCGT TCTGGTGT	900
CTCGTCAGGG CAAGCCTTAT TCACTGAATG AGCAGCTTTG TTACGTTGAT TTGGGTAATG	960
AATATCCGGT TCTTGTCAAG ATTACTCTTG ATGAAGGTCA GCCAGCCTAT GCGCCTGGTC	1020
TGTACACCGT TCATCTGTCC TCTTTCAAAG TTGGTCAGTT CGGTTCCCTT ATGATTGACC	1080
GTCTGCGCCT CGTTCCGGCT AAGTAACATG GAGCAGGTGCG CGGATTTCGA CACAATTAT	1140
CAGGCGATGA TACAAATCTC CGTTGTACTT TGTTTCGCGC TTGGTATAAT CGCTGGGGGT	1200

CAAAGATGAG	TGTTTTAGTG	TATTCTTCG	CCTCTTCGT	TTTAGGTTGG	TGCCTTCGTA	1260
GTGGCATTAC	GTATTTACC	CGTTTAATGG	AAACTTCCTC	ATGAAAAAGT	CTTTAGTCCT	1320
CAAAGCCTCT	GTAGCCGTTG	CTACCCCTCGT	TCCGATGCTG	TCTTTCGCTG	CTGAGGGTGA	1380
CGATCCCGCA	AAAGCGGCCT	TTAACTCCCT	GCAAGCCTCA	GCGACCGAAT	ATATCGGTTA	1440
TGCGTGGGCG	ATGGTTGTTG	TCATTGTCGG	CGCAACTATC	GGTATCAAGC	TGTTTAAGAA	1500
ATTCACCTCG	AAAGCAAGCT	GATAAAACCGA	TACAATTAAA	GGCTCCTTTT	GGAGCCTTTT	1560
TTTTTGGAGA	TTTCAACGT	GAAAAAAATTA	TTATTCGAA	TTCCTTTAGT	TGTTCCCTTC	1620
TATTCTCACT	CCGCTGAAAC	TGTTGAAAGT	TGTTTAGCAA	AAACCCATAC	AGAAAATTCA	1680
TTTACTAACG	TCTGGAAAGA	CGACAAAACT	TTAGATCGTT	ACGCTAACTA	TGAGGGTTGT	1740
CTGTGGAATG	CTACAGGCCT	TGTTGAAAGT	TGTTTAGCAA	AAACCCATAC	AGAAAATTCA	1800
TGGGTTCCCTA	TTGGGCTTGC	TATCCCTGAA	AATGAGGGTG	GTGGCTCTGA	GGGTGGCGGT	1860
TCTGAGGGTG	GCGGTTCTGA	GGGTGGCGGT	ACTAAACCTC	CTGAGTACGG	TGATACACCT	1920
ATTCCGGGCT	ATACTTATAT	CAACCCCTCTC	GACGGCACTT	ATCCGCCTGG	TACTGAGCAA	1980
AAACCCCGCTA	ATCCTAATCC	TTCTCTTGAG	GAGTCTCAGC	CTCTTAATAC	TTTCATGTTT	2040
CAGAATAATA	GGTTCCGAAA	TAGGCAGGGG	GCATTAACTG	TTTATACGGG	CACTGTTACT	2100
CAAGGCAC TG	ACCCCGTTAA	AACTTATTAC	CAGTACACTC	CTGTATCATC	AAAGCCATG	2160
TATGACGCTT	ACTGGAACGG	AAAATTCAA	GAUTGCGCTT	TCCATTCTGG	CTTTAATGAA	2220
GATCCATTCTG	TTTGTGAATA	TCAAGGCCAA	TCGTCTGACC	TGCCTCAACC	TCCTGTCAAT	2280
GCTGGCGGCG	GCTCTGGTGG	TGGTTCTGGT	GGCGGCTCTG	AGGGTGGTGG	CTCTGAGGGT	2340
GGCGGTTCTG	AGGGTGGCGG	CTCTGAGGGA	GGCGGTTCCG	GTGGTGGCTC	TGGTTCCGGT	2400
GATTTGATT	ATGAAAAGAT	GGCAAACGCT	AATAAGGGGG	CTATGACCGA	AAATGCCGAT	2460
AAAAACGCGC	TACAGTCTGA	CGCTAAAGGC	AAACTTGATT	CTGTCGCTAC	TGATTACGGT	2520
GCTGCTATCG	ATGGTTTCAT	TGGTGACGTT	TCCGGCCTTG	CTAATGGTAA	TGGTGCTACT	2580
GGTGATTTG	CTGGCTCTAA	TTCCCAAATG	GCTCAAGTCG	GTGACGGTGA	TAATTACACCT	2640
TTAATGAATA	ATTTCCGTCA	ATATTTACCT	TCCCTCCCTC	AATCGGTTGA	ATGTCGCCCT	2700
TTTGTCTTTA	GCGCTGGTAA	ACCATATGAA	TTTTCTATTG	ATTGTGACAA	AATAAACTTA	2760
TTCCCGTGGTG	TCTTTGCGTT	TCTTTATAT	GTTGCCACCT	TTATGTATGT	ATTTTCTACG	2820
TTTGCTAAC	TACTGCGTAA	TAAGGAGTCT	TAATCATGCC	AGTTCTTTG	GGTATTCCGT	2880
TATTATTGCG	TTTCCTCGGT	TTCCCTCTGG	TAACTTGTT	CGGCTATCTG	CTTACTTTTC	2940
TTAAAAAGGG	CTTCGGTAAG	ATAGCTATTG	CTATTCATT	GTTTCTTGCT	CTTATTATTG	3000
GGCTTAACTC	AATTCTTGTG	GGTTATCTCT	CTGATATTAG	CGCTCAATTA	CCCTCTGACT	3060
TTGTTCAAGG	TGTTCAAGTTA	ATTCTCCCGT	CTAATGCGCT	TCCCTGTTT	TATGTTATTG	3120
TCTCTGTAAA	GGCTGCTATT	TTCATTTTG	ACGTTAAACA	AAAAATCGTT	TCTTATTG	3180
ATTGGGATAA	ATAATATGGC	TGTTTATTTT	GTAACTGGCA	AATTAGGCTC	TGGAAAGACG	3240

CTCGTTAGCG	TTGGTAAGAT	TCAGGATAAA	ATTGTAGCTG	GGTGCAAAAT	AGCAACTAAT	3300
CTTGATTTAA	GGCTTCAAAA	CCTCCCGCAA	GTCGGGAGGT	TCGCTAAAAC	GCCTCGCGTT	3360
CTTAGAATAC	CGGATAAGCC	TTCTATATCT	GATTTGCTTG	CTATTGGGCG	CGGTAATGAT	3420
TCCTACGATG	AAAATAAAAA	CGGCTTGCTT	GTTCTCGATG	AGTGCAGTAC	TTGGTTTAAT	3480
ACCCGTTCTT	GGAATGATAA	GGAAAGACAG	CCGATTATTG	ATTGGTTCT	ACATGCTCGT	3540
AAATTAGGAT	GGGATATTAT	TTTCTTGTG	CAGGACTTAT	CTATTGTTGA	AAACAGGCG	3600
CGTTCTGCAT	TAGCTGAACA	TGTTGTTAT	TGTCGTCGTC	TGGACAGAAT	TACTTACCT	3660
TTTGTGGTA	CTTTATATTC	TCTTATTACT	GGCTCGAAAA	TGCCTCTGCC	AAATTACAT	3720
GTTGGCGTTG	TTAAATATGG	CGATTCTCAA	TTAAGCCCTA	CTGTTGAGCG	TTGGCTTTAT	3780
ACTGGTAAGA	ATTTGTATAA	CGCATATGAT	ACTAAACAGG	CTTTTCTAG	TAATTATGAT	3840
TCCGGTGT	TTTCTTATTT	AAAGCCTTAT	TTATCACACG	GTCGGTATT	CAAACCATTA	3900
AATTAGGTC	AGAAGATGAA	GCTTACTAAA	ATATATTGA	AAAAGTTTC	ACGCGTTCTT	3960
TGTCTTGC	TTGGATTTC	ATCAGCATT	ACATATAGTT	ATATAACCCA	ACCTAACGCCG	4020
GAGGTTAAA	AGGTAGTCTC	TCAGACCTAT	GATTTGATA	AATTCACTAT	TGACTCTTCT	4080
CAGCGTCTTA	ATCTAAGCTA	TCGCTATGTT	TTCAAGGATT	CTAAGGGAAA	ATTAATTAAT	4140
AGCGACGATT	TACAGAAGCA	AGGTTATTCA	CTCACATATA	TTGATTATG	TACTGTTCC	4200
ATTAAAAAAG	GTAATTCAAA	TGAAATTGTT	AAATGTAATT	AATTTGTTT	TCTTGATGTT	4260
TGTTTCATCA	TCTTCTTTG	CTCAGGTAAT	TGAAATGAAT	AATTGCGCTC	TGCGCGATT	4320
TGTAACCTGG	TATTCAAAGC	AATCAGGC	ATCCGTTATT	GTTTCTCCCG	ATGAAAAGG	4380
TACTGTTACT	GTATATTCA	CTGACGTTAA	ACCTGAAAAT	CTACGCAATT	TCTTATTTC	4440
TGTTTACGT	GCTAATAATT	TTGATATGGT	TGGTTCAATT	CCTTCCATAA	TTCAGAAGTA	4500
TAATCCAAAC	AATCAGGATT	ATATTGATGA	ATTGCCATCA	TCTGATAATC	AGGAATATGA	4560
TGATAATTCC	GCTCCTCTG	GTGGTTCTT	TGTTCCGCAA	AATGATAATG	TTACTCAAAC	4620
TTTTAAAATT	AATAACGTT	GGGCAAAGGA	TTAATACGA	GTTGTCGAAT	TGTTGTAAA	4680
GTCTAAACT	TCTAAATCCT	CAAATGTATT	ATCTATTGAC	GGCTCTAAC	TATTAGTTGT	4740
TAGTGCACCT	AAAGATATTT	TAGATAACCT	TCCTCAATT	CTTTCTACTG	TTGATTTGCC	4800
AACTGACCA	AGATTGATTG	AGGGTTGAT	ATTTGAGGTT	CAGCAAGGTG	ATGCTTTAGA	4860
TTTTTCATTT	GCTGCTGGCT	CTCAGCGTGG	CACTGTTGCA	GGCGGTGTTA	ATACTGACCG	4920
CCTCACCTCT	GTTTTATCTT	CTGCTGGTGG	TTCGTTCGGT	ATTTTTAATG	GCGATGTT	4980
AGGGCTATCA	GTTCGCGCAT	AAAGACTAA	TAGCCATTCA	AAAATATTGT	CTGTGCCACG	5040
TATTCTTACG	CTTTCAGGTC	AGAAGGGTTC	TATCTCTGTT	GGCCAGAATG	TCCCTTTAT	5100
TACTGGTCGT	GTGACTGGTG	AATCTGCCAA	TGTAATAAT	CCATTTCAGA	CGATTGAGCG	5160
TCAAAATGTA	GGTATTTCCA	TGAGCGTTT	TCCTGTTGCA	ATGGCTGGCG	GTAATATTGT	5220
TCTGGATATT	ACCAAGCAAGG	CCGATAGTTT	GAGTTCTTCT	ACTCAGGCAA	GTGATGTTAT	5280

TAATTAATCAA	AGAAGTATTG	CTACAACGGT	TAATTTGCGT	GATGGACAGA	CTCTTTACT	5340
CGGTGGCCTC	ACTGATTATA	AAAACACTTC	TCAAGATTCT	GGCGTACCGT	TCCTGTCTAA	5400
AATCCCTTA	ATCGGCCTCC	TGTTTAGCTC	CCGCTCTGAT	TCCAACGAGG	AAAGCACGTT	5460
ATACGTGCTC	GTCAAAGCAA	CCATAGTACG	CGCCCTGTAG	CGGCGCATT	AGCGCGCGG	5520
GTGTGGTGGT	TACGCGCAGC	GTGACCGCTA	CACTTGCCAG	CGCCCTAGCG	CCCGCTCCTT	5580
TCGCTTCTT	CCCTTCCCTT	CTCGCCACGT	TCGCCGGCTT	TCCCCGTCAA	GCTCTAAATC	5640
GGGGGCTCCC	TTTAGGGTTC	CGATTTAGTG	CTTTACGGCA	CCTCGACCCC	AAAAAACTTG	5700
ATTTGGGTGA	TGGTTCACGT	AGTGGGCCAT	CGCCCTGATA	GACGGTTTT	CGCCCTTGA	5760
CGTTGGAGTC	CACGTTCTT	AATAGTGGAC	TCTTGTCCA	AACTGGAACA	ACACTCAACC	5820
CTATCTCGGG	CTATTCTTT	GATTATAAG	GGATTTGCC	GATTTCGGAA	CCACCATCAA	5880
ACAGGATTTT	CGCCTGCTGG	GGCAAACCGAG	CGTGGACCGC	TTGCTGCAAC	TCTCTCAGGG	5940
CCAGGGCGGTG	AAGGGCAATC	AGCTGTTGCC	CGTCTCGCTG	GTGAAAAGAA	AAACCACCC	6000
GGCGCCCAAT	ACGCAAACCG	CCTCTCCCCG	CGCGTTGGCC	GATTCAATTAA	TGCAGCTGGC	6060
ACGACAGGTT	TCCCGACTGG	AAAGCGGGCA	GTGAGCGCAA	CGCAATTAAAT	GTGAGTTAGC	6120
TCACTCATTA	GGCACCCAG	GCTTACACT	TTATGCTTCC	GGCTCGTATG	TTGTGTGGAA	6180
TTGTGAGCGG	ATAACAATT	CACACGGTC	ACTTGGCACT	GGCCGTCGTT	TTACAACGTC	6240
GTGACTGGGA	AAACCCCTGGC	GTTACCCAAG	CTTTGTACAT	GGAGAAAATA	AAGTGAACACA	6300
AAGCACTATT	GCACGGCAC	TCTTACCGTT	ACCGTTACTG	TTTACCCCTG	TGACAAAAGC	6360
CGCCCAGGTC	CAGCTGCTCG	AGTCAGGCCT	ATTGTGCCA	GGGGATTGTA	CTAGTGGATC	6420
CTAGGCTGAA	GGCGATGACC	CTGCTAAGGC	TGCATTCAAT	AGTTTACAGG	CAAGTGTAC	6480
TGAGTACATT	GGCTACGCTT	GGGCTATGGT	AGTAGTTATA	GTTGGTGCTA	CCATAGGGAT	6540
TAAATTATTC	AAAAAGTTA	CGAGCAAGGC	TTCTTAAGCA	ATAGCGAAGA	GGCCCGCACC	6600
GATGCCCTT	CCCAACAGTT	GCGCAGCCTG	AATGGCGAAT	GGCGCTTGC	CTGGTTCCG	6660
GCACCAGAAG	CGGTGCCGGA	AAGCTGGCTG	GAGTGCATC	TTCCCTGAGGC	CGATACGGTC	6720
GTCGTCCCT	CAAACGGCA	GATGCACGGT	TACGATGC	CCATCTACAC	CAACGTAACC	6780
TATCCCATT	CGGTCAATCC	GCCGTTGTT	CCCACGGAGA	ATCCGACGGG	TTGTTACTCG	6840
CTCACATT	ATGTTGATGA	AAGCTGGCTA	CAGGAAGGCC	AGACGCGAAT	TATTTTGAT	6900
GGCGTTCTA	TTGGTTAAA	AATGAGCTGA	TTAACAAAA	ATTTAACGCG	AATTTAACAA	6960
AAATATTAAC	GTTCACATT	AAAATATTG	CTTATACAAT	CTTCCTGTT	TTGGGGCTTT	7020
TCTGATTATC	AACCAGGGTA	CATATGATTG	ACATGCTAGT	TTTACGATTA	CCGTTCATCG	7080
ATTCTCTTGT	TTGCTCCAGA	CTCTCAGGCA	ATGACCTGAT	AGCCTTGT	GATCTCTCAA	7140
AAATAGCTAC	CCTCTCCGGC	ATTAATTAT	CAGCTAGAAC	GGTTGAATAT	CATATTGATG	7200
GTGATTTGAC	TGTCTCCGGC	CTTCTCACC	CTTTGAATC	TTTACCTACA	CATTACTCAG	7260
GCATTGCATT	AAAAATATAT	GAGGGTTCTA	AAAATTTTA	TCCTTGCCTT	GAAATAAAGG	7320

CTTCTCCCGC AAAAGTATTA CAGGGTCATA ATGTTTTGG TACAACCGAT TTAGCTTTAT	7380
GCTCTGAGGC TTTATTGCTT AATTTGCTA ATTCTTGCC TTGCCTGTAT GATTTATTGG	7440
ACGTT	7445

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7409 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: both
- (D) TOPOLOGY: circular

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

AATGCTACTA CTATTAGTAG AATTGATGCC ACCTTTCAAG CTCGCGCCCC AAATGAAAAT	60
ATAGCTAAC AGGTTATTGA CCATTTGCGA AATGTATCTA ATGGTCAAAC TAAATCTACT	120
CGTTCGCAGA ATTGGGAATC AACTGTTACA TGGAATGAAA CTTCCAGACA CCGTACTTTA	180
GTTGCATATT TAAAACATGT TGAGCTACAG CACCAGATTC AGCAATTAAG CTCTAAGCCA	240
TCTGCAAAAA TGACCTCTTA TCAAAAGGAG CAATTAAAGG TACTCTCTAA TCCTGACCTG	300
TTGGAGTTG CTTCCGGTCT GGTCGCTTT GAAGCTCGAA TTAAAACGCG ATATTGAAAG	360
TCTTCGGGC TTCCTCTTAA TCTTTTGAT GCAATCCGCT TTGCTTCTGA CTATAATAGT	420
CAGGGTAAAG ACCTGATTT TGATTTATGG TCATTCTCGT TTTCTGAAC GTTAAAGCA	480
TTTGAGGGGG ATTCAATGAA TATTTATGAC GATTCCGCAG TATTGGACGC TATCCAGTCT	540
AAACATTTA CTATTACCCC CTCTGGAAA ACTTCTTTG CAAAAGCCTC TCGCTATTTT	600
GGTTTTATC GTCGTCTGGT AAACGAGGGT TATGATAGTG TTGCTCTTAC TATGCCTCGT	660
AATTCCCTTT GGCGTTATGT ATCTGCATTA GTTGAATGTG GTATTCTAA ATCTCAACTG	720
ATGAATCTTT CTACCTGTAA TAATGTTGTT CCGTTAGTTC GTTTTATTAA CGTAGATTTT	780
TCTTCCCAAC GTCCGTACTG GTATAATGAG CCAGTTCTTA AAATCGCATA AGGTAAATTCA	840
CAATGATTAA AGTTGAAATT AAACCATCTC AAGCCCAATT TACTACTCGT TCTGGTGT	900
CTCGTCAGGG CAAGCCTTAT TCACTGAATG AGCAGCTTG TTACGTTGAT TTGGGTAATG	960
AATATCCGGT TCTTGTCAAG ATTACTCTTG ATGAAGGTCA GCCAGCCTAT GCGCCTGGTC	1020
TGTACACCGT TCATCTGTCC TCTTCAAAG TTGGTCAGTT CGGTTCCCTT ATGATTGACC	1080
GTCTGCGCCT CGTTCCGGCT AAGTAACATG GAGCAGGTG CGGATTTCGA CACAATTAT	1140
CAGGCGATGA TACAAATCTC CGTTGTACTT TGTTTCGCGC TTGGTATAAT CGCTGGGGGT	1200
CAAAGATGAG TGTTTTAGTG TATTCTTCG CCTCTTCGT TTAGGTTGG TGCCTTCGTA	1260
GTGGCATTAC GTATTTACC CGTTAATGG AAACCTCCTC ATGAAAAAGT CTTTAGTCCT	1320
CAAAGCCTCT GTAGCCGTTG CTACCCCTCGT TCCGATGCTG TCTTTCGCTG CTGAGGGTGA	1380
CGATCCCGCA AAAGCGGCCT TAAACTCCCT GCAAGCCTCA GCGACCGAAT ATATCGGTTA	1440
TGCGTGGCG ATGGTTGTTG TCATTGTCGG CGCAACTATC GGTATCAAGC TGTTAAAGAA	1500

ATTCACCTCG	AAAGCAAGCT	GATAAACCGA	TACAATTAAA	GGCTCCTTTT	GGAGCCTTT	1560
TTTTGGAGA	TTTCAACGT	AAAAAAATTA	TTATTCCCAA	TTCCCTTAGT	TGTCCTTTC	1620
TATTCTCACT	CCGCTGAAAC	TGTTGAAAGT	TGTTAGCAA	AACCCCATAC	AGAAAATTCA	1680
TTTACTAACG	TCTGGAAAGA	CGACAAAACT	TTAGATCGTT	ACGCTAACTA	TGAGGGTTGT	1740
CTGTGGAATG	CTACAGGGGT	TGTAGTTGT	ACTGGTGACG	AAACTCAGTG	TTACGGTACA	1800
TGGGTTCCCTA	TTGGGCTTGC	TATCCCTGAA	AATGAGGGTG	GTGGCTCTGA	GGGTGGCGGT	1860
TCTGAGGGTG	GCGGTTCTGA	GGGTGGCGGT	ACTAAACCTC	CTGAGTACGG	TGATACACCT	1920
ATTCCGGGCT	ATACTTATAT	CAACCCCTCTC	GACGGCACTT	ATCCGCCTGG	TACTGAGCAA	1980
AACCCCGCTA	ATCCTAATCC	TTCTCTTGAG	GAGTCTCAGC	CTCTTAATAC	TTTCATGTTT	2040
CAGAATAATA	GGTTCCGAAA	TAGGCAGGGG	GCATTAACTG	TTTATACGGG	CACTGTTACT	2100
CAAGGCACTG	ACCCCGTTAA	AACTTATTAC	CAGTACACTC	CTGTATCATC	AAAAGCCATG	2160
TATGACGCTT	ACTGGAACGG	AAATTTCAGA	GAUTGCCCTT	TCCATTCTGG	CTTTAATGAA	2220
GATCCATTG	TTTGTGAATA	TCAAGGCCAA	TCGTCTGACC	TGCCCTCAACC	TCCTGTCAAT	2280
GCTGGCGCG	GCTCTGGTGG	TGGTTCTGGT	GGCGGCTCTG	AGGGTGGTGG	CTCTGAGGGT	2340
GGCGGTTCTG	AGGGTGGCGG	CTCTGAGGGA	GGCGGTTCCG	GTGGTGGCTC	TGGTTCCGGT	2400
GATTTGATT	ATGAAAAGAT	GGCAAAACGCT	AATAAGGGGG	CTATGACCGA	AAATGCCGAT	2460
AAAAACGCGC	TACAGTCTGA	CGCTAAAGGC	AAACTTGATT	CTGTCGCTAC	TGATTACGGT	2520
GCTGCTATCG	ATGGTTTCAT	TGGTGACGTT	TCCGGCCTTG	CTAATGGTAA	TGGTGCTACT	2580
GGTGATTTG	CTGGCTCTAA	TTCCCAAATG	GCTCAAGTCG	GTGACGGTGA	TAATTACACCT	2640
TTAATGAATA	ATTTCCGTCA	ATATTTACCT	TCCCTCCCTC	AATCGGTTGA	ATGTCGCCCT	2700
TTTGTCTTTA	GGCCTGGTAA	ACCATATGAA	TTTTCTATTG	ATTGTGACAA	AATAAAACTTA	2760
TTCCGTGGTG	TCTTTGCGTT	TCTTTATAT	GTTGCCACCT	TTATGTATGT	ATTTCTACG	2820
TTTGCTAACCA	TACTGCGTAA	TAAGGAGTCT	TAATCATGCC	AGTTCTTTG	GGTATTCCGT	2880
TATTATTGCG	TTTCCTCGGT	TTCCCTCTGG	TAACTTGTT	CGGCTATCTG	CTTACTTTTC	2940
TTAAAAAGGG	CTTCGGTAAG	ATAGCTATTG	CTATTCATT	GTTTCTTGCT	CTTATTATTG	3000
GGCTTAACTC	AATTCTTGTG	GGTTATCTCT	CTGATATTAG	CGCTCAATTAA	CCCTCTGACT	3060
TTGTTCAAGGG	TGTTCAAGTTA	ATTCTCCCGT	CTAATGCGCT	TCCCTGTTTT	TATGTTTATTC	3120
TCTCTGTAAA	GGCTGCTATT	TTCACTTTTG	ACGTTAAACA	AAAAATCGTT	TCTTATTTGG	3180
ATTGGGATAAA	ATAATATGGC	TGTTTATTTT	GTAACTGGCA	AATTAGGCTC	TGGAAAGACG	3240
CTCGTTAGCG	TTGGTAAGAT	TCAGGATAAA	ATTGTAGCTG	GGTGCAAAAT	AGCAACTAAT	3300
CTTGATTTAA	GGCTTCAAAA	CCTCCCGCAA	GTCGGGAGGT	TCGCTAAAAC	GCCTCGCGTT	3360
CTTAGAATAC	CGGATAAGCC	TTCTATATCT	GATTGCTTG	CTATTGGGCG	CGGTAATGAT	3420
TCCTACGATG	AAAATAAAAAA	CGGCTTGCTT	GTTCTCGATG	AGTGCAGGTAC	TTGGTTTAAT	3480
ACCCGTTCTT	GGAATGATAA	GGAAAGACAG	CCGATTATTG	ATTGGTTTCT	ACATGCTCGT	3540

AAATTAGGAT	GGGATATTAT	TTTTCTTGT	CAGGACTTAT	CTATTGTTGA	TAAACAGGCG	3600
CGTTCTGCAT	TAGCTGAACA	TGTTGTTAT	TGTCGTCGTC	TGGACAGAAT	TACTTTACCT	3660
TTTGTGCGTA	CTTTATATTC	TCTTATTACT	GGCTCGAAAA	TGCCTCTGCC	TAAATTACAT	3720
GTTGGCGTTG	TTAAATATGG	CGATTCTCAA	TTAAGCCCTA	CTGTTGAGCG	TTGGCTTTAT	3780
ACTGGTAAGA	ATTTGTATAA	CGCATATGAT	ACTAAACAGG	CTTTTTCTAG	TAATTATGAT	3840
TCCGGTGT	TTTCTTATT	AACGCCCTAT	TTATCACACG	GTCGGTATTT	CAAACCATTA	3900
AATTTAGGTC	AGAAGATGAA	GCTTACTAAA	ATATATTGA	AAAAGTTTTC	ACGCGTTCTT	3960
TGTCTTGC	TTGGATTTC	ATCAGCATT	ACATATAGTT	ATATAACCCA	ACCTAAGCCG	4020
GAGGTTAAA	AGGTAGTC	TCAGACCTAT	GATTTGATA	AATTCACTAT	TGACTCTTCT	4080
CAGCGTCTTA	ATCTAAGCTA	TCGCTATGTT	TTCAAGGATT	CTAAGGGAAA	ATTAATTAAT	4140
AGCGACGATT	TACAGAAGCA	AGGTTATTCA	CTCACATATA	TTGATTTATG	TACTGTTCC	4200
ATTAAAAAG	GTAATTCAAA	TGAAATTGTT	AAATGTAATT	AATTTGTTT	TCTTGATGTT	4260
TGTTTCATCA	TCTTCTTTG	CTCAGGTAAT	TGAAATGAAT	AATTGCGCTC	TGCGCGATTT	4320
TGTAACCTGG	TATTCAAAGC	AATCAGGCGA	ATCCGTTATT	GTTCTCCCG	ATGTAAGG	4380
TACTGTTACT	GTATATTCA	CTGACGTTAA	ACCTGAAAAT	CTACGCAATT	TCTTTATTT	4440
TGTTTACGT	GCTAATAATT	TTGATATGGT	TGGTTCAATT	CCTTCCATAA	TTCAGAAGTA	4500
TAATCCAAAC	AATCAGGATT	ATATTGATGA	ATTGCCATCA	TCTGATAATC	AGGAATATGA	4560
TGATAATTCC	GCTCCTTCTG	GTGGTTCTT	TGTTCCGCAA	AATGATAATG	TTACTCAAAC	4620
TTTTAAAATT	AATAACGTT	GGGCAAAGGA	TTTAATACGA	GTTGTCGAAT	TGTTGTAAA	4680
GTCTAATACT	TCTAAATCCT	CAAATGTATT	ATCTATTGAC	GGCTCTAATC	TATTAGTTGT	4740
TAGTGCACCT	AAAGATATT	TAGATAACCT	TCCTCAATT	CTTCTACTG	TTGATTTGCC	4800
AACTGACCAG	ATATTGATTG	AGGGTTGAT	ATTTGAGGTT	CAGCAAGGTG	ATGCTTCTA	4860
TTTTTCATTT	GCTGCTGGCT	CTCAGCGTGG	CACTGTTGCA	GGCGGTGTTA	ATACTGACCG	4920
CCTCACCTCT	GTTTTATCTT	CTGCTGGTGG	TTCGTTCGGT	ATTTTAATG	GCGATGTTT	4980
AGGGCTATCA	GTTCGCGCAT	TAAAGACTAA	TAGCCATTCA	AAAATATTGT	CTGTGCCACG	5040
TATTCTTACG	CTTTCAGGTC	AGAAGGGTTC	TATCTCTGTT	GGCCAGAATG	TCCCTTTAT	5100
TACTGGTCGT	GTGACTGGTG	AATCTGCCAA	TGTAAATAAT	CCATTTCAGA	CGATTGAGCG	5160
TCAAAATGTA	GGTATTTCCA	TGAGCGTTT	TCCTGTTGCA	ATGGCTGGCG	GTAATATTGT	5220
TCTGGATATT	ACCAGCAAGG	CCGATAGTTT	GAGTTCTTCT	ACTCAGGCAA	GTGATGTTAT	5280
TACTAATCAA	AGAAGTATTG	CTACAACGGT	TAATTTGCGT	GATGGACAGA	CTCTTTACT	5340
CGGTGGCCTC	ACTGATTATA	AAAACACTTC	TCAAGATTCT	GGCGTACCGT	TCCTGTCTAA	5400
AATCCCTTA	ATCGGCCTCC	TGTTAGCTC	CCGCTCTGAT	TCCAACGAGG	AAAGCACGTT	5460
ATACGTGCTC	GTCAAAGCAA	CCATAGTACG	CGCCCTGTAG	CGGCGCATT	AGCGCGGCGG	5520
GTGTGGTGGT	TACGCGCAGC	GTGACCGCTA	CACTTGCCAG	CGCCCTAGCG	CCCGCTCCTT	5580

TCGCTTCCTT	CCCTTCCTT	CTGCCACGT	TCGCCGGCTT	TCCCCGTCAA	GCTCTAAATC	5640
GGGGGCTCCC	TTTAGGGTTC	CGATTTAGTG	CTTACGGCA	CCTCGACCCC	AAAAAACTTG	5700
ATTTGGGTGA	TGGTTCACGT	AGTGGGCCAT	CGCCCTGATA	GACGGTTTTT	CGCCCTTTGA	5760
CGTTGGAGTC	CACGTTCTT	AATAGTGGAC	TCTTGTCCA	AACTGGAACA	ACACTCAACC	5820
CTATCTCGGG	CTATTCTTT	GATTTATAAG	GGATTTGCC	GATTCGGAA	CCACCATCAA	5880
ACAGGATTTT	CGCCTGCTGG	GGCAAACCAAG	CGTGGACCGC	TTGCTGCAAC	TCTCTCAGGG	5940
CCAGGCGGTG	AAGGGCAATC	AGCTGTTGCC	CGTCTCGCTG	GTGAAAAGAA	AAACCAACCCCT	6000
GGCGCCCAAT	ACGCAAACCG	CCTCTCCCCG	CGCGTTGCC	GATTCACTAA	TGCAGCTGGC	6060
ACGACAGGTT	TCCCGACTGG	AAAGCGGGCA	GTGAGCGAA	CGCAATTAAAT	GTGAGTTAGC	6120
TCACTCATTAA	GGCACCCCCAG	GCTTTACACT	TTATGCTTCC	GGCTCGTATG	TTGTGTGGAA	6180
TTGTGAGCGG	ATAACAATTT	CACACGCGTC	ACTTGGCACT	GGCCGTCGTT	TTACAACGTC	6240
GTGACTGGGA	AAACCCCTGGC	GTTACCCAAG	CTTTGTACAT	GGAGAAAATA	AAAGTGAACACA	6300
AAGCACTATT	GCACACTGGCAC	TCTTACCGTT	ACTGTTTACCC	CCTGTGGCAA	AAGCCTATGG	6360
GGGGTTTATG	ACTTCTGAGG	GATCCGGAGC	TGAAGGCGAT	GACCCTGCTA	AGGCTGCATT	6420
CAATAGTTTA	CAGGCAAGTG	CTACTGAGTA	CATTGGCTAC	GCTTGGGCTA	TGGTAGTAGT	6480
TATAGTTGGT	GCTACCATAG	GGATTAATT	ATTCAAAAAG	TTTACGAGCA	AGGCTTCTTA	6540
AGCAATAGCG	AAGAGGCCCG	CACCGATCGC	CCTTCCCAAC	AGTTGCGCAG	CCTGAATGGC	6600
GAATGGCGCT	TTGCCTGGTT	TCCGGCACCA	GAAGCGGTGC	CGGAAAGCTG	GCTGGAGTGC	6660
GATCTTCCTG	AGGCCGATAC	GGTCGTCGTC	CCCTCAAAC	GGCAGATGCA	CGGTTACGAT	6720
GCGCCCATCT	ACACCAACGT	AACCTATCCC	ATTACGGTCA	ATCCGCCGTT	TGTTCCCACG	6780
GAGAATCCGA	CGGGTTGTTA	CTCGCTCACA	TTTAATGTTG	ATGAAAGCTG	GCTACAGGAA	6840
GGCCAGACGC	GAATTATTTT	TGATGGCGTT	CCTATTGGTT	AAAAAAATGAG	CTGATTTAAC	6900
AAAAATTAA	CGCGAATTAA	AACAAAATAT	TAACGTTTAC	AATTAAATA	TTTGCCTTATA	6960
CAATCTTCCT	TTTTTGGGG	CTTTCTGAT	TATCAACCGG	GGTACATATG	ATTGACATGC	7020
TAGTTTACG	ATTACCGTTC	ATCGATTCTC	TTGTTGCTC	CAGACTCTCA	GGCAATGACC	7080
TGATAGCCTT	TGTAGATCTC	TCAAAAATAG	CTACCCTCTC	CGGCATTAAT	TTATCAGCTA	7140
GAACGGTTGA	ATATCATATT	GATGGTGATT	TGACTGTCTC	CGGCCTTTCT	CACCCCTTTG	7200
AATCTTACC	TACACATTAC	TCAGGCATTG	CATTTAAAAT	ATATGAGGGT	TCTAAAATT	7260
TTTATCCTTG	CGTTGAAATA	AAGGCTTCTC	CCGCAAAAGT	ATTACAGGGT	CATAATGTTT	7320
TTGGTACAAC	CGATTTAGCT	TTATGCTCTG	AGGCTTTATT	GCTTAATTAA	GCTAATTCTT	7380
TGCCTTGCCCT	GTATGATTAA	TTGGACGTT				7409

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7294 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: both
- (D) TOPOLOGY: circular

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

AATGCTACTA CTATTAGTAG AATTGATGCC ACCTTTCAAG CTCGCGCCCC	60
ATAGCTAAC AGGTTATTGA CCATTTGCGA AATGTATCTA ATGGTCAAAC TAAATCTACT	120
CGTTCGCAGA ATTGGGAATC AACTGTTACA TGGAATGAAA CTTCCAGACA CCGTACTTTA	180
GTTGCATATT TAAAACATGT TGAGCTACAG CACCAGATTG AGCAATTAAG CTCTAAGCCA	240
TCTGCAAAAA TGACCTCTTA TCAAAAGGAG CAATTAAAGG TACTCTCTAA TCCTGACCTG	300
TTGGAGTTG CTTCCGGTCT GGTCGCTTT GAAGCTCGAA TTAAAACGCG ATATTTGAAG	360
TCTTCGGGC TTCCTCTTAA TCTTTTGAT GCAATCCGCT TTGCTTCTGA CTATAATAGT	420
CAGGGTAAAG ACCTGATTT TGATTTATGG TCATTCTCGT TTTCTGAAC GTTAAAGCA	480
TTTGAGGGGG ATTCAATGAA TATTTATGAC GATTCCGCAG TATTGGACGC TATCCAGTCT	540
AAACATTTA CTATTACCCC CTCTGGCAAA ACTTCTTTG CAAAAGCCTC TCGCTATTTT	600
GGTTTTATC GTCGTCTGGT AAACGAGGGT TATGATAAGTG TTGCTCTTAC TATGCCCTCGT	660
AATTCCCTTT GGC GTTATGT ATCTGCATTA GTTGAATGTG GTATTCCCTAA ATCTCAACTG	720
ATGAATCTT CTACCTGTAA TAATGTTGTT CCGTTAGTTC GTTTTATTAA CGTAGATTTT	780
TCTTCCCAAC GTCCTGACTG GTATAATGAG CCAGTTCTTA AAATCGCATA AGGTAATTCA	840
CAATGATTAA AGTTGAAATT AAACCATCTC AAGCCCAATT TACTACTCGT TCTGGTGT	900
CTCGTCAGGG CAAGCCTTAT TCACTGAATG AGCAGCTTG TTACGTTGAT TTGGGTAATG	960
AATATCCGGT TCTTGTCAAG ATTACTCTTG ATGAAGGTCA GCCAGCCTAT GCGCCTGGTC	1020
TGTACACCGT TCATCTGTCC TCTTCAAAG TTGGTCAGTT CGGTTCCCTT ATGATTGACC	1080
GTCTCGCCT CGTTCCGGCT AAGTAACATG GAGCAGGTG CGGATTTCGA CACAATTTAT	1140
CAGGCATGA TACAAATCTC CGTTGTACTT TGTTTGCAGC TTGGTATAAT CGCTGGGGGT	1200
CAAAGATGAG TGTGTTAGTG TATTCTTCG CCTCTTCGTT TTTAGGTTGG TGCCTTCGTA	1260
GTGGCATTAC GTATTTACC CGTTAACATGG AAACCTCCCTC ATGAAAAAGT CTTTAGTCCT	1320
CAAAGCCTCT GTAGCCGTTG CTACCCCTCGT TCCGATGCTG TCTTTCGCTG CTGAGGGTGA	1380
CGATCCCGCA AAAGCGGCCT TTAACCTCCCT GCAAGCCTCA GCGACCGAAT ATATCGGTTA	1440
TGCGTGGGCG ATGGTTGTTG TCATTGTCGG CGCAACTATC GGTATCAAGC TGTTAAGAA	1500
ATTCACCTCG AAAGCAAGCT GATAAACCGA TACAATTAAA GGCTCCTTTT GGAGCCTTTT	1560
TTTTGGAGA TTTTCAACGT GAAAAAATTA TTATTGCAA TTCCCTTAGT TGTTCCCTTC	1620
TATTCTCACT CCGCTGAAAC TGTTGAAAGT TGTTAGCAA AACCCCCATAC AGAAAATTCA	1680

TTTACTAACG TCTGGAAAGA CGACAAAAGT TTAGATCGTT ACGCTAACTA TGAGGGTTGT	1740
CTGTGGAATG CTACAGGCCTG TGTAGTTGT ACTGGTACG AAAACTCAGTG TTACGGTACA	1800
TGGGTTCTA TTGGGCTTGC TATCCCTGAA AATGAGGGTG GTGGCTCTGA GGGTGGCGGT	1860
TCTGAGGGTG GCGGTTCTGA GGGTGGCGGT ACTAAACCTC CTGAGTACGG TGATACACCT	1920
ATTCCGGCT ATACTTATAT CAACCCTCTC GACGGCACTT ATCCGCCTGG TACTGAGCAA	1980
AAACCCGCTA ATCCTAATCC TTCTCTTGAG GAGTCTCAGC CTCTTAATAC TTTCATGTTT	2040
CAGAATAATA GGTTCCGAAA TAGGCAGGGG GCATTAACGT TTTATACGGG CACTGTTACT	2100
CAAGGCAGT GACCCGTTAA AACTTATTAC CAGTACACTC CTGTATCATC AAAAGCCATG	2160
TATGACGCTT ACTGGAACGG TAAATTCTAGA GACTGCGCTT TCCATTCTGG CTTTAATGAA	2220
GATCCATTCTG TTTGTGAATA TCAAGGCCAA TCGTCTGACC TGCCTCAACC TCCTGTCAAT	2280
GCTGGCGGCG GCTCTGGTGG TGGTTCTGGT GGCGGCTCTG AGGGTGGTGG CTCTGAGGGT	2340
GGCGGTTCTG AGGGTGGCGG CTCTGAGGGA GGCGGTTCCG GTGGTGGCTC TGGTTCCGGT	2400
GATTTGATT ATGAAAAGAT GGCAAACGCT AATAAGGGGG CTATGACCGA AAATGCCGAT	2460
AAAAACGCGC TACAGTCTGA CGCTAAAGGC AAACCTGATT CTGTCGCTAC TGATTACGGT	2520
GCTGCTATCG ATGGTTTCAT TGGTGACGTT TCCGGCCTTG CTAATGGTAA TGGTGCTACT	2580
GGTGATTTG CTGGCTCTAA TTCCCAAATG GCTCAAGTCG GTGACGGTGA TAATTGACCT	2640
TTAATGAATA ATTTCCGTCA ATATTTACCT TCCCTCCCTC AATCGGTTGA ATGTCGCCCT	2700
TTTGTCTTTA GCGCTGGTAA ACCATATGAA TTTTCTATTG ATTGTGACAA AATAAACTTA	2760
TTCCGGTGGT TCTTTGCGTT TCTTTTATAT GTTGCCACCT TTATGTATGT ATTTTCTACG	2820
TTTGCTAACAA TACTGCGTAA TAAGGAGTCT TAATCATGCC AGTTCTTTG GGTATTCCGT	2880
TATTATTGCG TTTCTCGGT TTCTTCTGG TAACTTTGTT CGGCTATCTG CTTACTTTTC	2940
TTAAAAAGGG CTTCGGTAAG ATAGCTATTG CTATTCATT GTTTCTTGCT CTTATTATTG	3000
GGCTTAACTC AATTCTTGTG GGTTATCTCT CTGATATTAG CGCTCAATTAA CCCTCTGACT	3060
TTGTTCAAGGG TGTTCAAGAT TCAGGATAAA ATTGTAGCTG GGTGCAAAAT AGCAACTAAT	3120
TCTCTGTAAA GGCTGCTATT TTCACTTTG ACGTTAAACA AAAAATCGTT TCTTATTG	3180
ATTGGGATAA ATAATATGGC TGTTTATTGTT GTAACTGGCA AATTAGGCTC TGGAAAGACG	3240
CTCGTTAGCG TTGGTAAGAT TCAGGATAAA ATTGTAGCTG GGTGCAAAAT AGCAACTAAT	3300
CTTGATTTAA GGCTTCAAAA CCTCCCGCAA GTCGGGAGGT TCGCTAAAC GCCTCGCGTT	3360
CTTAGAATAC CGGATAAGCC TTCTATATCT GATTGCTTG CTATTGGCG CGGTAATGAT	3420
TCCTACGATG AAAATAAAA CGGCTTGCTT GTTCTCGATG AGTGCAGGTAC TTGGTTAAT	3480
ACCCGTTCTT GGAATGATAA GGAAAGACAG CCGATTATTG ATTGGTTCT ACATGCTCGT	3540
AAATTAGGAT GGGATATTAT CTTCTTGTGTT CAGGACTTAT CTATTGTTGA TAAACAGGCG	3600
CGTTCTGCAT TAGCTGAACA TGTGTTTAT TGTCGTCGTC TGGACAGAAT TACTTTACCT	3660
TTTGTGGTA CTTTATATTC TCTTATTACT GGCTCGAAAA TGCCCTCTGCC TAAATTACAT	3720

GTTGGCGTTG TTAAATATGG CGATTCTCAA TTAAGCCCTA CTGTTGAGCG TTGGCTTTAT	3780
ACTGGTAAGA ATTTGTATAA CGCATATGAT ACTAAACAGG CTTTTCTAG TAATTATGAT	3840
TCCGGTGTTC ATTCTTATTT AACGCCTTAT TTATCACACG GTCGGTATT CAAACCATTAA	3900
AATTTAGGTC AGAAGATGAA GCTTACTAAA ATATATTTGA AAAAGTTTC ACGCGTTCTT	3960
TGTCTTGCAG TTGGATTTCGC ATCAGCATT ACATATAGTT ATATAACCCA ACCTAAGCCG	4020
GAGGTTAAAA AGGTAGTCTC TCAGACCTAT GATTTGATA AATTCACTAT TGACTCTTCT	4080
CAGCGTCTTA ATCTAAGCTA TCGCTATGTT TTCAAGGATT CTAAGGGAAA ATTAATTAAT	4140
AGCGACGATT TACAGAAGCA AGGTTATTCA CTCACATATA TTGATTTATG TACTGTTCC	4200
ATTAAAAAGG TAATTCAAAT GAAATTGTTA AATGTAATTA ATTTGTTTT CTTGATGTTT	4260
GTTTCATCAT CTTCTTTGC TCAGGTAATT GAAATGAATA ATTGCCTCT GCGCGATTTT	4320
GTAACCTGGT ATTCAAAGCA ATCAGGCAGA TCCGTTATTG TTTCTCCCGA TGTAAAAGGT	4380
ACTGTTACTG TATATTCATC TGACGTTAAA CCTGAAAATC TACGCAATT CTTTATTTCT	4440
GTTTACGTG CTAATAATTT TGATATGGTT GGTTCAATT CTTCCATTAT TTAGAAGTAT	4500
AATCCAAACA ATCAGGATTA TATTGATGAA TTGCCATCAT CTGATAATCA GGAATATGAT	4560
GATAATTCCG CTCCCTCTGG TGGTTCTTT GTTCCGAAA ATGATAATGT TACTCAAAC	4620
TTTAAAATTA ATAACGTCG GGCAAAGGAT TTAATACGAG TTGTCGAATT GTTGTAAAG	4680
TCTAATACCTT CTAAAATCCTC AAATGTATTAA TCTATTGACG GCTCTAATCT ATTGTTGTT	4740
AGTGCACCTA AAGATATTTT AGATAACCTT CCTCAATTCC TTTCTACTGT TGATTGCCA	4800
ACTGACCAGA TATTGATTGA GGGTTGATA TTTGAGGTT AGCAAGGTGA TGCTTAGAT	4860
TTTTCATTTG CTGCTGGCTC TCAGCGTGGC ACTGTTGCAG GCGGTGTTAA TACTGACCGC	4920
CTCACCTCTG TTTTATCTTC TGCTGGTGGT TCGTTGGTA TTTTAATGG CGATGTTTTA	4980
GGGCTATCAG TTCGCGCATT AAAGACTAAT AGCCATTCAA AAATATTGTC TGTGCCACGT	5040
ATTCTTACGC TTTCAGGTCA GAAGGGTTCT ATCTCTGTTG GCCAGAATGT CCCTTTATT	5100
ACTGGTCGTG TGACTGGTGA ATCTGCCAAT GTAAATAATC CATTTCAGAC GATTGAGCGT	5160
CAAATGTAG GTATTTCCAT GAGCGTTTT CCTGTTGCAG TGGCTGGCGG TAATATTGTT	5220
CTGGATATTAA CCAGCAAGGC CGATAGTTTG AGTTCTCTA CTCAGGCAAG TGATGTTATT	5280
ACTAATCAA AAGATATTGC TACAACGGTT AATTCGCGTG ATGGACAGAC TCTTTACTC	5340
GGTGGCCTCA CTGATTATAA AAACACTTCT CAAGATTCTG GCGTACCGTT CCTGTCTAAA	5400
ATCCCTTTAA TCGGCCTCCT GTTAGCTCC CGCTCTGATT CCAACGAGGA AAGCACGTTA	5460
TACGTGCTCG TCAAAGCAAC CATACTACGC GCCCTGTAGC GGCGCATTAA GCGCGGGGG	5520
TGTGGTGGTT ACGCGCAGCG TGACCGCTAC ACTTGCCAGC GCCCTAGCGC CCGCTCCTT	5580
CGCTTCTTC CCTTCCTTC TCGCCACGTT CGCCGGCTTT CCCCCGTCAAG CTCTAAATCG	5640
GGGGCTCCCT TTAGGGTTCC GATTTAGTGC TTTACGGCAC CTCGACCCCCA AAAAACTTGA	5700
TTTGGGTGAT GGTCACGTA GTGGGCCATC GCCCTGATAG ACGGTTTTTC GCCCTTGAC	5760

GTTGGAGTCC ACGTTCTTA ATAGTGGACT CTTGTTCAA ACTGGAACAA CACTCAACCC	5820
TATCTCGGGC TATTCTTTG ATTTATAAGG GATTTGCCG ATTCGGAAC CACCATCAA	5880
CAGGATTTG GCCTGCTGG GCAAACCAGC GTGGACCGCT TGCTGCAACT CTCTCAGGGC	5940
CAGGCCGTGA AGGGCAATCA GCTGTTGCCG GTCTCGCTGG TGAAAAGAAA AACCACCCCTG	6000
GCGCCAATA CGCAAACCGC CTCTCCCCGC GCGTTGCCG ATTCAATT GCAGCTGGCA	6060
CGACAGGTTT CCCGACTGGA AAGCGGGCAG TGAGCGCAAC GCAATTAAAT TGAGTTAGCT	6120
CACTCATTAG GCACCCCAGG CTTTACACTT TATGTTCCG GCTCGTATGT TGTGTGGAAT	6180
TGTGAGCGGA TAACAATTTC ACACAGGAAA CAGCTATGAC CAGGATGTAC GAATTCGAG	6240
GTAGGAGAGC TCGGCGGATC CGAGGCTGAA GGCGATGACC CTGCTAAGGC TGCATTCAAT	6300
AGTTTACAGG CAAGTGCTAC TGAGTACATT GGCTACGCTT GGGCTATGGT AGTAGTTATA	6360
GTTGGTGCTA CCATAGGGAT TAAATTATTC AAAAGTTTA CGAGCAAGGC TTCTTAACCA	6420
GCTGGCGTAA TAGCGAAGAG GCCCCCACCG ATCGCCCTTC CCAACAGTT CGCAGCCTGA	6480
ATGGCGAATG GCGCTTGCC TGGTTCCGG CACCAGAACG GGTGCCGGAA AGCTGGCTGG	6540
AGTGCATCT TCCTGAGGCC GATACTGTCG TCGTCCCTC AAAACTGGCAG ATGCACGGTT	6600
ACGATGCGCC CATCTACACC AACGTAACCT ATCCCATTAC GGTCAATCCG CCGTTGTTC	6660
CCACGGAGAA TCCGACGGGT TGTTACTCGC TCACATTAA TGTTGATGAA AGCTGGCTAC	6720
AGGAAGGCCA GACGCGAATT ATTTTGATG GCGTTCTAT TGTTAAAAAA ATGAGCTGAT	6780
TTAACAAAAA TTTAACGCGA ATTTAACAA AATATTAACG TTTACAATT AAATATTGCT	6840
TTATACAATC TTCTGTTT TGGGGCTTT CTGATTATCA ACCGGGGTAC ATATGATTGA	6900
CATGCTAGTT TTACGATTAC CGTCATCGA TTCTCTGTT TGCTCCAGAC TCTCAGGCAA	6960
TGACCTGATA GCCTTGATG ATCTCTAAA AATAGCTACC CTCTCCGGCA TTAATTATC	7020
AGCTAGAACG GTTGAATATC ATATTGATGG TGATTTGACT GTCTCCGGCC TTTCTCACCC	7080
TTTGAAATCT TTACCTACAC ATTACTCAGG CATTGCATT AAAATATATG AGGGTTCTAA	7140
AAATTTTAT CCTTGCCTTG AAATAAAGGC TTCTCCCGCA AAAGTATTAC AGGGTCATAA	7200
TGTTTTGGT ACAACCGATT TAGCTTATG CTCTGAGGCT TTATTGCTTA ATTTTGCTAA	7260
TTCTTGCTT TGCCTGTATG ATTATTTGGA CGTT	7294

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7394 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: both
 - (D) TOPOLOGY: circular

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

AATGCTACTA CTATTAGTAG AATTGATGCC ACCTTTCAAG CTCGCGCCCC AAATGAAAAT	60
ATAGCTAAC AGGTTATTGA CCATTGCGA AATGTATCTA ATGGTCAAAC TAAATCTACT	120

CGTTCGCAGA	ATTGGGAATC	AACTGTTACA	TGGAATGAAA	CTTCCAGACA	CCGTACTTTA	180
GTTGCATATT	AAAAACATGT	TGAGCTACAG	CACCAAGATT	AGCAATTAAG	CTCTAAGCCA	240
TCTGCAAAAA	TGACCTCTTA	TCAAAAGGAG	CAATTAAAGG	TACTCTCTAA	TCCTGACCTG	300
TTGGAGTTG	CTTCCGGTCT	GGTTCGCTT	GAAGCTCGAA	TTAAAACGCG	ATATTGAAAG	360
TCTTCGGGC	TTCCCTTTAA	TCTTTTGAT	GCAATCCGCT	TTGCTCTGA	CTATAATAGT	420
CAGGGTAAAG	ACCTGATTTT	TGATTTATGG	TCATTCTCGT	TTTCTGAAC	GTTAAAGCA	480
TTTGAGGGGG	ATTCAATGAA	TATTTATGAC	GATTCCGCAG	TATTGGACGC	TATCCAGTCT	540
AAACATTTA	CTATTACCCC	CTCTGGCAA	ACTTCTTTG	CAAAGCCTC	TCGCTATTTT	600
GGTTTTATC	GTCGTCTGGT	AAACGAGGGT	TATGATAGTG	TTGCTCTTAC	TATGCCCTCGT	660
AATTCCCTTT	GGCGTTATGT	ATCTGCATTA	GTTGAATGTG	GTATTCTAA	ATCTCAACTG	720
ATGAATCTTT	CTACCTGTAA	TAATGTTGTT	CCGTTAGTTC	TTTTTATTAA	CGTAGATTTT	780
TCTTCCCAAC	GTCCTGACTG	GTATAATGAG	CCAGTTCTTA	AAATCGCATA	AGGTAATTCA	840
CAATGATTAA	AGTTGAAATT	AAACCATCTC	AAGCCCAATT	TACTACTCGT	TCTGGTGT	900
CTCGTCAGGG	CAAGCCTTAT	TCACTGAATG	AGCAGCTTG	TTACGTTGAT	TTGGTAATG	960
AATATCCGGT	TCTTGTCAAG	ATTACTCTTG	ATGAAGGTCA	GCCAGCCTAT	GCGCCTGGTC	1020
TGTACACCGT	TCATCTGTCC	TCTTCAAAG	TTGGTCAGTT	CGGTTCCCTT	ATGATTGACC	1080
GTCTGCGCCT	CGTTCCGGCT	AAGTAACATG	GAGCAGGTGCG	CGGATTTCGA	CACAATTAT	1140
CAGGCGATGA	TACAAATCTC	CGTTGTACTT	TGTTTCGCGC	TTGGTATAAT	CGCTGGGGGT	1200
CAAAGATGAG	TGTTTTAGTG	TATTCTTCG	CCTCTTCGT	TTAGGTTGG	TGCCTTCGTA	1260
GTGGCATTAC	GTATTTTACC	CGTTTAATGG	AAACTCCCTC	ATGAAAAAGT	CTTTAGTCCT	1320
CAAAGCCTCT	GTAGCCGTTG	CTACCCCTCGT	TCCGATGCTG	TCTTCGCTG	CTGAGGGTGA	1380
CGATCCCGCA	AAAGCGGCCT	TTAACTCCCT	GCAAGCCTCA	GCGACCGAAT	ATATCGGTTA	1440
TGCGTGGGCG	ATGGTTGTTG	TCATTGTCGG	CGCAACTATC	GGTATCAAGC	TGTTTAAGAA	1500
ATTCACCTCG	AAAGCAAGCT	GATAAACCGA	TACAATTAAA	GGCTCCTTTT	GGAGCCTTTT	1560
TTTTGGAGA	TTTCAACGT	GAAAAAATTA	TTATTGCAA	TTCTTTAGT	TGTTCTTTTC	1620
TATTCTCACT	CCGCTGAAAC	TGTTGAAAGT	TGTTAGCAA	AACCCCATAC	AGAAAATTCA	1680
TTTACTAACG	TCTGGAAAGA	CGACAAAAC	TTAGATCGTT	ACGCTAACTA	TGAGGGTTGT	1740
CTGTGGAATG	CTACAGGCCT	TGTAGTTGT	ACTGGTGACG	AAACTCAGTG	TTACGGTACA	1800
TGGGTTCCCTA	TTGGGCTTGC	TATCCCTGAA	AATGAGGGTG	GTGGCTCTGA	GGGTGGCGGT	1860
TCTGAGGGTG	GCGGTTCTGA	GGGTGGCGGT	ACTAAACCTC	CTGAGTACGG	TGATACACCT	1920
ATTCCGGGCT	ATACTTATAT	CAACCCCTCTC	GACGGCACTT	ATCCGCTGG	TACTGAGCAA	1980
AACCCCGCTA	ATCCTAAATCC	TTCTCTTGAG	GAGTCTCAGC	CTCTTAATAC	TTTCATGTTT	2040
CAGAATAATA	GGTTCCGAAA	TAGGCAGGGG	GCATTAAC	TTTATACGGG	CACTGTTACT	2100
CAAGGCAC	ACCCCGTTAA	AACTTATTAC	CACTACACTC	CTGTATC	AAAAGCCATG	2160

TATGACGCTT	ACTGGAACGG	TAATTCAGA	GACTGCGCTT	TCCATTCTGG	CTTTAATGAA	2220
GATCCATTCTG	TTTGTGAATA	TCAAGGCCAA	TCGTCTGACC	TGCCTCAACC	TCCTGTCAAT	2280
GCTGGCGGCG	GCTCTGGTGG	TGGTTCTGGT	GGCGGCTCTG	AGGGTGGTGG	CTCTGAGGGT	2340
GGCGGTTCTG	AGGGTGGCGG	CTCTGAGGGA	GGCGGTTCCG	GTGGTGGCTC	TGGTTCCGGT	2400
GATTTGATT	ATGAAAAGAT	GGCAAACGCT	AATAAGGGGG	CTATGACCGA	AAATGCCGAT	2460
GAAAACGCGC	TACAGTCTGA	CGCTAAAGGC	AAACTTGATT	CTGTCGCTAC	TGATTACCGT	2520
GCTGCTATCG	ATGGTTTCAT	TGGTGACGTT	TCCGGCCTTG	CTAATGGTAA	TGGTGCTACT	2580
GGTGATTTG	CTGGCTCTAA	TTCCCAAATG	GCTCAAGTCG	GTGACGGTGA	TAATTACACCT	2640
TTAATGAATA	ATTTCCGTCA	ATATTTACCT	TCCCTCCCTC	AATCGGTTGA	ATGTCGCCCT	2700
TTTGTCTTTA	GCGCTGGTAA	ACCATATGAA	TTTTCTATTG	ATTGTGACAA	AATAAACTTA	2760
TTCCGTGGTG	TCTTTGCGTT	TCTTTATAT	GTTGCCACCT	TTATGTATGT	ATTTTCTACG	2820
TTTGCTAACAA	TACTGCGTAA	TAAGGAGTCT	TAATCATGCC	AGTTCTTTG	GGTATTCCGT	2880
TATTATTGCG	TTTCCTCGGT	TTCCCTCTGG	TAACTTGTT	CGGCTATCTG	CTTACTTTTC	2940
TTAAAAAGGG	CTTCGGTAAG	ATAGCTATTG	CTATTCATT	GTTTCTTGCT	CTTATTATTG	3000
GGCTTAACTC	AATTCTTGTG	GGTTATCTCT	CTGATATTAG	CGCTCAATTAA	CCCTCTGACT	3060
TTGTTCAAGGG	TGTTCAAGTTA	ATTCTCCCGT	CTAATGCGCT	TCCCTGTTTT	TATGTTATTTC	3120
TCTCTGTAAA	GGCTGCTATT	TTCATTTTG	ACGTTAAACA	AAAAATCGTT	TCTTATTTGG	3180
ATTGGGATAA	ATAATATGGC	TGTTTATTTT	GTAACTGGCA	AATTAGGCTC	TGGAAAGACG	3240
CTCGTTAGCG	TGGTAAGAT	TTAGGATAAA	ATTGTAGCTG	GGTGCAGGAAAT	AGCAACTAAT	3300
CTTGATTTAA	GGCTCAAAA	CCTCCCGCAA	GTCGGGACGT	TCGCTAAAAC	GCCTCGCGTT	3360
CTTAGAATAC	CGGATAAGCC	TTCTATATCT	GATTGCTTG	CTATTGGGCG	CGGTAATGAT	3420
TCCTACGATG	AAAATAAAAA	CGGCTTGCTT	GTTCTCGATG	AGTGCAGGTAC	TTGGTTAAAT	3480
ACCCGTTCTT	GGAATGATAA	GGAAAGACAG	CCGATTATTG	ATTGGTTTCT	ACATGCTCGT	3540
AAATTAGGAT	GGGATATTAT	TTTCTTGTT	CAGGACTTAT	CTATTGTTGA	AAAACAGGCG	3600
CGTTCTGCAT	TAGCTGAACA	TGTTGTTTAT	TGTCGTCGTC	TGGACAGAAAT	TACTTTACCT	3660
TTTGTGGTA	CTTTATATTC	TCTTATTACT	GGCTCGAAA	TGCGCTCGCC	AAAATTACAT	3720
GTTGGCGTTG	TTAAATATGG	CGATTCTCAA	TTAAGCCTA	CTGTTGAGCG	TTGGCTTTAT	3780
ACTGGTAAGA	ATTTGTATAA	CGCATATGAT	ACTAAACAGG	CTTTTTCTAG	TAATTATGAT	3840
TCCGGTGT	TTTCTTATTT	AACGCCCTAT	TTATCACACG	GTCGGTATT	CAAACCATTA	3900
AATTTAGGTC	AGAAGATGAA	GCTTACTAAA	ATATATTGA	AAAAGTTTC	ACGCGTTCTT	3960
TGTCTTGC	TTGGATTTC	ATCAGCATT	ACATATAGTT	ATATAACCCA	ACCTAAGCCG	4020
GAGGTTAAA	AGGTAGTCTC	TCAGACCTAT	GATTTGATA	AATTCACTAT	TGACTCTTCT	4080
CAGCGTCTTA	ATCTAAGCTA	TCGCTATGTT	TTCAAGGATT	CTAAGGGAAA	ATTAATTAAT	4140
AGCGACGATT	TACAGAAGCA	AGGTTATTCA	CTCACATATA	TTGATTTATG	TACTGTTCC	4200

100

ATTAAAAAAAG	GTAATTCAAA	TGAAATTGTT	AAATGTAATT	AATTTGTTT	TCTTGATGTT	4260
TGTTTCATCA	TCTTCTTTG	CTCAGGTAAT	TGAAATGAAT	AATTGCCTC	TGCGCGATTT	4320
TGTAACCTGG	TATTCAAAGC	AATCAGGCGA	ATCCGTTATT	GTTCCTCCCG	ATGTAAAAGG	4380
TACTGTTACT	GTATATTCAT	CTGACGTTAA	ACCTGAAAAT	CTACGCAATT	TCTTTATTTC	4440
TGTTTACGT	GCTAATAATT	TTGATATGGT	TGGTTCAATT	CCTTCCATAA	TTCAGAAGTA	4500
TAATCCAAAC	AATCAGGATT	ATATTGATGA	ATTGCCATCA	TCTGATAATC	AGGAATATGA	4560
TGATAATTCC	GCTCCTCTG	GTGGTTCTT	TGTTCCGAA	AATGATAATG	TTACTCAAAC	4620
TTTTAAAATT	AATAACGTTTC	GGGCAAAGGA	TTTAATACGA	GTGTCGAAT	TGTTTGTAAA	4680
GTCTAATACT	TCTAAATCCT	CAAATGTATT	ATCTATTGAC	GGCTCTAATC	TATTAGTTGT	4740
TAGTGCACCT	AAAGATATT	TAGATAACCT	TCCTCAATTC	CTTTCTACTG	TTGATTTGCC	4800
AACTGACCAG	ATATTGATTG	AGGGTTGAT	ATTTGAGGTT	CAGCAAGGTG	ATGCTTAGA	4860
TTTTTCATTT	GCTGCTGGCT	CTCAGCGTGG	CACTGTTGCA	GGCGGTGTTA	ATACTGACCG	4920
CCTCACCTCT	GTTCATCTT	CTGCTGGTGG	TTCGTTCGGT	ATTTTAATG	GCGATGTTTT	4980
AGGGCTATCA	GTTCGCGCAT	TAAAGACTAA	TAGCCATTCA	AAAATATTGT	CTGTGCCACG	5040
TATTCTTACG	CTTTCAGGTC	AGAAGGGTTC	TATCTCTGTT	GGCCAGAATG	TCCCTTTAT	5100
TACTGGTCGT	GTGACTGGTG	AATCTGCCAA	TGTAAATAAT	CCATTCAGA	CGATTGAGCG	5160
TCAAAATGTA	GGTATTTCCA	TGAGCGTTT	TCCTGTTGCA	ATGGCTGGCG	GTAATATTGT	5220
TCTGGATATT	ACCAGCAAGG	CCGATAGTTT	GAGTTCTTCT	ACTCAGGCAA	GTGATGTTAT	5280
TACTAATCAA	AGAAGTATTG	CTACAACGGT	TAATTTGCGT	GATGGACAGA	CTCTTTACT	5340
CGGTGGCCTC	ACTGATTATA	AAAACACTTC	TCAAGATTCT	GGCGTACCGT	TCCTGTCTAA	5400
AATCCCTTTA	ATCGGCCTCC	TGTTAGCTC	CCGCTCTGAT	TCCAACGAGG	AAAGCACGTT	5460
ATACGTGCTC	GTCAAAGCAA	CCATAGTACG	CGCCCTGTAG	CGCGCGATTA	AGCGCGGCGG	5520
GTGTGGTGGT	TACGCGCAGC	GTGACCGCTA	CACTTGCCAG	CGCCCTAGCG	CCCGCTCCCT	5580
TCGCTTTCTT	CCCTTCCCTT	CTCGCCACGT	TCGCCGGCTT	TCCCCGTCAA	GCTCTAAATC	5640
GGGGGCTCCC	TTTAGGGTTC	CGATTTAGTG	CTTACGGCA	CCTCGACCCCC	AAAAAAACTTG	5700
ATTTGGGTGA	TGGTTCACGT	AGTGGGCCAT	CGCCCTGATA	GACGGTTTT	CGCCCTTTGA	5760
CGTTGGAGTC	CACGTTCTT	AATAGTGGAC	TCTTGTCCA	AACTGGAACA	ACACTCAACC	5820
CTATCTCGGG	CTATTCTTT	GATTATAAG	GGATTTGCC	GATTCGGAA	CCACCATCAA	5880
ACAGGATTTT	CGCCTGCTGG	GGCAAACCGAG	CGTGGACCGC	TTGCTGCAAC	TCTCTCAGGG	5940
CCAGGGCGGTG	AAGGGCAATC	AGCTGTTGCC	CGTCTCGCTG	GTGAAAAGAA	AAACCACCC	6000
GGCGCCCAAT	ACGCAAACCG	CCTCTCCCCG	CGCGTTGGCC	GATTCAATTAA	TGCAGCTGGC	6060
ACGACAGGTT	TCCCGACTGG	AAAGCGGGCA	GTGAGCGCAA	CGCAATTAAT	GTGAGTTAGC	6120
TCACTCATTA	GGCACCCAG	GCTTACACT	TTATGCTTCC	GGCTCGTATG	TTGTGTGGAA	6180
TTGTGAGCGG	ATAACAATT	CACACCGTC	ACTTGGCACT	GGCCGTGTT	TTACAACGTC	6240

101

GTGACTGGGA	AAACCCTGGC	GTTACCCAAG	CTTTGTACAT	GGAGAAAATA	AAGTGAAACA	6300
AAGCACTATT	GCACTGGCAC	TCTTACCGTT	ACTGTTTACC	CCTGTGGCAA	AAGCCCTTCT	6360
GAGGCATCCG	GGAGCTGAAG	GCGATGACCC	TGCTAAGGCT	GCATTCATAA	GTTCACAGGC	6420
AAGTGCTACT	GAGTACATTG	GCTACGCTTG	GGCTATGGTA	GTAGTTATAG	TTGGTGCTAC	6480
CATAGGGATT	AAATTATTCA	AAAAGTTAC	GAGCAAGGCT	TCTTAAGCAA	TAGCGAAGAG	6540
GCCCCGACCG	ATCGCCCTTC	CCAACAGTTG	CGCAGCCTGA	ATGGCGAATG	GCGCTTGCC	6600
TGGTTTCCGG	CACCAGAACG	GGTGCCGGAA	AGCTGGCTGG	AGTGCATCT	TCCTGAGGCC	6660
GATACGGTCG	TCGTCCCCTC	AAACTGGCAG	ATGCACGGTT	ACGATGCGCC	CATCTACACC	6720
AACGTAACCT	ATCCCATTAC	GGTCAATCCG	CCGTTTGTTC	CCACGGAGAA	TCCGACGGGT	6780
TGTTACTCGC	TCACATTTAA	TGTTGATGAA	AGCTGGCTAC	AGGAAGGCCA	GACGCGAATT	6840
ATTTTGATG	GCGTTCCAT	TGGTTAAAAA	ATGAGCTGAT	TTAACAAAAA	TTAACCGCGA	6900
ATTTTAACAA	AATATTAACG	TTTACAATT	AAATATTGC	TTATACAATC	TTCTGTTTT	6960
TGGGGCTTTT	CTGATTATCA	ACCGGGGTAC	ATATGATTGA	CATGCTAGTT	TTACGATTAC	7020
CGTTCATCGA	TTCTCTTGT	TGCTCCAGAC	TCTCAGGCCA	TGACCTGATA	GCCTTTGTAG	7080
ATCTCTAAA	AATAGCTACC	CTCTCCGGCA	TTAATTATC	AGCTAGAACG	GTTGAATATC	7140
ATATTGATGG	TGATTTGACT	GTCTCCGGCC	TTTCTCACCC	TTTGAATCT	TTACCTACAC	7200
ATTACTCAGG	CATTGCATT	AAAATATATG	AGGGTTCTAA	AAATTTTTAT	CCTTGCGTTG	7260
AAATAAAGGC	TTCTCCCGCA	AAAGTATTAC	AGGGTCATAA	TGTTTTGGT	ACAACCGATT	7320
TAGCTTTATG	CTCTGAGGCT	TTATTGCTTA	ATTTGCTAA	TTCTTGCCT	TGCCTGTATG	7380
ATTTATTGGA	CGTT					7394

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 37 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

GATCCTAGGC TGAAGGCGAT GACCCTGCTA AGGCTGC

37

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 35 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

ATTCAATAGT TTACAGGCCA GTGCTACTGA GTACA

35

102

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 35 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

TTGGCTACGC TTGGGCTATG GTAGTAGTTA TAGTT

35

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 35 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

GGTGCTACCA TAGGGATTAA ATTATTCAAA AAGTT

35

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

TACGAGCAAG GCTTCTTA

18

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 39 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

AGCTTAAGAA GCCTTGCTCG TAAACTTTT GAATAATT

39

103

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

AATCCCTATG GTAGCACCAA CTATAACTAC TACCAT

36

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 35 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

AGCCCCAAGCG TAGCCAATGT ACTCAGTAGC ACTTG

35

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 34 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

CCTGTAAACT ATTGAATGCA GCCTTAGCAG GGTC

34

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

ATCGCCTTCA GCCTAG

16

104

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 bas pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

CTCGAATTCTG TACATCCTGG TCATAGC

27

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

CATTTTGCA GATGGCTTAG A

21

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

TAGCATTAAAC GTCCAATA

18

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

ATATATTTA GTAAGCTTCA TCTTCT

26

105

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

GACAAAGAAC GCGTGAAAAC TTT

23

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 35 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

GCGGGCCTCT TCGCTATTGC TTAAGAAGCC TTGCT

35

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 48 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

TTCAGCCTAG GATCCGCCGA GCTCTCCTAC CTGCGAATTC GTACATCC

48

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

TGGATTATAC TTCTAAATAA TGGA

24

106

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

TAACACTCAT TCCGGATGGA ATTCTGGAGT CTGGGT

36

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

AATTGCCAA GGAGACAGTC AT

22

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 39 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

AATGAAATAC CTATTGCCCTA CGGCAGCCGC TGGATTGTT

39

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 39 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

ATTACTCGCT GCCCAACCAAG CCATGGCCGA GCTCGTGAT

39

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 39 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

GACCCAGACT CCAGATATCC AACAGGAATG AGTGTAAAT

39

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 13 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

TCTAGAACGC GTC

13

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 35 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

ACGTGACGCG TTCTAGAATT AACACTCATT CCTGT

35

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 39 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

TGGATATCTG GAGTCTGGGT CATCACGAGC TCGGCCATG

39

108

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 39 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

GCTGGTTGGG CAGCGAGTAA TAACAATCCA GCGGCTGCC

39

(2) INFORMATION FOR SEQ ID NO:34:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 37 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

GTAGGGCAATA GGTATTCAT TATGACTGTC CTTGGCG

37

(2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

TGACTGTCTC CTTGGCGTGT GAAATTGTTA

30

(2) INFORMATION FOR SEQ ID NO:36:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

TAACACTCAT TCCGGATGGA ATTCTGGAGT CTGGGT

36

109

(2) INFORMATION FOR SEQ ID NO:37:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

CAATTTTATC CTAAATCTTA CCAAC

25

(2) INFORMATION FOR SEQ ID NO:38:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

CATTTTGCA GATGGCTTAG A

21

(2) INFORMATION FOR SEQ ID NO:39:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

CGAAAGGGGG GTGTGCTGCA A

21

(2) INFORMATION FOR SEQ ID NO:40:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

TAGCATTAAAC GTCCAATA

18

110

(2) INFORMATION FOR SEQ ID NO:41:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 43 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

AAACGACGGC CAGTGCCAAG TGACGCGTGT GAAATTGTTA TCC

43

(2) INFORMATION FOR SEQ ID NO:42:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 43 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

GGCGAAAGGG AATTCTGCAA GCGGATTAAG CTTGGGTAAC GCC

43

(2) INFORMATION FOR SEQ ID NO:43:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

GGCGTTACCC AAGCTTGTA CATGGAGAAA ATAAAG

36

(2) INFORMATION FOR SEQ ID NO:44:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 42 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

TGAAACAAAG CACTATTGCA CTGGCACTCT TACCGTTACC GT

42

111

(2) INFORMATION FOR SEQ ID NO:45:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 42 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

TACTGTTTAC CCCTGTGACA AAAGCCGCC AGGTCCAGCT GC

42

(2) INFORMATION FOR SEQ ID NO:46:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 44 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

TCGAGTCAGG CCTATTGTGC CCAGGGATTG TACTAGTGGA TCCG

44

(2) INFORMATION FOR SEQ ID NO:47:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 38 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

TGGCGAAAGG GAATTCCGGAT CCACTAGTAC AATCCCTG

38

(2) INFORMATION FOR SEQ ID NO:48:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 42 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

GGCACAAATAG GCCTGACTCG AGCAGCTGGA CCAGGGCGGC TT

42

112

(2) INFORMATION FOR SEQ ID NO:49:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 42 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:

TTGTCACAGG GGTAAACAGT AACGGTAACG GTAAGTGTGC CA

42

(2) INFORMATION FOR SEQ ID NO:50:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 42 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:

GTGCAAATAGT GCTTTGTTTC ACTTTATTTC CTCCATGTAC AA

42

(2) INFORMATION FOR SEQ ID NO:51:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:

TAACGGTAAG AGTGCAGTG C

21

(2) INFORMATION FOR SEQ ID NO:52:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 68 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: misc_difference
- (B) LOCATION: replace(25, "")
- (D) OTHER INFORMATION: /note= "'M represents an equal mixture of A and C at this location and at locations 28, 31, 34, 37, 40, 43, 46 & 49'"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:

AGCTCCCGGA TGCCTCAGAA GATGMNNMNN MNNMNNMNNM NNMNNMNNM NGGCTTTGC

60

CACAGGGG

68

113

(2) INFORMATION FOR SEQ ID NO:53:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 54 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ix) FEATURE:
 (A) NAME/KEY: misc_difference
 (B) LOCATION: replace(17, "")
 (D) OTHER INFORMATION: /note= ""M represents an equal
 mixture of A and C at this location and at
 locations 20, 23, 26, 29, 32, 35, 38, 41, 44 &

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:

CAGCCTCGGA TCCGCCMNMM NNMNNMNNMN NMNNMNNMNN MNNMNNATGM GAAT

54

(2) INFORMATION FOR SEQ ID NO:54:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 27 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:

GGTAAACAGT AACGGTAAGA GTGCCAG

27

(2) INFORMATION FOR SEQ ID NO:55:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 19 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:

GGGCCTTTGC CACAGGGGT

19

(2) INFORMATION FOR SEQ ID NO:56:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 63 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:

AGGGTCATCG CCTTCAGCTC CGGATCCCTC AGAAGTCATA AACCCCCCAT AGGCTTTGCG

60

CAC

63

(2) INFORMATION FOR SEQ ID NO:57:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 47 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:

TCGCCTTCAG CTCCCGGATG CCTCAGAAGC ATGAACCCCC CATAGGC

47

(2) INFORMATION FOR SEQ ID NO:58:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:

CAATTTATC CTAATCTTA CCAAC

25

(2) INFORMATION FOR SEQ ID NO:59:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:

GCCTTCAGCC TCGGATCCGC C

21

(2) INFORMATION FOR SEQ ID NO:60:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:

CGGATGCCTC AGAAGCCCCN N

21

(2) INFORMATION FOR SEQ ID NO:61:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 bas pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:

CGGATGCCCTC AGAAGGGCTT TTGCCACAGG

30

(2) INFORMATION FOR SEQ ID NO:62:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:

Thr Gln Ser Lys Cys Ser Thr Asp His Trp Leu Gly Tyr Ile Glu Tyr
1 5 10 15Phe Ile Met Cys Thr Tyr
20

(2) INFORMATION FOR SEQ ID NO:63:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:

Cys Asp Asp Gln Tyr Tyr Thr Asp His Glu Gln Gly Lys Cys Glu Val
1 5 10 15Ala Leu Tyr Tyr Thr Gly
20

(2) INFORMATION FOR SEQ ID NO:64:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: both

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:

Thr Gln Ser Lys Cys Ser Thr Asp His Trp Leu Gly Tyr Ile Glu Tyr
1 5 10 15

Phe Ile Met Cys Thr Tyr Arg Arg
20

(2) INFORMATION FOR SEQ ID NO:65:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:

Thr Cys Leu Arg Glu Glu Phe Ile Leu Gln Cys Tyr Ile Val Met Ile
1 5 10 15

Glu Asp Trp Tyr
20

(2) INFORMATION FOR SEQ ID NO:66:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:

Ile Cys Glu His His Gln Met Leu Leu Gln Cys Ser Leu Val Cys Glu
1 5 10 15

Glu Cys Met Met
20

(2) INFORMATION FOR SEQ ID NO:67:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:

Lys Cys Ile Ile Gly Trp Tyr Thr Leu Thr Cys Tyr Met Ser Asp Arg
1 5 10 15
Pro Arg Met Glu
20

(2) INFORMATION FOR SEQ ID NO:68:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:

Ala Cys Thr Gln Asp Met Asn Trp Ile Thr Cys Pro Met Tyr Cys Glu
1 5 10 15
Val Leu Cys Phe
20

(2) INFORMATION FOR SEQ ID NO:69:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:

Val Cys Phe Tyr Phe Pro Phe Lys Met Met Cys His Met Glu Tyr Ile
1 5 10 15
Ala Tyr Glu Tyr
20

(2) INFORMATION FOR SEQ ID NO:70:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:

Asp	Ala	Asn	Cys	Gly	His	Cys	Thr	Tyr	Met	Cys	Ile	Cys	Lys	Ile	Met
1					5						10				15
Tyr	Tyr	Ile	Ser												
			20												

(2) INFORMATION FOR SEQ ID NO:71:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:

Trp	His	Arg	His	Val	Ser	Ser	Pro	Met	Ser	Cys	Trp	Trp	Tyr	Asp	Gln
1				5					10					15	
Cys	Ala	Val	Ala												
		20													

(2) INFORMATION FOR SEQ ID NO:72:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:

Cys	Val	Gln	Ile	Asp	Phe	Phe	Thr	Val	Gln	Cys	Asn	Ile	Ser	Ser	His
1				5					10					15	
Met	Phe	Leu	Pro												
		20													

I CLAIM:

1. A composition of matter comprising a plurality of cells containing a diverse population of expressible oligonucleotides, each of said oligonucleotides encoding a soluble peptide having 5 constrained secondary structure in solution, wherein each of said oligonucleotides is operationally linked to expression elements, said expressible oligonucleotides having a desirable bias of random codon sequences.
2. The composition of claim 1, wherein said oligonucleotides have more than one codon encoding an amino acid capable of forming a covalent bond.
3. The composition of claim 2, wherein said amino acid is an amino acid selected from the group consisting of cysteine, glutamic acid, lysine, leucine or tyrosine.
4. The composition of claim 2, wherein said oligonucleotide is selected from the group consisting of
TCLREEFILQCYIVMIEDWY, ICEHHQMLLQCSLVCEECMM,
KCIIGWYTLTCYMSDRPRME, ACTQDMNWITCPMYCEVLCF,
VCFYFPFKMMCHMEYIAYEY, DANCGHCTYMCICKIMYYIS,
WHRHVSSPMSCWWYDQCAVA and CVQIDFFTVCQCNISSHMFLP

120

5. The composition of claim 1, wherein said cells are prokaryotes.

6. The composition of claim 4, wherein said prokaryotic cells are E. coli.

7. The composition of claim 1, wherein said expressible oligonucleotides are expressed as peptide fusion proteins on the surface of a filamentous bacteriophage.

8. A composition of matter comprising a plurality of cells containing a diverse population of expressible oligonucleotides, each of said oligonucleotides encoding a soluble peptide having constrained secondary structure in solution, wherein each of said oligonucleotides is operationally linked to expression elements, said expressible oligonucleotides having a desirable bias of random codon sequences produced from random combinations of first and second oligonucleotide precursor populations, each or either of said first and second precursor having a desirable bias of random codon sequences.

9. The composition of claim 8, wherein said first or second precursor oligonucleotides are biased.

10. The composition of claim 8, wherein said first and second precursor oligonucleotides are biased.

11. The composition of claim 8, wherein said first or second precursor oligonucleotides have more than one codon encoding an amino acid capable of forming a covalent bond.

12. The composition of claim 8, wherein said first and second precursor oligonucleotides have at least one codon encoding an amino acid capable of forming a covalent bond.

13. The composition of claim 8, wherein said oligonucleotide is selected from the group consisting of
TCLREEFILQCYIVMIEDWY, ICEHHQMLLQCSLVCEECMM,
KCIIGWYTLTCYMSDRPRME, ACTQDMNWITCPMYCEVLCF,
VCFYFPPFKMMCHMEYIAYEY, DANCGHCTYMCICKIMYYIS,
WHRHVSSPMSCWWYDQCAVA and CVQIDFFTVCQCNISSHMFLP

14. The composition of claim 11 or 12, wherein said amino acid is an amino acid selected from the group consisting of cysteine, glutamic acid, lysine, leucine or tyrosine.

15. The composition of claim 8, wherein said cells are procaryotes.

16. The composition of claim 15, wherein said procaryotic cells are E. coli.

17. The composition of claim 8, wherein said expressible oligonucleotides are expressed as peptide fusion proteins on the surface of a filamentous bacteriophage.

18. A kit for the preparation of vectors useful for the expression of a diverse population of random soluble peptides having constrained secondary structure in solution, said peptides being generated from 5 combined first and second precursor oligonucleotides when combined having a desirable bias of random codon sequences, comprising: two vectors: a first vector having a cloning site for said first precursor oligonucleotides and a pair of restriction sites for operationally 10 combining first precursor oligonucleotides with second precursor oligonucleotides; and a second vector having a cloning site for said second precursor oligonucleotides and a pair of restriction sites complementary to those on said first vector, one or both vectors containing 15 expression elements capable of being operationally linked to said combined first and second precursor oligonucleotides.

19. The kit of claim 18, wherein said vectors are in a filamentous bacteriophage.

20. The kit of claim 18, wherein said filamentous bacteriophage are M13.

21. The kit of claim 18, wherein said vectors are plasmids or phagemids.

22. The kit of claim 18, wherein said first or second precursor oligonucleotides are biased toward a pre-determined sequence.

23. The kit of claim 18, wherein said first and second precursor oligonucleotides are biased toward a predetermined sequence.

24. The kit of claim 18, wherein said first or second precursor oligonucleotides have more than one codon encoding an amino acid capable of forming a covalent bond.

25. The kit of claim 18, wherein said first and second precursor oligonucleotides have at least one codon encoding an amino acid capable of forming a covalent bond.

26. The kit of claim 24 or 25, wherein said amino acid is an amino acid selected from the group consisting of cysteine, glutamic acid, lysine, leucine or tyrosine.

27. A cloning system for expressing oligonucleotides encoding random, soluble peptides having constrained secondary structure in solution, said oligonucleotides being generated from a desirable bias of 5 random codon sequences, comprising a vector having a pair of restriction sites so as to allow the operational combination of said oligonucleotides into a contiguous oligonucleotide encoding said soluble peptide having constrained secondary structure in solution.

28. The cloning system of claim 27, wherein said oligonucleotides have more than one codon encoding an amino acid capable of forming a covalent bond.

29. A cloning system for expressing oligonucleotides encoding random, soluble peptides having constrained secondary structure in solution, said oligonucleotides being generated from diverse populations of combined first and second precursor oligonucleotides each or either having a desirable bias of random codon sequences, comprising: a set of first vectors having a desirable bias of random codon sequences and a second set of vectors having a diverse population of second precursor oligonucleotides having a desirable bias of random codon sequences, said first and second vectors each having a pair of restriction sites so as to allow the operational combination of said oligonucleotides into a contiguous oligonucleotide encoding said soluble peptide having constrained secondary structure in solution.

30. The composition of claim 29, wherein said first or second precursor oligonucleotides are biased.

31. The composition of claim 29, wherein said first and second precursor oligonucleotides are biased.

32. The cloning system of claim 29, wherein said first or second precursor oligonucleotides have more than one codon encoding an amino acid capable of forming a covalent bond.

33. The cloning system of claim 29, wherein said first and second precursor oligonucleotides have at least one codon encoding an amino acid capable of forming a covalent bond.

34. The cloning system of claim 32 or 33, wherein said amino acid is an amino acid selected from the group consisting of cysteine, glutamic acid, lysine, leucine or tyrosine.

35. The cloning system of claim 29, wherein said combined first and second vectors is through a pair of restriction sites.

36. The cloning system of claim 29, wherein said expressible oligonucleotides are expressed as peptide fusion proteins on the surface of a filamentous bacteriophage.

37. A vector comprising an oligonucleotide, said oligonucleotide having a desirable bias of random codon sequences, and more than one codon encoding an amino acid capable of forming a covalent bond.

38. A vector of claim 37, wherein said amino acid is an amino acid selected from the group consisting of cysteine, glutamic acid, lysine, leucine or tyrosine.

39. An isolated, soluble peptide having a constrained secondary structure in solution.

40. An expressible oligonucleotide produced by the cloning system of claim 29.

41. A host cell containing the cloning system of claim 29.

42. A host cell containing the vector of claim 38.

43. A method of isolating a soluble peptide having a constrained secondary structure in solution, which comprises growing said host cell of claim 41 or 42 under suitable conditions favoring expression of said 5 peptide, and isolating said peptide so produced.

44. A method of constructing a diverse population of vectors containing combined first and second precursor oligonucleotides, wherein each or either precursor oligonucleotides has a desirable bias of random 5 codon sequences, and capable of expressing said combined oligonucleotides as random, soluble peptides having constrained secondary structure in solution, comprising the steps of:

(a) operationally linking sequences from a diverse population of first precursor oligonucleotides having a desirable bias of random codon sequences to a first vector;

5

(b) operationally linking sequences from a diverse population of second precursor oligonucleotides having a desirable bias of random codon sequences to a second vector;

10

(c) wherein said first or second, or first and second precursor oligonucleotides have at least one codon capable of forming a covalent bond,

15


(d) combining the vector products of steps (a) and (b) under conditions where said populations of first and second precursor oligonucleotides are joined together into a population of combined vectors capable of being expressed.

20

45. The method of claim 44, wherein said amino acid is an amino acid selected from the group consisting of cysteine, glutamic acid, lysine, leucine or tyrosine.

130

46. The method of claim 44, wherein steps (a) through (d) are repeated two or more times.






FIG. 2




FIG. 3

SUBSTITUTE SHEET




FIG. 4

	10	20	30	40	50	60
1	AATGCTACTA	CTATTAGTAG	AATTGATGCC	ACCTTTCAAG	CTCGCGCCCC	AAATGAAAAT
61	ATAGCTAAAC	AGGTTATTGA	CCATTTGCAGA	AATGTATCTA	ATGGTCAAAC	TAAATCTACT
121	CGTTCGCAGA	ATTGGGAATC	AACTGTTACA	TGGAATGAAA	CTTCCAGACA	CCGTACTTTA
181	GTTGCATATT	TAAAACATGT	TGAGCTACAG	CACCAAGATTG	AGCAATTAAAG	CTCTAAGCCA
241	TCTGCAAAAA	TGACCTCTTA	TCAAAAGGAG	CAATTAAAGG	TACTCTCTAA	TCCTGACCTG
301	TTGGAGTTTG	CTTCCGGTCT	GGTTCGCTT	GAAGCTCGAA	TTAAAACGCG	ATATTGAGAG
361	TCTTCGGGC	TTCCCTCTAA	TCTTTTGAT	GCAATCCGCT	TTGCTTCTGA	CTATAATAGT
421	CAGGGTAAAG	ACCTGATTTT	TGATTTATGG	TCATTCTCGT	TTTCTGAACT	GTTTAAAGCA
481	TTTGAGGGGG	ATTCAATGAA	TATTTATGAC	GATTCCGCAG	TATTGGACGC	TATCCAGTCT
541	AAACATTTA	CTATTACCCC	CTCTGGCAAA	ACTTCTTTG	CAAAAGCCTC	TCGCTATTT
601	GGTTTTATC	GTCGCTCTGGT	AAACGAGGGT	TATGATAGTG	TTGCTCTTAC	TATGCCTCGT
661	AATTCTTTT	GGCGTTATGT	ATCTGCATTA	GTGAAATGTG	GTATTCTAA	ATCTCAACTG
721	ATGAATCTT	CTACCTGTAA	TAATGTTGT	CCGTTAGTTT	GTTTTATTAA	CGTAGATTT
781	TCTTCCAAC	GTCCTGACTG	GTATAATGAG	CCAGTTCTTA	AAATCGCATA	AGGTAATTCA
841	CAATGATTAA	AGTTGAAATT	AAACCATCTC	AAGCCCAATT	TACTACTCGT	TCTGGTGT
901	CTCGTCAGGG	CAAGCCTTAT	TCACTGAATG	AGCAGCTTTG	TTACGTTGAT	TTGGGTAATG
961	AATATCGGT	TCTTGTCAAG	ATTACTCTG	ATGAAGGTCA	GCCAGCCTAT	GCGCCTGGTC
1021	TGTACACCGT	TCATCTGTCC	TCTTCTAAAG	TTGGTCAGTT	CGGTTCCCTT	ATGATTGACC
1081	GTCTGCGCCT	CGTTCGGCT	AAGTAACATG	GAGCAGGTGCG	CGGATTTCGA	CACAATTAT
1141	CAGGCGATGA	TACAAATCTC	CGTTGTACTT	TGTTTCGCGC	TTGGTATAAT	CGCTGGGGGT
1201	CAAAGATGAG	TGTTTAGTG	TATTCTTTCG	CCTCTTCTCGT	TTAGGTTGG	TGCCTTCGTA
1261	GTGGCATTAC	GTATTTTACC	CGTTTAATGG	AAACTTCCTC	ATGAAAAAGT	CTTTAGTCT
1321	CAAAGCCTCT	GTAGCCGTTG	CTACCCCTCGT	TCCGATGCTG	TCTTCGCTG	CTGAGGGTGA
1381	CGATCCCGCA	AAAGCggcct	TTAACTCCCT	GCAAGCCTCA	GCGACCGAAT	ATATCGGTTA
1441	TGCGTGGCG	ATGGTTGTTG	TCATTGTCGG	CGCAACTATC	GGTATCAAGC	TGTTTAAGAA
1501	ATTCACCTCG	AAAGCAAGCT	GATAAACCGA	TACAATTAAA	GGCTCCTTTT	GGAGCCTTTT
1561	TTTTGGAGA	TTTCAACGT	AAAAAAATTA	TTATTCGCAA	TTCCCTTAGT	TGTTCCCTTC
1621	TATTCTCACT	CCGCTGAAAC	TGTTGAAAGT	TGTTTAGCAA	AACCCCATAC	AGAAAATTCA
1681	TTTACTAAGC	TCTGGAAAGA	CGACAAAATC	TTAGATCGTT	ACGCTAACTA	TGAGGGTTGT
1741	CTGTTGAATG	CTACAGGCCT	TGTTAGTTGT	ACTGGTGACG	AAACTCAGTG	TTACGGTACA
1801	TGGGTTCTA	TTGGGCTTGC	TATCCCTGAA	AATGAGGGTG	GTGGCTCTGA	GGGTGGCGGT
1861	TCTGAGGGGT	GCGGTTCTGA	GGGTGGCGGT	ACTAAACCTC	CTGAGTACGG	TGATACACCT
1921	ATTCGGGCT	ATACTTATAT	CAACCCCTC	GACGGCACTT	ATCCGCCTGG	TACTGAGCAA
1981	AAACCCCGCTA	ATCCTAATCC	TTCTTCTTGT	GAGTCTCAGC	CTCTTAATAC	TTTCATGTTT
2041	CAGAATAATA	GGTTCCGAAA	TAGGCAGGGG	GCATTAACCT	TTTATACGGG	CACTGTTACT
2101	CAAGGCACTG	ACCCCCGTTAA	AACTTATTAC	CAGTACACTC	CTGTATCATC	AAAAGCCATG
2161	TATGACGCTT	ACTGGAACCG	TAATTCAGA	GACTGCGCTT	TCCATTCTGG	CTTTAATGAA
2221	GATCCATTCTG	TTTGTGAATA	TCAGGCCAA	TCGTCCTGACC	TCGGTCAACC	TCTGTCAAT
2281	GCTGGCGGGCG	GCTCTGGTGG	TGGTTCTGGT	GGCGGCTCTG	AGGGTGGTGG	CTCTGAGGGT
2341	GGCGGTTCTG	AGGGTGGCGG	CTCTGAGGGG	GGCGGTTCCG	GTGGTGGCTC	TGGTTCCGGT
2401	GATTTTGATT	ATGAAAAGAT	GGCAAAACGCT	AAATAAGGGGG	CTATGACCGA	AAATGCCGAT
2461	GAAAACGCGC	TACAGTCTGA	CGCTAAAGGC	AAACTTGTATT	CTGTCGCTAC	TGATTACGGT
2521	GCTGCTATCG	ATGGTTTCAT	TGGTGACGTT	TCCGGCCTTG	CTAATGGTAA	TGGTGCTACT
2581	GGTGATTTTG	CTGGCTCTAA	TTCCCAAATG	GCTCAAGTCG	GTGACGGTGA	TAATTCAACCT
2641	TTAATGAATA	ATTTCCGTCA	ATATTTCACCT	TCCCTCCCTC	AATCGGTTGA	ATGTCGCCCT
2701	TTTGTCTTTA	CGCCTGGTAA	ACCATATGAA	TTTTCTATTG	ATTGTGACAA	AATAAAACTTA
2761	TTCCGTGGTG	TCTTGTGCGT	TCTTTTATAT	GTTGCCACCT	TTATGTATGT	ATTTCTACG
2821	TTTGCTAAC	TACTCGCTAA	TAAGGAGCT	TAATCATGCC	AGTTCTTTG	GGTATTCCGT
2881	TATTATTGCG	TTTCCCTCGGT	TTCCCTCTGG	TAACTTTGTT	GCCGTATCTG	CTTACTTTTC
2941	TTAAAAAAGGG	CTTCGGTAAAG	ATAGCTATTG	CTATTTCATT	GTTTCTTGCT	CTTATTATTG
3001	GGCTTAACCTC	AATTCTGTG	GGTTATCTCT	CTGATATTAG	CGCTCAATT	CCCTCTGACT
3061	TTGTTCAAGGG	TGTTCACTTA	ATTCTCCCGT	CTAATGCGCT	TCCCTGTTT	TATGTTATT
3121	TCTCTGTAAA	GGCTGCTATT	TTCATTTTG	ACGTTAAACA	AAAAATCGTT	TCTTATTGTTG
3181	ATTGGGATAAA	ATAATATGGC	TGTTTATTGT	GTAACTGGCA	AATTAGGCTC	TGGAAAGACG
3241	CTCGTTAGCG	TTGGTAAGAT	TCAGGATAAA	ATTGAGCTG	GGTGCAGGAAAT	AGCAACTAAT
3301	CCTGATTTAA	GGCTCAAAA	CCTCCCGCAA	GTCGGGAGGT	TCGCTAAAAC	GCCTCGCGTT
3361	CTTAGAATAC	CGGATAAGCC	TTCTATATCT	GATTGCTTGT	CTATTGGCG	CGGTAATGAT
3421	TCCTACGATG	AAAATAAAAA	CGGCTTGCCT	GTTCTCGATG	AGTGCAGGTAC	TTGGTTTAAT
3481	ACCCGTTCTT	GGAAATGATAA	GGAAAGACAG	CCGATTATTG	ATTGGTTCT	ACATGCTCGT
3541	AAATTAGGAT	GGGATATTAT	CTTCCTTGT	CAGGACTTAT	CTATTGTTGA	TAAACAGGCG
3601	CGTTCTGCAT	TAGCTGAACA	TCTTGTATTAT	TGTCGTCGTC	TGGACAGAAAT	TACTTTACCT
3661	TTTGTGGTGA	CTTTATATTG	TCTTATTACT	GGCTCGAAAA	TGCCTCTGCC	TAAATTACAT
3721	GTTGGCGTTG	TTAAATATGG	CGATTCTCAA	TTAAGCCCTA	CTGTTGAGCG	TTGGCTTTAT
3781	ACTGGTAAGA	ATTGTATAA	CGCATATGAT	ACTAAACAGG	CTTTTTCTAG	TAATTATGAT

FIG. 5-1

SUBSTITUTE SHEET

3841	TCCGGTGT	TTT ATTCTTATT	T AAGCCTTAT	TTATCACACG	GTCGGTATT	CAAACCATT	3900
3901	AATTTAGGTC	AGAAGATGAA	GCTTACTAAA	ATATATTG	AAAAGTTTC	ACCGGTTCTT	3960
3961	TGTCTTGC	GA TTGGATTTC	TCAGACATT	ACATATAGTT	ATATAACCCA	ACCTAAGCCG	4020
4021	GAGGTAAAAA	AGGTAGTCTC	TCAGACCTAT	GATTTGATA	AATTCACTAT	TGACTCTTCT	4080
4081	CAGCGTCTTA	ATCTAACGTA	TCGCTATGTT	TTCAAGGATT	CTAAGGGAAA	ATTAATTAAT	4140
4141	AGCGACGATT	TACAGAACG	AGGTTATTCA	CTCACATATA	TTGATTTATG	TACTGTTTCC	4200
4201	ATTAAGG	TAATTCAAAT	GAAATTGTTA	AATGTAATT	ATTTTGT	CTTGATGTTT	4260
4261	GTTTCA	TCTCTTTGC	TCAGGTAATT	GAAATGAATA	ATTGCCCTCT	GCGCGATTTT	4320
4321	GTAAC	TTGGT ATTCAAAAGCA	ATCAGGCGAA	TCGTTATTG	TTTCTCCCGA	TGTAAGG	4380
4381	ACTGTTACTG	TATATTCA	TGACGTTAAA	CCTGAAAATC	TACGCAATT	CTTATTTC	4440
4441	GTTTACGT	CTAATAATT	TGATATGGTT	GGTCAATT	CTTCCATTAT	TTAGAAGTAT	4500
4501	AATCCAAACA	ATCAGGATT	TATTGATGAA	TTGCCATCAT	CTGATAATCA	GGAATATGAT	4560
4561	GATAATTCCG	CTCCCTCTGG	TGGTTCTT	GTTCCGAAA	ATGATAATGT	TACTCAA	4620
4621	TTTAAAATT	ATAACGTTCG	GGCAAAGGAT	TAAATACGAG	TTGTCGAATT	GTTGTAAG	4680
4681	TCTAATAC	CTAAATCC	AAATGTATT	TCTATTGACG	GCTCTAATCT	ATTAGTTGTT	4740
4741	AGTGCACCTA	AAGATATT	AGATAACCTT	CCTCAATT	TTTCTACTGT	TGATTTGCCA	4800
4801	ACTGACCAGA	TATTGATTGA	GGGTTGATA	TTTGAGGTT	AGCAAGGTGA	TGCTTTAGAT	4860
4861	TTTCA	TTTG CTGCTGGCTC	TCAGCGTGGC	ACTGTTGCAG	GCGGTGTTA	TACTGACCGC	4920
4921	CTCAC	CTCTTATCTC	TGCTGGTGGT	TCGTTGGTA	TTTTAATGG	CGATGTTTTA	4980
4981	GGGCTAT	TCAG	AAAGACTAAT	AGCCATTCAA	AAATATTGTC	TGTCACGT	5040
5041	ATTCTTAC	GC	TTTCAGGTCA	GAAGGGTTCT	ATCTCTGTT	GCCAGAA	5100
5101	ACTGGT	CGTG	TGACTGGTGA	ATCTGCCAAT	GTAATAATC	CATTTCAGAC	5160
5161	CAAAATG	TAG	GTATTTCAT	GAGCGTTT	CCTGTTGCAA	TGGCTGGCG	5220
5221	CTGG	ATTA	CCAGCAAGGC	CGATAGTTT	AGTTCTTCTA	CTCAGGCAAG	5280
5281	ACTAAT	AAA	GAAGTATTG	TACAACGGTT	AATTGCGT	ATGGACAGAC	5340
5341	GGTGGC	CTCA	TCGATTATAA	AAACACTT	CAAGATTCTG	GCGTACCGT	5400
5401	ATCC	CTTAA	TCGGCCTC	GTTAGCTC	CGCTCTGATT	CCAACGAGGA	5460
5461	TACGT	GCTG	TCAAAGCAAC	CATAGTACG	GCCCTGTAGC	GGCGCATTAA	5520
5521	TGTGG	GGGT	ACGCGCAGCG	TGACCGCTAC	ACTTGC	GCCCTAGCGC	5580
5581	CGCT	TTCTC	CCTTCCTT	TCGCCACGTT	CGCGGCTT	CCCCGTCAAG	5640
5641	GGGG	CTCC	CTAGGGT	GATTTAGTGC	TTTACGGC	CTCGACCCCA	5700
5701	TTTGGG	G	GTGTTACGTA	GTGGGCCATC	GCCCTGATAG	ACGGTTTTC	5760
5761	GTTGG	GATC	ACGTTCTT	ATAGTGGACT	CTTGT	ACTGGAACAA	5820
5821	TATCT	C	TATTCTTT	ATTATAAGG	GATTTGCG	ATTTCGGAAC	5880
5881	CAGG	ATTT	GCCTGCTGGG	GCAAACCAGC	GTGGACCGC	TGCTGCAAC	5940
5941	CAGG	CGGT	GAAGGCAATCA	GCTGTTGCC	GTCTCGCTG	TGAAAAGAAA	6000
6001	GC	GCCCA	ATA	CGCAAACCGC	CGT	AACCAACCTG	6060
6061	CGAC	AGGTT	CCC	GA	GGC	ATTCAATT	6120
6121	CACT	CATT	AG	AA	G	GCAATTAA	6180
6181	TGTGAG	CGG	TAACAATT	ACACAGGAAA	CTG	TATGTTAGCT	6240
6241	GTAGGAG	AG	TCGGCGGATC	CTAGGCTGAA	CG	GAGGATGTAC	6300
6301	AGTTT	ACAGG	CAAGT	GCTAC	CG	GAATTCAAT	6360
6361	GTTGG	TGCTA	CCATAGGG	TGAGTACATT	GG	TGAGTATA	6420
6421	GCTGG	CGTAA	TAAATT	TT	CT	CGAGCAAGGC	6480
6481	ATGGC	GAATG	AGAG	GCCC	CG	TTCTTAACCA	6540
6541	AGTGC	GATCT	TGCT	CGAC	CA	CCAACGATTG	6600
6601	ACGAT	GC	TGCT	GGTC	AC	CGCAGCCTGA	6660
6661	CCACGG	AGGAA	TCCGACGGG	TGTTACT	AA	AGCTGGCTAC	6720
6721	AGGA	AGG	GACGCGAATT	TCG	AA	AGCTGGCTG	6780
6781	TTAAC	AAAAA	TTAACGCGA	GGT	TT	ATGAGCTGAT	6840
6841	TTATA	CAAC	ATTTAACAA	GAT	TA	AAATATTG	6900
6901	CATG	GCTAG	TTACGATTAC	GGT	TT	ATATGATTGA	6960
6961	TGAC	CTTGATA	GCCTTTG	TCATCGA	CT	TCTAGGCAA	7020
7021	AGCT	AGAACG	GTTGAATATC	ATCTCTAA	CT	TTAATTTC	7080
7081	TTT	GAATCT	TTACCTACAC	ATATTGATGG	CT	TTCTCACC	7140
7141	AAAT	TTT	CCTTGCGT	ATTACTCAGG	CT	TTCTCCGCA	7200
7201	TGTTT	GGT	ACAACCGATT	AAATAAGGC	CT	AAAGTATTAC	7260
7261	TTCTT	GCCT	TGCGTGTATG	ATTATTGGA	CGT	AGGGTCA	7294

FIG. 5-2

	10	20	30	40	50	60
1	AATGCTACTA	CTATTAGTAG	AATTGATGCC	ACCTTTCAAG	CTCGCGCCCC	AAATGAAAAT
61	ATAGCTAAC	AGGTTATTGA	CCATTGCGA	AATGTATCTA	ATGGTCAAAC	TAAATCTACT
121	CGTTCGCAGA	ATTGGGAATC	AACTGTACAG	TGGAATGAAA	CTTCAGACAA	CCGTACTTTA
181	GTTGCATATT	TAAAACATGT	TGAGCTACAG	CACCAAGATT	AGCAATTAAAG	CTCTAAGCCA
241	TCTGCAAAAA	TGACCTCTTA	TCAAAAGGAG	CAATTAAAGG	TACTCTCTAA	TCCTGACCTG
301	TTGGAGTTG	CTTCCGGTCT	GGTTCGCTT	GAAGCTCGAA	TTAAAACGCG	ATATTTGAAG
361	TCTTCGGGC	TTCCCTCTAA	TCTTTTGAT	GCAATCCGCT	TTGCTTCTGA	CTATAATAGT
421	CAGGGTAAAG	ACCTGATTG	TGATTTATGG	TCATTCTCGT	TTCTGAACT	GTTAAAGCA
481	TTTGAGGGGG	ATTCATGAA	TATTTATGAC	GATTCCGAG	TATTGGACGC	TATCCAGTCT
541	AAACATTTA	CTATTACCCC	CTCTGGCAAA	ACTTCTTTG	CAAAAGCCTC	TCGCTATTTT
601	GTTTTTATC	GTCGTCTGGT	AAACGAGGGT	TATGATAGTG	TTGCTTAC	TATGCCCTCGT
661	AATTCTTTT	GGCGTTATGT	ATCTGACATTA	GTTGAATGTC	GTATCTTAA	ATCTCAACTG
721	ATGAATCTT	CTACCTGTAA	TAATGTGTT	CCGTTAGTTC	GTTTTATTAA	CGTAGATTTT
781	TCTTCCCAAC	GTCCTGACTG	GTATAATGAG	CCAGTTCTTA	AAATCGCATA	AGGTAATTCA
841	CAATGATTAA	AGTTGAAATT	AAACCATCTC	AAGCCCAATT	TACTACTCGT	TCTGGTGT
901	CTCGTCAGGG	CAAGCCTTAT	TCACTGAATG	AGCAGCTTG	TTACGTTGAT	TTGGGTAATG
961	AATATCCGGT	TCTTGTCAAG	ATTACTCTTG	ATGAAGGTCA	GCCAGCCTAT	GCGCCTGGTC
1021	TGTACACCGT	TCATCTGTCC	TCTTCAAAG	TTGGTCAGTT	CGGTTCCCTT	ATGATTGACC
1081	GTCTGCGCCT	CGTTCGGCT	AAGTAACATG	GAGCAGGGTCG	CGGATTTCGA	CACAATTAT
1141	CAGGCATGAA	TACAAATCTC	CGTTGACTT	TGTTTCGCGC	TTGGTATAAT	CGCTGGGGGT
1201	CAAAGATGAG	TGTTTTAGTG	TATTCTTCG	CCTCTTCG	TTTAGGTTGG	TGCCTTCGTA
1261	GTGGCATTAC	GTATTTTACC	CGTTTAATGG	AAACCTCCCTC	ATGAAAAAGT	CTTTAGTCCT
1321	CAAAGCCTCT	GTAGCCGTTG	CTACCCCTCGT	TCCGATGCTG	TCTTCGCTG	CTGAGGGTGA
1381	CGATCCCGCA	AAAGCGGCCT	TTAACTCCCT	GCAAGCCTCA	GCGACCGAAT	ATATCGGTTA
1441	TGGTGGGGCG	ATGGTTGTTG	TCATTGTCGG	CGCAACTATC	GGTATCAAGC	TGTTAAAGAA
1501	ATTCACCTCG	AAAGCAAGCT	GATAAACCGA	TACAATTAA	GGCTCCCTTT	GGAGCCTTTT
1561	TTTTGGAGA	TTTCAACGT	GAAAAAAATTA	TATTCGCAA	TTCTTCTTACT	TGTTCTTTTC
1621	TATTCTCACT	CCGCTGAAAC	TGTTGAAAGT	TGTTTAGCAA	AACCCCATAC	AGAAAATTCA
1681	TTTACTAACG	TCTGGAAAGA	CGACAAACACT	TTAGATCGT	ACGCTAACTA	TGAGGGTTGT
1741	CTGTGGAATG	CTACAGGCCT	TGTAGTTGT	ACTGGTGACG	AAACTCAGTG	TTACGGTACA
1801	TGGGTTCTA	TTGGGCTTGC	TATCCCTGAA	ATGAGGGTG	GTGGCTCTGA	GGGTGGCGGT
1861	TCTGAGGGTG	GCGGTTCTGA	GGGTGGCGGT	ACTAAACCTC	CTGAGTACGG	TGATACACCT
1921	ATTCCGGGCT	ATACCTATAT	CAACCCCTCTC	GACGGCACCT	ATCCGCTTGG	TACTGAGCAA
1981	AACCCCGCTA	ATCCTAATATCC	TTCTCTTGAG	GGAGTCTCAGC	CTCTTAATAC	TTTCATGTTT
2041	CAGAATAATA	GGTTCGAAA	TAGGCAGGGG	GCATTAACCTG	TTTATACGGG	CACTGTTACT
2101	CAAGGCACTG	ACCCCCTTAA	AACTTATTAC	CAGTACACTC	CTGTATCATC	AAAAGCCATG
2161	TATGACGCTT	ACTGGAACCGG	TAAATTCTAGA	GAUTCGCGCTT	TCCATTCTGG	CTTTAATGAA
2221	GATCCATTCTG	TTTGTAATA	TCAAGGCCA	TCGTCTGACC	TGCCTCAACC	TCCTGTCAT
2281	GCTGGCGGCG	GCTCTGGTGG	TGGTTCTGGT	GGCGGCTCTG	AGGGTGGTGG	CTCTGAGGGT
2341	GGCGGTTCTG	AGGGTGGCGG	CTCTGAGGGG	GGCGGTTCCG	GTGGTGGCTC	TGGTTCCGGT
2401	GATTTTGATT	ATGAAAAGAT	GGCAACAGCT	AATAAGGGGG	CTATGACCGA	AAATGCCGAT
2461	AAAAAACGCGC	TACAGTCTGA	CGCTAAAGGC	AAACCTTGATT	CTGTCGCTAC	TGATTACGGT
2521	GCTGCTATCG	ATGGTTTCAT	TGGTGAACGT	TCCGGCCTTG	CTAATGGTAA	TGGTGCCT
2581	GGTGATTCTG	CTGGCTCTAA	TTCCCAAATG	GCTCAAGTCG	GTGACGGTGA	TAATTACACCT
2641	TTAATGAATA	ATTTCCGTCA	ATATTACCT	TCCCTCCCTC	AATCGGTTGA	ATGTGCCCT
2701	TTTGTCTTA	GCCTGTTGAA	ACCATATGAA	TTTTCTATTG	ATTTGACAA	AATAAACTTA
2761	TTCCGTGGTG	TCTTGTGCGT	TCTTTATAT	GTTGCCACCT	TTATGTATGT	ATTTTCTACG
2821	TTTGCTAAC	TACTGCGTAA	TAAGGGAGTC	TAATCATGCC	AGTTCTTTG	GGTATTCCGT
2881	TATTATTGCG	TTTCTCGGT	TTCTTCTGG	TAACTTTGTT	CGGCTATCTG	CTTACTTTTC
2941	TTAAAAAGGG	CTTCGGTAAAG	ATAGCTATTG	CTATTCATT	GTTCCTTGCT	CTTATTATTG
3001	GGCTTAACCTC	AATTCTTGTG	GGTTATCTCT	CTGATATTAG	CGCTCAATT	CCCTCTGACT
3061	TTGTTCAAGGG	TGTTCACTTA	ATTCTCCGT	GTAATGCGCT	TCCCTGTTT	TATGTTTATT
3121	TCTCTGTAAA	GGCTGCTATT	TTCATTTTG	ACGTTAAACA	AAAAAATCGTT	TCTTATTTGG
3181	ATTGGGATAA	ATAATATGGC	TGTTTATTTT	GTAACTGGCA	AATTAGGCTC	TGGAAAGACG
3241	CTCGTTAGCG	TTGGTAAGAT	TTAGGATAAA	ATTGTAGCTG	GGTGCAGGAAAT	AGCAACTAAT
3301	CTTGATTAA	GGGATCAAAA	CCTCCCGCAA	GTCGGGAGGT	TCGCTAAAAC	GCCTCGCGTT
3361	CTTAGAATAC	CGGATAAGCC	TTCTATATCT	GATTTGCTTG	CTATTGGCG	CGGTAAATGAT
3421	TCCTACGATG	AAAATAAAAA	CGGCTGCTT	GTTCTCGATG	AGTGCAGGTAC	TTGGTTTAAT
3481	ACCCGTTCTT	GGAAATGATAA	GGAAAGACAG	CCGATTATTG	ATTGGTTCT	ACATGTCGTT
3541	AAATTAGGAT	GGGATATTAT	CTTCCTTGT	CAGGACTTAT	CTATTGTTGA	TAAACAGGCG
3601	CGTTCTGCA	TAGCTGAACA	TGTTGTTAT	TGTCGTCGTC	TGGACAGAAT	TACTTTACCT
3661	TTTGTGCGTA	CTTATATTC	TCTTATTACT	GGCTCGAAAA	TGCTCTGCCC	TAAATTACAT
3721	GTTGGCGTTG	TTAAATATGG	CGATTCTCAA	TTAAGCCCTA	CTGTTGAGCG	TTGGCTTAT
3781	ACTGGTAAGA	ATTGTATAAA	CGCATATGAT	ACTAAACAGG	CTTTTTCTAG	TAATTATGAT

FIG. 6-1

SUBSTITUTE SHEET

3841	TCCGGTGT	TTT	ATTCTTATTT	AACGCC	TTATCACACG	GTCGGT	ATTTT	CA	3900
3901	AATTTAGGTC	AGAAGATGAA	ATTA	ACTAAA	ATATATTG	AAAAGTTT	TCGCGT	CTT	3960
3961	TGTCTTGCGA	TTGGATTG	TCAGC	ATTT	ACATATAG	ATATAACCC	ACCTAAG	CCG	4020
4021	GAGGTTAAAA	AGG	AGTAGTCTC	TCAGAC	GATTTG	ATTCACTAT	TGACT	CTTCT	4080
4081	CAGCGTCTT	ATCTAAGCTA	TCGCT	ATGTT	TCAGGATT	CTAAGGGAAA	ATTAATT	AA	4140
4141	AGCGACGATT	TACAGAAGCA	AGGTT	TATTCA	CTCACATATA	TTGATT	TACTG	TTTCC	4200
4201	ATTA	AAAG	GTAATTCAAA	TGAA	AAATG	AAATT	TCTTG	ATGTT	4260
4261	TGTTTCTATCA	TCTT	CTTTTG	CTCAGG	TAAT	AAATG	AATT	TCGCG	4320
4321	TGTA	ACTTGG	TATTCAAAAGC	AATCAGG	ATCGT	TTTCT	ATG	AAAAGG	4380
4381	TACTGTTACT	GTATATT	CAT	CTGACG	TTG	CTTCAATT	TCTT	TATTC	4440
4441	TGTTTACGT	GCTAATA	ATT	TTGAT	GGT	CCTCC	TCAGAAG	TA	4500
4501	TAATCCAAAC	AATCAGG	ATT	GATGA	ATTG	CCATCA	TCTG	ATAATC	4560
4561	TGATAATTCC	GCTC	TTCTG	GTGG	TGTT	TGCGCAA	AATG	TAATG	4620
4621	TTT	AAAATT	AATAACG	GGG	TTTCT	TTAATACG	TTG	TGCAAT	4680
4681	GTCTAAT	ACT	TCTAA	AAATG	ATCTATT	ATCTATTGAC	GGCT	TAAATC	4740
4741	TAGTGCAC	CCT	AAAGAT	TTT	TCCTCA	CTT	TACTG	TTGATT	4800
4801	AACTGACCAG	ATATTG	AGGG	TTGAT	ATTTGAGG	CAGCAAGG	ATG	TTT	4860
4861	TTTTCAT	TTT	GCTGCTGG	CTCAGC	GGCGT	CACTG	GGCG	GTGTT	4920
4921	CCTCAC	CTCT	GT	CTGG	TTG	TCGTT	ATTTT	TAATG	4980
4981	AGGGCTATCA	GTTC	CGC	TAAG	TTG	CGGT	AAA	ATTG	5040
5041	TATTCTTACG	CTT	CAGG	TC	AGAAGG	TTCTG	GGCC	AGAATG	5100
5101	TACTGGTC	GTG	ACTGG	TTG	AATCT	TAAT	CCATT	TAGA	5160
5161	TCAAAATG	TA	GGT	TTTCA	TGAGC	TTGCA	ATGGC	TGGCG	5220
5221	TCTGG	ATT	ACCAG	CAAGG	CCGAT	TTCT	GAGT	TCTT	5280
5281	TACTA	ATCAA	AGAAGT	TATTG	CTACAA	TTTGC	TAATT	GCGAT	5340
5341	CGGTGGC	CTC	ACTG	ATTATA	AAAAC	GGT	TCAAG	GGCGT	5400
5401	AATCC	CTTA	ATCGG	CTC	TGTT	GGCT	CCGCT	TGAT	5460
5461	ATACGTG	GTC	TCAAA	GCA	CCATAG	TCT	GGCCT	GGG	5520
5521	GTGTGG	TGGT	TACG	CGC	TGACCG	TTCACT	GGG	CGG	5580
5581	TCG	TTTCTT	CCCT	CC	TCG	GGG	TCG	CCG	5640
5641	GGGGG	CTCCC	TTAGGG	TT	CGATT	GGCT	CC	GGG	5700
5701	ATTTGGG	GTA	TG	TACGT	AGTGG	CGCC	CG	GGG	5760
5761	CGTTGG	GAGTC	CACG	TTT	AATAG	GTC	GGG	GGG	5820
5821	CTATCT	CGGG	CTATT	CTTT	GATT	GGAT	GGG	GGG	5880
5881	ACAGG	ATTT	CGC	CTG	GGC	GGG	CGT	GGG	5940
5941	CCAGG	GGGT	AAGGG	CAATC	AGCT	GGG	CGT	GGG	6000
6001	GGCG	CCC	AAAT	ACG	CC	GGG	CGC	GGG	6060
6061	ACGAC	AGGTT	TCCC	GACT	AAAG	GGG	GTG	GGG	6120
6121	TC	ACTC	CATTA	GGC	ACCCCC	GGG	TTATG	GGCTG	6180
6181	TTGTG	GAGC	GG	ATAACA	TTT	GG	GGAGA	CAGTC	6240
6241	TACGG	CAGCC	GCT	GGATT	TATT	GG	TGCCC	AAAC	6300
6301	GACCC	CAGACT	CCAGA	ATT	TC	GG	AGT	AAAC	6360
6361	ACTGG	CGTC	TTT	TACAA	TC	GG	TTAATT	CTAGAAC	6420
6421	CCTTG	CGCA	CA	CCCC	GG	GG	GGAAA	GGCGT	6480
6481	CCCTT	CCCAA	CAG	TTG	CG	GG	GGTAAT	GAAGAGG	6540
6541	AGAAG	GGGT	CCGG	AAAGCT	GG	GG	GGAT	GGGCC	6600
6601	CCC	CTCAAAC	TGG	CAGAT	GG	GG	GGCCC	GGGCC	6660
6661	CATTAC	GGTC	AAT	CCG	GG	GG	GGAGA	GGCG	6720
6721	ATTTA	ATG	TG	AAAGCT	GG	GG	GGG	GGG	6780
6781	TCCT	ATTG	T	AAAAA	GT	GG	GGG	GGG	6840
6841	TTAAC	GTTT	CA	TTTAA	GG	GG	GGGG	GGG	6900
6901	TTATCA	ACCCG	GGG	TACAT	GG	GG	GGGG	GGG	6960
6961	CTTGT	TTGCT	CC	AGACT	GG	GG	GGGG	GGG	7020
7021	GCTAC	CCCT	CC	GGCATT	GG	GG	GGGG	GGG	7080
7081	TTGACT	GTCT	CC	GGC	GG	GG	GGGG	GGG	7140
7141	GCAT	TTAAAA	TAT	ATGAGGG	GG	GG	GGGG	GGG	7200
7201	CCCG	CAAAAG	TAT	ACAGGG	GG	GG	GGGG	GGG	7260
7261	GAGG	CTT	TAT	TGCTTA	GG	GG	GGGG	GGG	7320

1	10	20	30	40	50	60
---	----	----	----	----	----	----

FIG. 6-2

	10	20	30	40	50	60
1	AATGCTACTA	CTATTAGTAG	AATTGATGCC	ACCTTTCAAG	CTCGCGCCCC	AAATGAAAAT
61	ATAGCTAAC	AGGTTATTGA	CCATTTGCGA	AATGTATCTA	ATGGTCAAAAC	TAAATCTACT
121	CGTTCGCAGA	ATTGGGAATC	AACTGTTACA	TGGAATGAAA	CTTCCAGACA	CGGTACTTTA
181	GTTGCATATT	TAAAACATGT	TGAGCTACAG	CACCAAGATT	AGCAATTAAAG	CTCTAACGCCA
241	TCTGAAAAAA	TGACCTCTTA	TCAAAAGGAG	CAATTAAAGG	TACTCTCTAA	TCCTGACCTG
301	TTGGAGTTTG	CTTCGGTCT	GGTCGCTT	GAAGCTCGAA	TTAAAACGCG	ATATTGAAAG
361	TCTTCGGGC	TTCCCTTTAA	TCTTTTGT	GCAATCCGCT	TTGCTCTGA	CTATAATAGT
421	CAGGGTAAAG	ACCTGATTTT	TGATTATGG	TCATTCTCGT	TTTCTGAACT	GTAAAGCA
481	TTTGAGGGGG	ATTCAATGAA	TATTTATGAC	GATTCCGCAG	TATGGACGC	TATCCAGTCT
541	AAACATTITA	CTATTACCCC	CTCTGGCAAA	ACTTCTTTG	CAAAAGCCTC	TCGCTATTTC
601	GGTTTTATC	GTGCTCTGGT	AAACGAGGGT	TATGATAGTG	TTGCTCTTAC	TATGCCCTCGT
661	AATTCCCTTT	GGCGTTATGT	ATCTGCATTA	GTTGAATGTG	GTATTCTCAA	ATCTCAACTG
721	ATGAATCTTT	CTACCTGTAA	TAATGTTGTT	CCGTTAGTTC	GTTTATTAA	CGTAGATTTC
781	TCTTCCCAAC	GTCCTGACTG	GTATAATGAG	CCAGTTCTTA	AAATCGCATA	AGGTAATTCA
841	CAATGATTAA	AGTTGAAATT	AAACCATCTC	AAGCCCAATT	TACTACTCGT	TCTGGTGT
901	CTCGTCAGGG	CAAGCCTTAT	TCACTGAATG	AGCAGCTTG	TTACGTTGAT	TTGGGTAATG
961	AATAACCGGT	TCTTGTCAAG	ATTACTCTTG	ATGAAGGTCA	GCCAGCCTAT	GCGCCTGGTC
1021	TGTACACCGT	TCATCTGTCC	TCTTCAAAG	TTGGTCAGTT	CGGTTCCCTT	ATGATTGACC
1081	GTCTGCGCCT	CGTTCGGCT	AAGTAACATG	GAGCAGGTGCG	CGGATTTCGA	CACAATTAT
1141	CAGGCATGA	TACAAATCTC	CGTTGACTT	TGTTTGCAGC	TTGGTATAAT	CGCTGGGGGT
1201	CAAAGATGAG	TGTTTGTAGTG	TATTCTTTCG	CCTCTTTCTG	TTAGGTTGG	TGCCTTCGTA
1261	GTGGCATTAC	GTATTTTACC	CGTTTAATGG	AAACTCTCTC	ATGAAAAAAGT	CTTCTAGTCCT
1321	CAAAGCCTCT	GTAGCCGTTG	CTACCCCTCGT	TCCGATGCTG	TCTTCGCTG	CTGAGGGTGA
1381	CGATCCCGCA	AAAGCGGCCT	TTAACCTCCCT	GCAAGCCTCA	GCGACCGAAT	ATATCGGTTA
1441	TGCGTGGGGCG	ATGGTTGTTG	TCATTGTCGG	CGCAACTATC	GGTATCAAGC	TGTTTAAGAA
1501	ATTCACCTCG	AAAGCAAGCT	GATAAACCGA	TACAATTAAA	GGCTCCTTTT	GGAGCCTTTT
1561	TTTTTGGAGA	TTTCAACGT	GAAAAAAATT	TTATTGCAA	TTCTTTAGT	TGTTCCCTTC
1621	TATTCTCACT	CCGCTGAAAC	TGTTGAAAGT	TGTTTAGCAA	AACCCCATAC	AGAAAATTCA
1681	TTTACTAAAG	TCTGGAAAGA	CGACAAAACT	TTAGATCGTT	ACGCTAACTA	TGAGGGTTGT
1741	CTGTGGAATG	CTACAGGCCT	TGTAGTTGT	ACTGGTGAACG	AAACTCAGTG	TTACGGTACA
1801	TGGGTTCTA	TTGGGCTTGC	TATCCCTGAA	AATGAGGGTG	GTGGCTCTGA	GGGTGGCGGT
1861	TCTGAGGGTG	GGCGTTCTGA	GGGTGGCGGT	ACTAAACCTC	CTGAGTACGG	TGATACACCT
1921	ATTCCGGGCT	ATACTTATAT	CAACCCCTCTC	GACGGCACTT	ATCCGCCCTGG	TACTGAGCAA
1981	AACCCCGCTA	ATCTTAATCC	TTCTCTTGAG	GAGTCTCAGC	CTCTTAATAC	TTTCATGTTT
2041	CAGAATAATA	GGTTCGAAA	TAGGCAGGGG	GCATTAACGT	TTTATACGGG	CACTGTTACT
2101	CAAGGCACTG	ACCCCGTTAA	AACTTATTAC	CAGTACACTC	CTGTATCATC	AAAAGCCATG
2161	TATGACGCTT	ACTGGAACCG	TAAATTCTAGA	GAATGCGCTT	TCCATTCTGG	CTTAAATGAA
2221	GATCCATTCTG	TTTGTGAATA	TCAAGGCCAA	TCGTCTGACC	TGCTCAACC	TCCTGTCAAT
2281	GCTGGCGGCG	GCTCTGGTGG	TGGTTCTGGT	GGCGGCTCTG	AGGGTGGTGG	CTCTGAGGGT
2341	GGCGGTTCTG	AGGGTGGCGG	CTCTGAGGGG	GGCGGTTCCG	GTGGTGGCTC	TGGTTCCGGT
2401	GATTGTTGATT	ATGAAAAGAT	GGCAACACGT	ATAAGGGGG	CTATGACCGA	AAATGCCGAT
2461	AAAAACGCGC	TACAGTCTGA	CGCTAAAGGC	AAACTTGTATT	CTGTGCGCTAC	TGATTACGGT
2521	GCTGCTATCG	ATGGTTTCTAT	TGGTGAACGTT	TCCGGCCTTG	CTAATGGTAA	TGGTGTACT
2581	GGTGATTTTG	CTGGCTCTAA	TTCCCAAATG	GCTCAAGTCG	GTGACGGTGA	TAATTACACT
2641	TTAATGAATA	ATTTCCGTCA	ATATTACCT	TCCCTCCCTC	AATCGGTTGA	ATGTCGCCCT
2701	TTTGTCTTA	GCGCTGGTAA	ACCATATGAA	TTTCTATTG	ATTGTGACAA	AATAAAACTTA
2761	TTCCGTGGTG	TCTTGTGCGTT	TCTTTATAT	GTTGCCACCT	TTATGTATGT	ATTTTCTACG
2821	TTTGCTAAC	TACTGCGTAA	TAAGGAGTCT	TAATCATGCC	AGTTCTTTG	GGTATTCCGT
2881	TATTATTGCG	TTTCTCTGGT	TTCTCTCTGG	TAACTTTGTT	CGGCATATCTG	CTTACTTTTC
2941	TTAAAAAGGG	CTTCGGTAAG	ATAGCTATTG	CTATTTCATT	GTTTCTTGCT	CTTATTATTG
3001	GGCTTAAC	AATTCTTGTG	GGTTATCTCT	CTGATATTAG	CGCTCAATTAA	CCCTCTGACT
3061	TTGTTCAAGGG	TGTTCACTTAA	ATTCTCCCGT	CTAATGCGCT	TCCCTGTTTT	TATGTTATTTC
3121	TCTCTGTAAA	GGCTGCTATT	TTCATTTTG	ACGTTAAACAA	AAAAATCGTT	TCTTATTATTG
3181	ATTGGGATAAA	ATAATATGGC	TGTTTATTG	GTAACTGCGA	AATTAGGGCTC	TGGAAGAGACG
3241	CTCGTTAGCG	TTGGTAAGAT	TCAGGATAAA	ATTGTAGCTG	GGTGCAAAAT	AGCAACTAAT
3301	CTTGATTAA	GGCTCAAAA	CCTCCCGCAA	GTCGGGAGGT	TCGCTAAAAC	GCCTCGCGTT
3361	CTTAGAATAC	CGGATAAGCC	TTCTATATCT	GATTTGCTTG	CTATTGGGC	CGGTAAATGAT
3421	TCCTACGATG	AAAATAAAAA	CGGCTGCTT	GTTCTCGATG	AGTGCAGGTAC	TTGGTTTAAT
3481	ACCCGTTCTT	GGAATGATAA	GGAAAGACAG	CCGATTATTG	ATTGGTTTCT	ACATGCTCGT
3541	AAATTAGGAT	GGGATATTAT	TTTCTTGTGTT	CAGGACTTAT	CTATTGTTGA	AAACAGGCG
3601	CGTTCTGCAT	TAGCTGAACA	TGTTGTTTAT	TGTCGTCGTC	TGGACAGAAAT	TACTTACCT
3661	TTTGTGGTAA	CTTTATATTCT	TCTTATTACT	GGCTCGAAAA	TGCTCTTGCC	AAATTACAT
3721	GTTGGCGTTG	TTAAATATGG	CGATTCTCAA	TTAAGCCCTA	CTGTTGAGCG	TTGGCTTTAT

FIG. 7-1

3781	ACTGGTAAGA	ATTTGTATAA	CGCATATGAT	ACTAAACAGG	CTTTTTCTAG	TAATTATGAT	3840
3841	TCCGGTGT	TTT	ATTCTTATT	AACGCC	TTATCACACG	GTCGGTATT	3900
3901	AATTAGGT	TC	AGAAGATGAA	GCTTACTAAA	ATATATTG	AAAAGTTTC	3960
3961	TGTCTTGC	GA	TTGGATTG	ATCAGCATT	ACATATAGT	ACGCGITCTT	4020
4021	GAGGTAA	AA	AGGTAGTCTC	TCAGACCTAT	GATTTGATA	ATATAACCCA	4080
4081	CAGCGTCT	TA	ATCTAAGCTA	TCGCTATGTT	TTCAAGGATT	ACCTAAGCCG	4140
4141	AGCGACG	GATT	TACAGAAGCA	AGGTTATTCA	CTCACATATA	CTAAGGGAAA	4200
4201	ATTA	AAAAG	GTAATTCAA	TGAAATTGTT	AAATGTAATT	ATTAATTAAAT	4260
4261	TGTTT	CATCA	TCTTCTT	CTCAGGTAAT	TGAAATGAAT	TGACTCTTCT	4320
4321	TGTA	ACTT	GG	AATCAGGCGA	ATCCGTTATT	GTTTCTCCG	4380
4381	TACTGTT	ACT	GTATATT	CTGACGTTAA	ACCTGAAAAT	ATGTAAAAGG	4440
4441	TGTTT	TACGT	GCTAATAATT	TTGATATGGT	TGGTTCAATT	TCTTCATAA	4500
4501	TAAT	CCAAAC	AATCAGGATT	ATATTGATGA	ATTGCCATCA	TCTGATAATC	4560
4561	TGATA	ATTCC	GCTCCTT	GTGGTTCTT	TGTTCCGCAA	AGGAATATGA	4620
4621	TTTT	AAAATT	AATAACGT	GGGCAAAGGA	TTAATACGA	TTACTCAAAC	4680
4681	GTCT	AA	TACT	TCTAAATCCT	CAAATGATT	TCTTATTGAC	4740
4741	TAGT	GCAC	CT	AAAGATATT	TAGATAACCT	GGCTCTAATC	4800
4801	AACT	GACCA	AG	ATATTGATTG	AGGGTTGAT	TCTTCTACTG	4860
4861	TTTT	TATT	GCTGCTGG	CTCAGCGTGG	ATTGAGGTT	TTGATTTGCC	4920
4921	CCTCAC	CT	GT	TTTATCTT	CTGCTGGTGG	GGCAAGGTG	4980
4981	AGGG	TATCA	GT	TTGC	TTCAGGCTA	ATGCTTGT	5040
5041	TATT	CTTACG	CTT	CAGGTC	AGAAGGGTTC	CTGCTTGTAA	5100
5101	TACT	GGTC	GT	GACTGGT	AATCTGCCA	TGTAATAAT	5160
5161	TCAAA	ATGTA	GG	TATT	TGAGCGTTT	CCATTTCAGA	5220
5221	TCTGG	ATATT	AC	CAAGG	CCGATAGTT	CGAGTCTTCT	5280
5281	TACT	AA	AG	AGTATT	CTACAA	ACTCAGGCAA	5340
5341	CGGT	GGC	CTC	ACTGATT	AAAACACTTC	GATGGACAGA	5400
5401	AAT	CCCTT	TA	TCG	TGTTAGCTC	CTCCTTACT	5460
5461	ATAC	GTG	CT	GTCAAAGCAA	CCATAGTACG	GGCGTACCGT	5520
5521	GTG	GGT	GGT	TAC	GTGACCGCTA	GGCGCTAGCG	5580
5581	TCG	CTT	CTT	CCCT	CACTTGCCAG	CCCCTAGCG	5640
5641	GGGG	GCT	CCC	TTA	TCGCGGCTT	TCCCCGTCAA	5700
5701	TTT	GGG	TTT	AGGG	CGATTAGTG	TTTACGGCA	5760
5761	CGTT	GG	GG	GTG	TGAGGCCAT	GGCCCTGATA	5820
5821	CTAT	CT	GGG	CTATT	AGTGGAC	GACGGTTTT	5880
5881	ACAGG	ATT	TT	CGC	TGTTATAAG	GGAGGTTG	5940
5941	CCAGG	GGG	TTG	GG	GGAAACCAG	GATTCATTAA	6000
6001	GGC	GCC	AA	AAG	AGCTGTTGCC	TGCAGCTGGC	6060
6061	ACG	ACAGG	TT	TCCG	CCCTCTCCCG	GATTCTAA	6120
6121	TCA	CT	TT	ACTG	AAAGCGGGCA	GTGAGCGCAA	6180
6181	TTGT	GAG	GG	GCTT	GCTTACACT	GGCAATTAA	6240
6241	GTG	ACT	GGG	AA	CAAC	GGTGTAG	6300
6301	AAG	CACT	TT	GG	CCACTGGC	TTTACCCCTG	6360
6361	CGCC	CAGG	TC	AG	TCTTACCGCT	GGGGATTGTA	6420
6421	CTAGG	GCT	GA	GG	CTGCTAAGGC	TGCAATTCAAT	6480
6481	TGAG	TAC	AT	GG	GGGCTATGGT	AGTTACAGG	6540
6541	TAA	ATT	TT	GG	CGAGCAAGGC	TTCTTAAGCA	6600
6601	GAT	CGC	CC	GG	GCGCAGCCTG	ATAGCGAAGA	6660
6661	GCAC	CAGA	AG	GG	AAGCTGGCTG	GGCGCTTGC	6720
6721	GTC	GT	CC	AA	GATGCAACGGT	TTCTTGAGGC	6780
6781	TAT	CCC	ATTA	CGG	GCCGTTTGTT	CCATCTACAC	6840
6841	CTC	CAC	TTA	GG	CCCACGGAGA	CAACGTAACC	6900
6901	GGC	GT	TTA	GG	AAGCTGGCTA	ATCCGACGGG	6960
6961	AAAT	ATT	AA	AA	CAGGAAGGCC	TTGTTACTCG	7020
7021	TCT	GATT	AT	TT	AGTGGAC	AGACGCGAAT	7080
7081	ATT	CTT	GT	GG	TTAACAAAA	TATTTTGAT	7140
7141	AAAT	AGCT	AC	GG	ATTAA	ATTAAACGCG	7200
7201	GTG	ATT	TC	GG	TTTCTCACC	TTTACCTACA	7260
7261	GCAT	TG	CC	GG	CTTTCACC	CATTACTCAG	7320
7321	CTT	CT	CC	GG	AAAATT	GAAATAAAGG	7380
7381	GCT	CT	GG	GG	ATGTTTTGG	TTAGCTTAT	7440
7441	ACG	TT	GG	CT	AATT	TTGCTGTAT	7445

FIG. 7-2

SUBSTITUTE SHEET

	10	20	30	40	50	60
1	AATGCTACTA	CTATTAGTAG	AATTGATGCC	ACCTTTTCAG	CTCGCGCCCC	AAATGAAAAT
61	ATAGCTAAC	AGGTTATTGA	CCATTGCGA	AATGTATCTA	ATGGTCAAAC	TAAATCTACT
121	CGTCGCAGA	ATTGGGAATC	AACTGTTACA	TGGAATGAAA	CTTCCAGACA	CCGTACTTTA
181	GTTGCATATT	TAAAACATGT	TGAGCTACAG	CACCAAGATT	AGCAATTAAAG	CTCTAAGCCA
241	TCTGCAAAAAA	TGACCTCTTA	TCAAAAGGAG	CAATTAAAGG	TACTCTCTAA	TCCTGACCTG
301	TTGGAGTTTG	CTTCCGGTCT	GGTTCGCTT	GAAGCTCGAA	TTAAAACGCG	ATATTGAAAG
361	TCTTCGGGC	TTCCCTTAA	TCTTTTGAT	GCAATCCGCT	TTGCTTCTGA	CTATAATAGT
421	CAGGGTAAAG	ACCTGATTTT	IGATTTATGG	TCATTCTCGT	TTTCTGAACT	GTTTAAAGCA
481	TTTGAGGGGG	ATTCAATGAA	TATTTATGAC	GATTCCGCGAG	TATTGGACGC	TATCCAGTCT
541	AAACATTTTA	CTATTACCCC	CTCTGGCAAA	ACTTCTTTG	CAAAGCCCTC	TCGCTATTT
601	GGTTTTATC	GTCGCTGTT	AAACAGGGGT	TATGATAGTG	TTGCTCTTAC	TATGCCTCGT
661	AATTCCCTTT	GGCGTTATGT	ATCTGCATTA	GTTGAATGTG	GTATTCTCAA	ATCTCAACTG
721	ATGAATCTTT	CTACCTGTAA	TAATGTTGTT	CCGTTAGTTC	GTTTATTAA	CGTAGATTT
781	TCTTCCCAAC	GTCTCGACTG	GTATAATGAG	CCAGTTCTTA	AAATCGCATA	AGGTAATTCA
841	CAATGATTAA	AGTTGAAATT	AAACCATCTC	AAGGCCAATT	TACTACTCGT	TCTGGTGT
901	CTCGTCAGGG	CAAGCCTTAT	TCACTGAATG	AGCAGCTTTG	TTACGTTGAT	TTGGGTAATG
961	AATATCCGGT	TCTTGTCAAG	ATTACTCTG	ATGAAGGTCA	GCCAGCTAT	GCGCCTGGTC
1021	TGTACACCGT	TCATCTGTCC	TCTTCAAAAG	TTGGTCAGTT	CGGTTCCCTT	ATGATTGACC
1081	GTCTGCGCT	CGTTCGGCT	AAGTAACATG	GAGCAGGTG	CGGATTCGA	CACAATTAT
1141	CAGCGATGA	TACAAATCTC	CGTTGTACTT	TGTTTCGCGC	TTGGTATAAT	CGCTGGGGGT
1201	CAAAGATGAG	TGTTTTAGTG	TATTCTTCG	CCTCTTCTGT	TTTAGGTTGG	TGCCCTCGTA
1261	GTGGCATTAC	GTATTTACC	CGTTTAATGG	AAACCTTCCTC	ATGAAAAAGT	CTTAGTCTCT
1321	CAAAGCCTCT	GTAGCCGTTG	CTACCCCTGT	TCCGATGCTG	TCTTCGCTG	CTGAGGGTGA
1381	CGATCCCGCA	AAAGCGGCCT	TTAACCTCC	GCAAGCCTCA	GCGACCGAAT	ATATCGGTTA
1441	TGCGTGGGCG	ATGGTTGTTG	TCATTGTCGG	CGCAACTATC	GGTATCAAGC	TGTTTAAGAA
1501	ATTCACCTCG	AAAGCAAGCT	GATAAACCGA	TACAATTAAA	GGCTCCTTTT	GGAGCCTTT
1561	TTTTGGAGA	TTTCAACGT	AAAAAAATTA	TTATTGCA	TTCCCTTACT	TGTTCTTT
1621	TATTCTCACT	CCGCTGAAAC	TGTTGAAAGT	TGTTTAGCAA	AACCCCATAC	AGAAAATTCA
1681	TTTACTAACG	TCTGGAAAGA	CGACAAAAC	TTAGATCGT	ACGCTAACTA	TGAGGGTTGT
1741	CTGTGGAATG	CTACAGGCCT	TGTAGTTGT	ACTGGTGAACG	AAACTCAGTG	TTACGGTACA
1801	TGGGTTCTTA	TGGGCTTGC	TATCCCTGAA	AATGAGGGTG	GTGGCTCTGA	GGGTGGCGGT
1861	TCTGAGGGTG	GCGGTTCTGA	GGGTGGCGGT	ACTAAACCTC	CTGAGTACGG	TGATACACCT
1921	ATTCGGGCT	ATACTTATAT	CAACCCCTCTC	GACGGCACTT	ATCCGCCTGG	TACTGAGCAA
1981	AACCCCGCTA	ATCCTAATCC	TTCTCTTGAG	GAGTCTCAGC	CTCTTAATAC	TTTCATGTTT
2041	CAGAATAATA	GGTCCGAAA	TAGGCAGGGG	GCATTAACTG	TTTATACGGG	CACTGTTACT
2101	CAAGGCACTG	ACCCCGTTAA	AACTTATTAC	CACTACACTC	CTGTATCATC	AAAAGCCATG
2161	TATGACGCTT	ACTGGAACGG	TAATTTCAGA	GACTGCGCTT	TCCATTCTGG	CTTTAATGAA
2221	GATCCATTG	TTTGTGAATA	TCAAGGCCAA	TCGTCCTGACC	TGCCTCAACC	TCCTGTCAT
2281	GCTGGCGGCC	CGTCTGGTGG	TGGTCTGGT	GGCAGCTCTG	AGGGTGGTGG	CTCTGAGGGT
2341	GGCGGTTCTG	AGGGTGGCGG	CTCTGAGGGG	GGCGGTTCCG	GTGGTGGCTC	TGGTTCGGT
2401	GATTTGATT	ATGAAAAGAT	GGCAAAACGCT	AATAAGGGGG	CTATGACCGA	AAATGCCGAT
2461	GAAAACGCGC	TACAGTCTGA	CGCTAAAGGC	AAACTTGATT	CTGTCGCTAC	TGATTACGGT
2521	GCTGCTATCG	ATGGTTTCAT	TGGTACGTT	TCCGGCCTTG	CTAATGGTAA	TGGTGTACT
2581	GGTATTTTG	CTGGCTCTAA	TTCCCAAATG	GCTCAAGTCG	GTGACGGTGA	TAATTACCT
2641	TTAATGAATA	ATTTCCGTCA	ATATTACCT	TCCCTCCCTC	AATCGGTTGA	ATGTCGCCCT
2701	TTTGTCTTTA	GCGCTGGTAA	ACCATATGAA	TTTTCTATG	ATTGTGACAA	AATAAACCTA
2761	TTCCGTGGTG	TCTTGTGTT	TCTTTATAT	GTTGCCACCT	TTATGTATGT	ATTTTCTACG
2821	TTTGCTAACAA	TACTGCGTAA	TAAGGAGTCT	TAATCATGCC	AGTTCTTTG	GGTATTCGGT
2881	TATTGTCG	TTCCCTCGGT	TTCCCTCTGG	TAACTTTGT	CGGCTATCTG	CTTACTTT
2941	TTAAAAAGGG	CTTCGGTAAAG	ATAGCTATTG	CTATTTCATT	GTTTCTTGCT	CTTATTATTG
3001	GGCTTAAC	AATTCTGTG	GGTTATCTC	CTGATATTAG	CGCTCAATT	CCCTCTGACT
3061	TTGTCAGGG	TGTTCAAGTAA	ATTCTCCCGT	CTAATGCCT	TCCCTGTTTT	TATGTTATT
3121	TCTCTGTAAA	GGCTGCTATT	TTCAATTTCG	ACGTTAAACA	AAAAATCGTT	TCTTATTGTT
3181	ATTGGGATAA	ATAATATGGC	TGTTTATT	GTAACTGGCA	AATTAGGCTC	TGGAAAGACG
3241	CTCGTTAGCG	TTGGTAAGAT	TTAGGATAAA	ATTGTAGCTG	GGTGCAGGAAAT	AGCAACTAAT
3301	CTTGATTTAA	GGCTTCAAAA	CCTCCCGCAA	GTCGGGAGGT	TCGCTAAAAC	GCCTCGCGTT
3361	CTTAGAATAC	CGGATAAGCC	TTCTATATCT	GATTTGCTTG	CTATTGGCG	CGGTAATGAT
3421	TCCTACGATG	AAAATAAAAA	CGGCTTGCTT	GTTCTCGATG	AGTGCCTGAC	TTGGTTAAAT
3481	ACCCGTTCTT	GGAATGATAA	GGAAAGACAG	CCGATTATTG	ATTGGTTCT	ACATGCTCGT
3541	AAATTAGGAT	GGGATATTAT	TTTCTTGTT	CAGGACTTAT	CTATTGTTGA	TAAACAGGCG
3601	CGTTCTGCAT	TAGCTGAACA	TGTTGTTAT	TGTCGTCGTC	TGGACAGAAAT	TACTTTACCT
3661	TTTGTGCGTA	CTTTATATT	TCTTATTACT	GGCTCGAAA	TGCTCTGCCC	TAAATTACAT
3721	GTTGGCGTTG	TTAAATATGG	CGATTCTCAA	TTAAGCCCTA	CTGTTGAGCG	TTGGCTTTAT
3781	ACTGGTAAGA	ATTGTATAA	CGCATATGAT	ACTAAACAGG	CTTTTCTAG	TAATTATGAT

FIG. 8-1

3841	TCCGGTGT	TTT	ATTCTTAT	TTT	AACGCC	TTT	TTATCACAC	GG	GTCCGG	TTT	CAAACC	TTA	3900
3901	AATTAGGTC	AGAAGATGAA	GCTTACTAAA	ATATATTG	AAAAGTTTC	ACCGCG	TTCT	ACCGCG	TTCT	ACCTAAG	CCG	3960	
3961	TGTC	TGCGA	TTGGATTG	ATCAGCATT	ACATATAG	TTA	ACCA	ACCTAAG	CCG	4020			
4021	GAGGTTAAAA	AGGTAGCTC	TCAGACCT	GATTGATA	AATTCACT	TGACTCTT	CTAAGGGAAA	ATTAATTAA	TGACTCTT	CTAAGGGAAA	ATTAATTAA	4080	
4081	CAGCGTCTT	ATCTAAGCTA	TCGCTATG	TTCAAGGATT	CTAACAT	TTGATT	TGACTCTT	CTAACAT	TTGATT	TGACTCTT	CTAACAT	4140	
4141	AGCGACGATT	TACAGAAGCA	AGGTTATTC	CTCACAT	TTGATT	TGACTCTT	CTAACAT	TTGATT	TGACTCTT	CTAACAT	TTGATT	4200	
4201	ATTA	AAAAAG	GTAATTCAA	TGAAATTG	AAATGTA	AATTGTT	TCTTGATG	TTT	TCTTGATG	TTT	TCTTGATG	TTT	4260
4261	TGTT	CATCA	TCTTCTT	CTCAGGTA	TGAAATGA	AATTGCC	TGCGCG	ATT	TGCGCG	ATT	TGCGCG	ATT	4320
4321	TGTAAC	TTGG	TATTCAAAGC	AATCAGGCGA	ATCCGTT	GTTTCTCCG	ATGTAAAAGG	ATGTAAAAGG	ATGTAAAAGG	ATGTAAAAGG	ATGTAAAAGG	ATGTAAAAGG	4380
4381	TACTGTT	ACT	GTATATTCA	CTGACGTT	ACCTGAA	CTACGCA	TCTTTATT	TCTT	TCTTTATT	TCTT	TCTTTATT	TCTT	4440
4441	TGTTT	TACGT	GCTAATAATT	TTGATATG	TGGTTCA	CCTTCATAA	TTCAAGAGTA	4500					
4501	TAATCC	AAAC	AATCAGGATT	ATATTGATG	ATTGCC	TCTGATA	AGGAATATG	4560					
4561	TGATA	ATTCC	GCTCCTCTG	GTGGTTCTT	TGTTCCG	AATGATAATG	TTACTCAAAC	4620					
4621	TTT	AAAATT	AATAACGTT	GGGCAAAGGA	TTTAATACG	GTTGTCGA	TGTTGTAAA	4680					
4681	GTCT	AAACT	TCTAAATCCT	CAAATG	ATCTATTG	GGCTCTAATC	TATTAGTTG	4740					
4741	TAGT	GCACCT	AAAGATATT	TAGATAACCT	TCCTCAATT	CTTCTACTG	TTGATTTG	4800					
4801	AACTG	ACCA	ATATTGATTG	AGGGTTG	ATTGAGGTT	CAGCAAGGTG	ATGCTTTAGA	4860					
4861	TTT	TCATT	GCTGCTGGCT	CTCAGCGT	CACTGTTG	GGCGGTGTTA	ATACTGACCG	4920					
4921	CCTCAC	CTCT	GTTTATCTT	CTGCTGGT	TTCGTTCG	ATTTTAATG	GCGATGTTT	4980					
4981	AGGG	CATCA	GTTCGCG	TAAAGACTAA	TAGCCATT	AAAATATTG	CTGTGCCACG	5040					
5041	TATT	CTACG	CTTTCAGG	AGAAGGG	TATCTCTG	GGCCAGAATG	TCCCTTTTAT	5100					
5101	TACTG	GTCG	GTGACTGGT	AATCTGCCA	TGAAATAAT	CCATTTCAGA	CGATTGAGCG	5160					
5161	TCAA	AAATG	GGTATT	CCAA	TGAGCG	ATGGCTGGCG	GTAATATTG	5220					
5221	TCTGG	ATATT	ACCAGCAAGG	CCGATAG	GAGTCTT	ACTCAGG	GTGATGTT	5280					
5281	TACTA	ATCAA	AGAAGTATTG	CTACAA	TAATTG	GATGGACAGA	CTCTTTTACT	5340					
5341	CGGT	GGCCTC	ACTGATTATA	AAAACACTC	TCAAGATT	GGCGTACCG	TCCTGTCTAA	5400					
5401	AAT	CCCTTTA	ATCGGCC	TGTTTAG	CCGCTCTG	TCCAACG	AAAGCACGTT	5460					
5461	ATACG	TGCTC	GTCAAAGC	CCATAGTAC	CGCCCTG	CGGCGC	AGCGCGGCGG	5520					
5521	GTGT	GGTG	TACGCG	GTGACCG	CACTTG	CGCCCTAG	CCCCTCT	5580					
5581	TCG	CTTCTT	CCCTT	CTCGCAC	TCGCCG	TCCCCGTCAA	GCTCTAAATC	5640					
5641	GGGG	GCTCCC	TTTAGGG	CGATT	TGTTAC	CCTCGAC	AAAAAAACTG	5700					
5701	ATT	GGGTG	TGTT	CACG	AGTGGG	CGCCCTG	CGCCCTTGA	5760					
5761	CGT	GGGAG	CGT	TTT	AAATAG	TCTGTT	AACTGGAACA	5820					
5821	CTAT	CTCGGG	CTATT	TTT	GATT	GGATT	CCACCATCAA	5880					
5881	ACAGG	ATT	CGC	CTG	GGCAAAC	CGTGGAC	TCTCTCAGGG	5940					
5941	CCAGG	CGGTG	AAGG	CAATC	AGCTG	CGTCTCG	GTGAAAAGAA	AAACCACCT	6000				
6001	GGCG	CCCAAT	ACG	CAAACCG	CCTCT	CGCGT	GATT	TGAGCTGGC	6060				
6061	ACG	ACAGG	TCCC	GACTG	AAAGCGG	GTGAGCG	CGCAATT	6120					
6121	TCA	CTTCA	GGC	ACCC	GCTT	TGTTCTC	GGCTCGT	TTGTGTG	6180				
6181	TTG	GAGCG	ATAAC	ATT	CACAGCG	ACTTGG	GGCCGTC	TTACAACGTC	6240				
6241	GTG	ACTGGG	AAAC	CTG	GTTACCA	CTTGTAC	GGAGAAAATA	AAGTGAAACA	6300				
6301	AAG	CACT	GCA	TCT	TACCG	ACTGTT	CCTGTG	AAGCCTATGG	6360				
6361	GGGG	TATG	CTT	CTG	AGTCCC	TGAAGG	GACCCTG	AGGCTGCATT	6420				
6421	CAAT	AGTT	CAGG	CAAGT	CTACTG	CATTGG	GCTTGG	TGGTAGTAGT	6480				
6481	TATAG	TTG	GCT	ACATAG	GGATTAA	ATTCAAA	TTTACG	AGGCTCTTA	6540				
6541	AGCA	ATAGCG	AAG	AGGCCG	CACCG	CTTCC	AGTTG	CCTGAATGGC	6600				
6601	GAAT	GGCG	TTG	CTG	GGT	GAAGCG	CGGAAAGCTG	GCTGGAGTGC	6660				
6661	GAT	CTT	CGT	AGG	CCG	CCCT	GGCAGATG	CGGTTACGAT	6720				
6721	GCG	CCC	CAT	ACAC	AACT	ATTACG	ATCCGCC	TGTTCCCACG	6780				
6781	GAGA	ATCCG	CGGG	TTG	CTCG	TTAATG	ATGAAAGCTG	GCTACAGGAA	6840				
6841	GGC	CAGAC	GAAT	TTT	TGAT	GGCGT	CTTATTG	CTGATTAAAC	6900				
6901	AAA	AAATT	CGC	AAATT	AACAA	TAACG	TTAC	TTTGCTTATA	6960				
6961	CAAT	CTTC	GT	TTT	CTT	TATCAAC	GGTAC	ATTGACATGC	7020				
7021	TA	TTT	ACG	TT	ATCG	ATTCTC	TTGTTT	GGCAATGACC	7080				
7081	TG	ATAGC	TG	TA	TCA	ACCC	CTG	TTATCAGCTA	7140				
7141	GAAC	GGTTG	ATAT	CATATT	GATGGT	TGACT	GGCGT	CACCC	7200				
7201	AA	TCTT	TAC	ACATTAC	TCAGG	CATT	ATATGAGGGT	TCTAAAATT	7260				
7261	TTT	ATC	CGT	GAAATA	AAGG	CTC	ATTACAGGGT	CATAATGTTT	7320				
7321	TTG	GTACA	AC	CGATT	TTATG	CTG	AGGCTT	GCTTAATT	7380				
7381	TG	CC	TGCT	GTATG	TTGG	ACGTT	T	7409					

FIG. 8-2

	10	20	30	40	50	60
1	AATGCTACTA	CTATTAGTAG	AATTGATGCC	ACCTTTTCAG	CTCGCGCCCC	AAATGAAAAT
61	ATAGCTAAC	AGGTTATTGA	CCATTGCGA	AATGTATCTA	ATGGTCAAAC	TAAATCTACT
121	CGTTCGAGA	ATTGGGAATC	AACTGTTACA	TGGAATGAAA	CTTCCAGACA	CCGTACTTTA
181	GTTCATATT	TAAAACATGT	TGAGCTACAG	CACCAAGATT	AGCAATTAAAG	CTCTAAGGCCA
241	TCTGCAAAAA	TGACCTCTTA	TCAAAAAGGAG	CAATTAAAGG	TACTCTCTAA	TCCTGACCTG
301	TTGGAGTTTG	CTTCCGGTCT	GGTTCGCTT	GAAGCTCGA	TTAAAACGCG	ATATTGAAAG
361	TCTTCGGGC	TTCCTCTAA	TCTTTTGAT	GCAATCCGCT	TTGCTCTGA	CTATAATAGT
421	CAGGGTAAAG	ACCTGATTT	TGATTTATGG	TCATTCTCGT	TTTCTGAACT	GTTTAAAGCA
481	TTTGAGGGG	ATTCAATGAA	TATTTATGAC	GATTCCGAG	TATTGGACGC	TATCCAGTCT
541	AAACATTTA	CTATTACCCC	CTCTGGCAA	ACTTCTTTG	CAAAAGCCTC	TCGCTATTT
601	GGTTTTATC	GTCGCTCTGGT	AAACGAGGGT	TATGATAGTG	TTGCTCTTAC	TATGCCTCGT
661	AATTCTTTT	GGCGTTATGT	ATCTGCATTA	GTTGAATGTG	GTATTCTAA	ATCTCAACTG
721	ATGAATCTTT	CTACCTGTAA	TAATGTTGTT	CCGTTAGTTC	TTTTTATTAA	CGTAGATTT
781	TCTTCCCAAC	GTCCTGACTG	GTATAATGAG	CCAGTTCTTA	AAATCGCATA	AGGTAATTCA
841	CAATGATTAA	AGTTGAAATT	AAACCACATCTC	AAGCCCCAATT	TACTACTCGT	TCTGGTGT
901	CTCGTCAGGG	CAAGCCTTAT	TCACTGAATG	AGCAGCTTTG	TTACGTTGAT	TTGGGTAATG
961	AATATCCGGT	TCTTGTCAAG	ATTACTCTTG	ATGAAGGTCA	GCCAGCCTAT	GCGCCTGGTC
1021	TGTACACCGT	TCATCTGTCC	TCTTCAAAAG	TTGGTCAGTT	CGGTTCCCTT	ATGATTGACC
1081	GTCGCGCCT	CGTTCCGGCT	AAGTAACATG	GAGCAGGTGCG	CGGATTTCGA	CACAATTAT
1141	CAGGCGATGA	TACAAATCTC	CGTTGTACTT	TGTTTGCGC	TTGGTATAAT	CGCTGGGGGT
1201	CAAAGATGAG	TGTTTTAGTG	TATTCTTTCG	CCCTTTTCGT	TTTAGGTTGG	TGCGCTCGTA
1261	GTGGCATTAC	GTATTTTACC	CGTTTAATGG	AAACTTCTC	ATGAAAAGT	CTTTAGTCCT
1321	CAAAGCCTCT	GTAGCCGTTG	CTACCCCTCGT	TCCGATGCTG	TCTTCGCTG	CTGAGGGTGA
1381	CGATCCCGCA	AAAGCGGCCT	TTAACCTCCCT	GCAAGCCTCA	GCGACCGAAT	ATATCGGTTA
1441	TGCGTGGGCG	ATGGTTGTTG	TCATTGTCGG	CGCAACTATC	GGTATCAAGC	TGTTTAAGAA
1501	ATTCACCTCG	AAAGCAAGCT	GATAAACCGA	TACAATTAAA	GGCTCCTTT	GGAGCCTTT
1561	TTTTGGAGA	TTTTCAACGT	GAAAAAATTA	TTATTGCAA	TTCTTTAGT	TGTTCCCTTC
1621	TATTCTCACT	CCGCTGAAAC	TGTTGAAAGT	TGTTTAGCAA	AACCCCATAC	AGAAAATTCA
1681	TTTACTAACG	TCTGAAAGA	CGACAAAAC	TTAGATCGTT	ACGCTAACTA	TGAGGGTTGT
1741	CTGTGGAATG	CTACAGGCGT	TGTAGTTGT	ACTGGTGACG	AAACTCAGTG	TTACGGTACA
1801	TGGGTTCCCTA	TTGGGCTTGC	TATCCCTGAA	AATGAGGGGTG	GTGGCTCTGA	GGGTGGCGGT
1861	TCTGAGGGGTG	GGGGTTCTGA	GGGTGGCGGT	ACTAAACCTC	CTGAGTACGG	TGATACACCT
1921	ATTCCGGGCT	ATACCTATAT	CAACCCCTCTC	GACGGCACTT	ATCCGCTGG	TACTGAGCAA
1981	AACCCCGCTA	ATCCTAATCC	TTCTCTTGAG	GAGTCTCAGC	CTCTTAATAC	TTTCATGTT
2041	CAGAATAATA	GGTTCGAAA	TAGGCAGGGG	GCATTAAC	TTTATACGGG	CACTGTTACT
2101	CAAGGCACTG	ACCCCGTTAA	AACTTATTAC	CAGTACACTC	CTGTATCATC	AAAAGCCATG
2161	TATGACGCTT	ACTGGAACGG	TAATTCTCAGA	GA	TCCATTCTGG	CTTTAATGAA
2221	GATCCATTG	TTTGGAATA	TCAAGGCCAA	TCGTTCTGAGC	TGCCCTCAACC	TCCGTCAAT
2281	GCTGGCGGCG	GCTCTGGTGG	TGGTTCTGGT	GGCGGCTCTG	AGGGTGGTGG	CTCTGAGGGT
2341	GC	GGGTTCTG	AGGGTGGCGG	CTCTGAGGG	GGCGGTTCCG	TGGTTCCGGT
2401	GATTTTGATT	ATGAAAAGAT	GGCAAAACGCT	ATAAAGGGGG	CTATGACCGA	AAATGCCGAT
2461	AAAAACGCGC	TACAGTCTGA	CGCTAAAGGC	AAACTTGATT	CTGTCGCTAC	TGATTACGGT
2521	GCTGCTATCG	ATGGTTTCAT	TGGTGA	CTC	GGG	TTG
2581	GGTGA	TTG	CTG	TAAGGAGTCT	GTGACGGTGA	TAATTACACCT
2641	TTAATGAA	ATTTCCGTCA	ATATTACCT	TCCCTCCCTC	AATCGGTTGA	ATGTCGCCCT
2701	TTTGTCTTA	GGCGTGGTAA	ACCATATGAA	TTTCTATTG	ATTGTGACAA	AATAAACTTA
2761	TTCCGTGGTG	TCTTGTGCGT	TCTTTATAT	GTTGCCACCT	TTATGTATGT	ATTTCTACG
2821	TTTGCTAAC	TACTGCGTAA	TAAGGAGTCT	TAATCATGCC	AGTTCTTTG	GGTATTCCGT
2881	TATTATTGCG	TTTCTCTCGGT	TTCTCTCTGG	TAACTTTGTT	CGGCTATCTG	CTTACTTTTC
2941	TTAAAAAGGG	CTTCGGTAAG	ATAGCTATTG	CTATTCATT	GTTCTTGT	CTTATTATTG
3001	GGCTTAAC	AATTCTTGTG	GGTTATCTC	CTGATATTAG	CGCTCAATT	CCCTCTGACT
3061	TTGTTCA	GGTTCA	ATTCTCCGT	CTAATGCGCT	TCCCTGTTT	TATGTTATT
3121	TCTCTGTAA	GGCTGCTATT	TTCATTTTG	ACGTTAAACA	AAAAATCGTT	TCTTATTG
3181	ATTGGGATAA	ATAATATGGC	TGTTTATTTT	GTAACTGGCA	AATTAGGCTC	TGGAAAGACG
3241	CTCGTTAGCG	TTGGTAAGAT	TCAGGATAAA	ATTGTAGCTG	GGTGC	AAAG
3301	CTTGATTAA	GGCTTCAAAA	CCTCCCGCAA	TCG	GGGAGGT	TGCTAAAC
3361	CTTAGAATAC	CGGATAAGCC	TTCTATATCT	GATTGCTG	CTATTGGGCG	CGGTAATGAT
3421	TCCTACGATG	AAAATAAAAA	CGGCTGCTT	GTTCTCGAT	AGTGC	GGTAC
3481	ACCCGTTCTT	GGAATGATAA	GGAAAAGACAG	CCGATTATTG	ATTGGTTCT	ACATGCTCGT
3541	AAATTAGGAT	GGGATATTAT	CTTCCCTGTT	CAGGACTTAT	CTATTGTTGA	TAAACAGGCG
3601	CGTTCTGCA	TAGCTGAACA	TGTTGTTTAT	TGTCGTCGTC	TGGACAGAAT	TACTTTACCT
3661	TTTGTGCGTA	CTTTATATT	TCTTATTACT	GGCTCGAAAA	TGCGCTCTG	TAAATTACAT
3721	GTTGGCGTTG	TTAAATATGG	CGATTCTCAA	TTAAGCCCTA	CTGTTGAGCG	TTGGCTTAT
3781	ACTGGTAAGA	ATTGTATAA	CGCATATGAT	ACTAAACAGG	CTTTTCTAG	TAATTATGAT

FIG. 9-1
SUBSTITUTE SHEET

3841	TCCGGTGT	TTT	ATTCTTAT	T	AACGCCTT	TT	TTATCACACG	GTCGGTATT	CAAACCATTA	3900	
3901	AATTTAGGTC	AGAAGATGAA	GCTTACTAAA	ATATATTG	AAAAGTTT	AC	ACGCCTT	CTT	3960		
3961	TGTCTTGC	GA	TTGGATT	TC	ATCAGCATT	AC	ACATATA	AG	4020		
4021	GAGGT	AAAAA	AGGTAGTCTC	T	TCAGACCT	G	TTTTGATA	AATTCA	4080		
4081	CAGCGTCT	TA	ATCTAAGCTA	T	TCGCTATG	T	TCAGGATT	CTAAGGGAAA	4140		
4141	AGCGACG	ATT	TACAGAAGCA	A	AGGTTATTCA	C	CTCACATA	TTGATT	4200		
4201	ATTAAAAA	AGG	TAATTCAAAT	G	AAATTGTTA	A	AATGTAATT	TTTTGTTT	4260		
4261	GTTTCATCAT	CTT	CTTCTTTGC	T	TCAGGTAA	G	AAATGAATA	ATTGCCTCT	4320		
4321	GTAAC	TTGGT	ATTCAAAGCA	A	TCAGGCCAA	T	TCGGTATTG	TTTCTCCC	4380		
4381	ACTGTTACTG	TAT	TATTCATC	T	TGACGTTAAA	C	CCTGAAAATC	TACGCAATT	4440		
4441	GTTTACGTG	CTA	ATAATT	T	TGATATTGTT	C	CTTCAATT	CTTCCATT	4500		
4501	AATCCAAACA	ATCAGGATT	T	TATTGATGAA	T	TTGCCATCAT	CTGATAATCA	GGAATATGAT	4560		
4561	GATAATTCCG	CTC	CTTCTG	T	TGGTTCTT	G	TTCCGCAA	ATGATAATG	4620		
4621	TTTAAATT	ATAACGTT	G	GGCAAAGGAT	T	TTAATACGAG	TTGTCGAATT	TTTTGTAAG	4680		
4681	TCTAATACT	CTAAATC	T	AAATGTTA	T	TCTATTGACG	GCTCTAATCT	ATTAGTTGTT	4740		
4741	AGTGCACCTA	AAGA	TATTTT	A	AGATAACCTT	C	CCTCAATT	TTTCTACTG	TGATTGCA	4800	
4801	ACTGACCA	AGA	TATTGATTG	G	GGGTTGATA	T	TTTGAGGTT	AGCAAGGTGA	TGCTTAGAT	4860	
4861	TTTCATTG	CTG	CTGGCTC	T	TCAGCGT	G	ACTGTTGCAG	GCGGTGTTA	TACTGACCGC	4920	
4921	CTCACCTCTG	TTT	TATCTT	T	TGCTGGT	G	TCGTTGGTA	TTTTAATGG	CGATGTTTTA	4980	
4981	GGGCTATCG	TTC	CGCATT	A	AAAGACTAAT	A	AGCCATTCAA	AAATATTGTC	TGTGCCACGT	5040	
5041	ATTCTTACG	TC	TAGGTCA	G	GAAGGGTTCT	A	ATCTCTGTT	GCCAGAATGT	CCCTTTTATT	5100	
5101	ACTGGTCGT	TG	ACTGGT	G	ATCTGCCAAT	G	GTAAATAATC	CATTTCAGAC	GATTGAGCGT	5160	
5161	CAAAATGTAG	GT	ATTTCCAT	G	GAGCGTTT	C	CCTGTTGCAA	TGGCTGGCG	TAATATTGTT	5220	
5221	CTGGATATT	TA	CCAGCAAGGC	C	CGATAGTTG	A	AGTTCTTCTA	CTCAGGCAAG	TGATGTTATT	5280	
5281	ACTAATCAA	GA	AGTATTG	T	TACAACGGTT	A	ATTTCGCGT	ATGGACAGAC	TCTTTACTC	5340	
5341	GGTGGCCTCA	CTG	ATTATAA	A	AAACACTTCT	C	CAAGATTCTG	GCGTACCGTT	CCTGTCTAAA	5400	
5401	ATCCCTTAA	TCG	GCCTCCT	G	TTTAGCTCC	C	CGCTCTGATT	CCAACGAGGA	AAGCACGTTA	5460	
5461	TACGTGCTG	TCA	AAAGCAAC	C	CATAGTACG	G	CCCTGTAGC	GGCGCATTAA	GCGGGCGGG	5520	
5521	TGTGGTGGT	ACG	CGCAGCG	T	TGACCGCTAC	A	ACTTGCCAGC	GCCCTAGCGC	CCGCTCTTT	5580	
5581	CGCTTCTTC	CC	TCTTTT	T	TCGCACCGT	C	CGCGGCTT	CCCCGTCAAG	CTCTAAATCG	5640	
5641	GGGGCTCC	TT	AGGGTT	C	GATTAGTGC	T	TTTACGGCAC	CTCGACCCCCA	AAAAACTTGA	5700	
5701	TTTGGGTGAT	GGT	TACGTA	G	GTGGGCCATC	G	CCCTGTAG	ACGGTTTTTC	GCCCTTTGAC	5760	
5761	TTTGGAGTCC	ACG	TTCTT	A	ATAGTGGACT	C	TTTGTCCAA	ACTGGAACAA	CACTCAACCC	5820	
5821	TATCTCGGGC	TAT	TCTTTT	T	ATTATAAAGG	G	ATTTTGCCG	ATTTCGGAAC	CACCATCAAA	5880	
5881	CAGGATTTC	GC	CTGCTGGG	G	CAAACCCAGC	G	GTGGACCGCT	TGCTGCAACT	CTCTCAGGGC	5940	
5941	CAGGC	GGTGA	AGGGCAATCA	G	CTGTTGCC	G	GTCTCGCTGG	TGAAAAGAAA	AACCACCTG	6000	
6001	GCGCCCAATA	CG	CAAACCCGC	C	CTCTCCCCGC	G	GC	GC	GCAGCTGGCA	6060	
6061	CGACAGGTTT	CCC	GACTGGA	A	AAGGGGCAG	T	AGCGCAAC	GCAATTAAATG	TGAGTTAGCT	6120	
6121	CACTCATTAG	GC	ACCCCAAGG	C	TTTACACTT	T	TATGTTCCG	GCTGTTATGT	TGTGTGAAT	6180	
6181	TGTGAGCGGA	TA	ACAATT	T	ACACAGGAAA	C	CAGCTATGAC	CAGGATGTAC	GAATTGCGAG	6240	
6241	GTAGGAGAGC	TC	GGCGGATC	C	CGAGGCTGAA	G	GGCGATGACC	CTGCTAAGGC	TGCAATTCAAT	6300	
6301	AGTTTACAGG	CA	AGTGTCTAC	T	TGAGTACATT	G	GGCTACGCTT	GGGCTATG	AGTAGTTATA	6360	
6361	GTTGGTGT	CA	CATAGGGAT	T	AAATTATT	A	AAAAAGTTA	CGAGCAAGGC	TTCTTAACCA	6420	
6421	GCTGGCGTAA	TAG	CGAAGAG	G	CCCCGACCG	A	ATCGCCCTTC	CCAACAGTTG	CGCACGCTGA	6480	
6481	ATGGCGAATG	GCG	TTTGC	T	TGGTTCCGG	C	CACCAAGAGC	GGTGCCGGAA	AGCTGGCTGG	6540	
6541	AGTGCATCT	TCC	TGAGGCC	G	GATACTGGTCG	T	TCGCCCCCTC	AAACTGGCAG	ATGCACGGTT	6600	
6601	ACGATGCGC	CAT	TACAC	A	AACGTAACCT	A	ATCCCATTAC	GGTCAATT	CCGTTTGTTC	6660	
6661	CCACGGAGAA	TCC	GACGGG	T	GTGTTACTCGC	T	TCACATTAA	TGTTGATGAA	AGCTGGCTAC	6720	
6721	AGGAAGGCCA	GAC	CGAATT	A	TTTTTGATG	G	CGGTTCTT	TGGTTAAAAA	ATGAGCTGAT	6780	
6781	TTAACAAAAA	TTA	ACGCGA	A	TTTTAACAA	A	AATATTAA	CG	TTTACAATT	AAATATTG	6840
6841	TTATACAA	TT	CTGTT	T	GGGGCTTT	C	CTGATTATCA	ACC	GGGGTAC	ATATGATTGA	6900
6901	CATGCTAGTT	TTA	CGGATTAC	C	CGTTCATCGA	T	TTCTCTTGT	TGCTCCAGAC	TCTCAGGCAA	6960	
6961	TGACCTGATA	GC	CTTGT	T	ATCTCTAA	A	AATAGCTACC	CTCTCCGGCA	TTAATT	7020	
7021	AGCTAGAACG	GTT	GAATATC	A	ATATTGATGG	T	TGATTTGACT	GTCTCCGGCC	TTTCTCACCC	7080	
7081	TTTTGAATCT	TTA	CCCTACAC	A	ATTACTCAGG	C	CATTGCATT	AAAATATATG	AGGGTTCTAA	7140	
7141	AAATTTTAT	CCT	CGCTT	A	AAATAAGGC	T	TTCTCCCGCA	AAAGTATTAC	AGGGTCATAA	7200	
7201	TGTTTTGGT	ACA	ACCGATT	T	AGCTTTATG	C	CTCTGAGGCT	TTATTGCTT	ATTTTGCTAA	7260	
7261	TTCTTGCCT	TG	CGCTGTATG	A	TTTATTGGA	C	CGTT			7294	

FIG. 9-2

	10	20	30	40	50	60
1	AATGCTACTA	CTATTAGTAG	AATTGATGCC	ACCTTTCAAG	CTCGCGCCCC	AAATGAAAAT
61	ATAGCTAAAC	AGGTTATTGA	CCATTTGCGA	AATGTATCTA	ATGGTCAAAC	TAAATCTACT
121	CGTTCGCAGA	ATTGGGAATC	AACTGTTACA	TGGAATGAAA	CTTCCAGACCA	CCGTACTTTA
181	GTTGCATATT	AAAACATGT	TGAGCTACAG	CACCAAGATTC	AGCAATTAAAG	CTCTAAGCCA
241	TCTGCAAAAAA	TGACCTCTTA	TCAAAAGGAG	CAATTAAAGG	TACTCTCTAA	TCCTGACCTG
301	TTGGAGTTTG	CTTCCGGTCT	GGTCGCTTT	GAAGCTCGAA	TTAAAACGCG	ATATTTGAAG
361	TCTTTCGGC	TTCCCTCTAA	TCTTTTGAT	GCAATCCGCT	TTCGTTCTGA	CTATAATAGT
421	CAGGGTAAAG	ACCTGATTTT	TGATTTATGG	TCATTCTCGT	TTTCTGAACT	GTTTAAAGCA
481	TTTGAGGGGG	ATTCAATGAA	TATTTATGAC	GATTCCGCGAG	TATTGGACGC	TATCCAGTCT
541	AAACATTTTA	CTATTACCCC	CTCTGGCAAA	ACTTCTTTTG	CAAAGGCCCTC	TCGCTATTTT
601	GGTTTTTATC	GTCGTCTGGT	AAACGAGGGT	TATGATAGTG	TTGCTCTTAC	TATGCCTCGT
661	AATTCCCTTT	GGCGTTATGT	ATCTGCATTA	GTTGAATGTG	GTATTCCCTAA	ATCTCAACTG
721	ATGAATCTTT	CTACCTGTAA	TAATGTTGTT	CCGTTAGTTC	TTTTTATTAA	CGTAGATTTT
781	TCTTCCCAAC	GTCCCTGACTG	GTATAATGAG	CCAGTTCTTA	AAATCGCATA	AGGTAATTCA
841	CAATGATTAA	AGTTGAAATT	AAACCATCTC	AAGCCCAATT	TACTACTCGT	TCTGGTGT
901	CTCGTCAGGG	CAAGCCTTAT	TCACTGAATG	AGCAGCTTTG	TTACGTTGAT	TTGGGTAATG
961	AATATCCGGT	TCTTGTCAAG	ATTACTCTTG	ATGAAGGTCA	GCCAGCCTAT	GCGCCTGGTC
1021	TGTACACCGT	TCATCTGTCC	TCTTCAAAAG	TTGGTCAGTT	CGGTTCCCTT	ATGATTGACC
1081	GTCTGCGCT	CGTTCCGGT	AAGTAACATG	GAGCAGGTCG	CGGAGTTCGA	CACAATTAT
1141	CAGGGCAGTGA	TACAAATCTC	CGTTGTACTT	TGTTTGC CGC	TTGGTATAAT	CGCTGGGGT
1201	CAAAGATGAG	TGTTTAGTG	TATTCTTCG	CCTCTTTCG	TTAGGTTGG	TGCCTTCGTA
1261	GTGGCATTAC	GTATTCTTAC	CGTTTAATGG	AAACTCTCTC	ATGAAAAAAGT	CTTTAGTCCT
1321	CAAAGCCTCT	GTAGCCGTTG	CTACCCCTCGT	TCCGATGCTG	TCTTCGCTG	CTGAGGGTGA
1381	CGATCCCAGCA	AAAGCGGCC	TTAACCTCCCT	GCAAGCCTCA	GCGACCAGAAT	ATATCGGTTA
1441	TGCGTGGGCG	ATGGTTGTTG	TCATTGTCGG	CGCAACTATC	GGTATCAAGC	TGTTTAAGAA
1501	ATTCACCTCG	AAAGCAAGCT	GATAAAACCGA	TACAATTAAA	GGCTCCTTTT	GGAGCCTTTT
1561	TTTTGGAGA	TTTCAACGT	GAAAAAATTA	TTATTCGCAA	TTCCCTTAGT	TGTTCCCTTC
1621	TATTCTCACT	CCGCTGAAAC	TGTTGAAAGT	TGTTAGCAA	AACCCCATAC	AGAAAATTCA
1681	TTTACTAACG	TCTGGAAAGA	GCACAAAAC	TTAGATCGTT	ACGCTAACTA	TGAGGGTTGT
1741	CTGTGGAATG	CTACAGGCGT	TGTAGTTGT	ACTGGTGACG	AAACTCAGTG	TTACGGTACA
1801	TGGGTTCTTA	TTGGGCTTGC	TATCCCTGAA	AATGAGGGGTG	GTGGCTCTGA	GGGTGGCGGT
1861	TCTGAGGGGTG	GCGGTTCTGA	GGGTGGCGGT	ACTAAACCTC	CTGAGTACGG	TGATACACCT
1921	ATTCGGGCT	ATACCTTATAT	CAACCCCTCTC	GACGGCACCT	ATCCGCTGG	TACTGAGCAA
1981	AACCCCGCTA	ATCCTAATCC	TTCTCTTGAG	GAGTCTCAGC	CTCTTAATAC	TTTCATGTTT
2041	CAGAATAATA	GGTTCCCGAAA	TAGGCAGGGG	GCATTAACCTG	TTTATACGGG	CACTGTTACT
2101	CAAGGCACTG	ACCCCGTTAA	AACTTATTAC	CACTACACTC	CTGTATCATC	AAAAGCCATG
2161	TATGACGCTT	ACTGGAACCGG	TAATTTCAGA	GACTCGCGCT	TCCATTCTGG	CTTTAAATGAA
2221	GATCCATTG	TTTGTGAATA	TCAAGGCCAA	TCGTCTGACC	TGCCCTCAACC	TCCTGTCAAT
2281	GCTGGCGGCG	GCTCTGGTGG	TGGTTCTGGT	GGCGGGCTCTG	AGGGTGGTGG	CTCTGAGGGT
2341	GGCGGGTTCTG	AGGGTGGCGG	CTCTGAGGGG	GGCGGGTTCCG	GTGGTGGCTC	TGGTCCGGT
2401	GATTTTGATT	ATGAAAAGAT	GGCAACGCT	AATAAGGGGG	CTATGACCGA	AAATGCCGAT
2461	AAAAACGCGC	TACAGTCTGA	CGCTAAAGGC	AAACTTGATT	CTGTCGCTAC	TGATTACGGT
2521	GCTGCTATCG	ATGGTTTCAT	TGGTGACGTT	TCCGGCCTTG	CTAATGGTAA	TGGTGTACT
2581	GGTGATTTG	CTGGCTCTAA	TTCCCAAATG	GCTCAAGTCG	GTGACGGTGA	TAATTACACCT
2641	TTAATGAATA	ATTTCCGTCA	ATATTACCT	TCCCTCCCTC	AATCGGTTGA	ATGTCGCCCT
2701	TTTGTCTTTA	GCCTGGTAA	ACCATATGAA	TTTTCTATTG	ATTGTGACAA	AATAAACTTA
2761	TTCCGTGGT	TCTTTCGCTT	TCTTTATAT	GTTGCCACCT	TTATGTATGT	ATTTCTACG
2821	TTTGCTAAC	TACTCGTAA	TAAGGAGTCT	TAATCATGCC	AGTTCTTTG	GGTATTCCGT
2881	TATTATTGCG	TTCCCTCGGT	TTCCCTCTGG	TAACTTTGTT	CGGCTATCTG	CTTACTTTTC
2941	TTAAAAAGGG	CTTCGGTAAG	ATAGCTATTG	CTATTCATT	GTTCTTCTGCT	CTTATTATTG
3001	GGCTTAACTC	AATTCTTGTG	GGTTATCTCT	CTGATATTAG	CGCTCAATTAA	CCCTCTGACT
3061	TTGTTCAAGGG	TGTTCACTTA	ATTCTCCCGT	CTAATGCCCT	TCCCTGTTTT	TATGTTTATT
3121	TCTCTGTAAA	GGCTGCTATT	TTCAATTCTT	ACGTTAAACAA	AAAAATCGTT	TCTTATTGG
3181	ATTGGGATAA	ATAATATGGC	TGTTTATTG	GTAACCTGCA	AATTAGGCTC	TGGAAAGACG
3241	CTCGTTAGCG	TTGGTAAGAT	TTAGGATAAA	ATTGTAGCTG	GGTGCAAAAT	AGCAACTAAT
3301	CTTGATTAA	GGCTTCAAAA	CCTCCCGCAA	GTCGGGGAGGT	TCGCTAAAAC	GCCTCGCGTT
3361	CTTAGAATAC	CGGATAAGCC	TTCTATATCT	GATTTGCTTG	CTATTGGGCG	CGGTAAATGAT
3421	TCCTACGATG	AAAATAAAAAA	CGGCTGCTT	GTTCTCGATG	AGTGCAGGTAC	TTGGTTTAAT
3481	ACCCGTTCTT	GGAATGATAA	GGAAAGACAG	CCGATTATTG	ATTGGTTTCT	ACATGCTCGT
3541	AAATTAGGAT	GGGATATTAT	TTTTCTTGTT	CAGGACTTAT	CTATTGTTGA	TAAACAGGCG
3601	CGTTCTGCAT	TAGCTGAACA	TGTTGTTAT	TGTCGTGTC	TGGACAGAAT	TACTTTACCT
3661	TTTGTGCGTA	CTTTATATT	TCTTATTACT	GGCTCGAAAA	TGCCTCTGCG	TAAATTACAT
3721	GTTGGCGTTG	TTAAATATGG	CGATTCTCAA	TTAAGCCCTA	CTGTTGAGCG	TTGGCTTAT
3781	ACTGGTAAGA	ATTGTATAA	CGCATATGAT	ACTAAACAGG	CTTTTCTAG	TAATTATGAT

FIG. 10-1

SUBSTITUTE SHEET

3841	TCCGGTGT	TTT	ATTCTTAT	TTT	AACGCC	TTT	TTATCACAC	GG	GTCCGG	TTT	CAAACCA	TTA	3900			
3901	AATTTAGG	TG	TC	AGAAGA	GAA	GCTT	ACTAAA	ATAT	ATTTG	AAAAG	TTT	TTC	ACCG	GTCT	3960	
3961	TGTCTTG	CGA	TTG	GAT	TTG	ATCAG	CATT	ACAT	ATAGT	ATATAAC	CCCA	ACCTAAG	CCG	4020		
4021	GAGGTT	AAA	AGG	TAG	TCT	TCAG	ACCTAT	GAT	TTTGATA	AATT	CACTAT	TGACT	CTTCT	4080		
4081	CAGCGT	CTT	ATC	TAAG	GCT	TCG	CATGTT	TTCA	AGGGATT	CTAAG	GGAAA	ATTA	ATTAAT	4140		
4141	AGCGAC	GATT	TAC	AGAG	CA	AGG	TATTCA	CTC	CACATATA	TTG	ATTTATG	TACT	GT	TTTCC	4200	
4201	ATTA	AAAAG	GTA	ATT	CAA	TGAA	ATTGTT	AAAT	GTAATT	AATT	TTGTT	TCTT	GAT	GTT	4260	
4261	TGTTT	CAT	CA	TCT	TTT	CTC	AGG	TAAT	TGAA	AATT	CGC	CTC	TGCG	GAT	4320	
4321	TGTA	ACT	TTG	TAT	CAA	AGC	AAT	CAGG	CGA	ATC	CGTT	TATT	TTT	CTCCG	4380	
4381	TACT	GTT	ACT	GT	TAT	TCAT	CTG	ACGTT	AA	CTG	AAA	AT	ACG	CAATT	4440	
4441	TGTTT	ACGT	GCT	TAATA	ATT	TTG	ATATG	TTG	TTCAATT	CCT	CCATAA	TT	CAGAAG	TA	4500	
4501	TAAT	CCAAAC	AAT	CA	GGG	ATT	TGATG	ATT	GCC	ATCA	TCT	GATA	ATC	AGGA	ATATG	4560
4561	TGATA	ATT	CC	GCT	CTT	GTG	GGTT	TTT	CCG	CAA	AAT	GATA	ATG	TTACT	CAAAC	4620
4621	TTT	AAA	TT	AAT	ACG	GGG	CAA	AGGA	TTA	ATACG	GTT	GTC	GAAT	TGTTT	GTA	4680
4681	GTCT	AA	TAT	CCT	CAA	ATG	TATT	ATC	TATTG	AC	GCT	TAATC	T	TATTAG	TGT	4740
4741	TAGT	GCA	CCT	AAAG	ATAT	TG	AGATAAC	TC	TCAATT	CTT	TCACTG	TG	TGATT	TGCC	4800	
4801	AACT	GAC	CAG	ATAT	GATT	AGG	GGTT	ATT	TGAGG	TG	CAGAAG	GTG	CTT	AGA	4860	
4861	TTT	TAT	TT	GCT	GGG	CT	TG	CGT	GG	ACT	TTG	GCA	GG	GGT	GTTA	4920
4921	CCT	CAC	CT	GT	TTT	TAT	CTG	GGT	TT	TG	TTG	CA	AT	GGT	GGCG	4980
4981	AGGG	C	TAT	CA	TT	GGC	GCG	CAT	TA	AAAG	TAA	TG	CCATT	AA	AA	5040
5041	TATT	CTT	ACG	GG	T	CTT	CAG	GG	AGG	TT	TCT	TGTT	GG	CCAGAA	TG	5100
5101	TACT	GG	TG	GT	TT	GTG	ACT	GG	AA	TG	AA	TAA	CC	ATT	TGAG	5160
5161	TCAAA	AT	GTA	GG	T	TTT	TCCA	TG	AGC	GGT	TTT	TGCA	AT	GGT	GGCG	5220
5221	TCT	GG	GAT	ATT	AC	CA	AGCA	CC	GAT	AGT	TTT	TCT	ACT	CAGG	CAA	5280
5281	TACT	AA	ATCAA	AGA	AG	TATT	GGT	CTA	AC	GG	TG	CGT	TA	TG	GACAGA	5340
5341	CGGT	GG	CC	TC	TC	ACT	GATT	ATA	AA	AC	ACT	TCT	TG	GG	GTACCG	5400
5401	AAT	CC	CT	TA	AT	CGG	C	CT	TT	AG	TG	CT	TC	CC	ACGAGG	5460
5461	ATAC	GT	GTC	T	GT	CAA	AGC	CA	CC	ATAG	TAC	CG	CC	CT	GCGCATT	5520
5521	GTG	TGG	TG	GT	TAC	GC	CAG	GT	ACCG	CTA	TG	CG	CC	CT	AGCG	5580
5581	TCG	CTT	CT	CC	CTT	CC	TG	CG	CG	AC	CGT	GG	CC	GT	CTAA	5640
5641	GGGGG	G	CT	CC	TT	GGG	GT	G	ATT	TTAG	GT	TT	AC	CG	ACCCC	5700
5701	ATT	TTG	GG	GT	GA	GG	TG	GG	GG	GG	GG	GG	GG	GG	TTGA	5760
5761	CGT	GG	AG	TC	CAG	TT	TT	GG	GG	GG	GG	GG	GG	GG	GG	5820
5821	CTAT	CT	CGG	T	ATT	CTT	TTT	TT	TT	TATAA	GG	TTT	TG	GG	GG	5880
5881	ACAGG	ATT	TT	CGC	CTG	CTG	GG	GG	AA	AC	AC	GG	GG	GG	GG	5940
5941	CCAGG	CG	GT	GG	AAG	GG	CAAT	AG	CTG	TTG	CG	TG	TC	GG	CAAC	6000
6001	GGC	G	CC	AA	AT	CG	AA	CC	CT	CCCC	CG	CG	TT	GG	CC	6060
6061	ACG	AC	AG	GT	T	CC	CG	ACT	GG	GGG	CA	TG	AG	CG	TG	6120
6121	TC	ACT	CAT	TA	TT	GG	AC	CCC	AA	AG	GG	CG	TA	TT	TG	6180
6181	TT	TG	GAG	GG	TT	AA	ACA	ATT	CA	AC	GG	CT	CG	TT	ACAAC	6240
6241	GT	ACT	GG	GA	AA	AC	CC	CT	GG	GG	GG	GG	GG	GG	GG	6300
6301	AAG	CA	CT	ATT	TT	GG	CA	AC	GG	GG	GG	GG	GG	GG	GG	6360
6361	GAGG	CAT	CC	GG	GG	AG	GCT	GA	GG	AGG	GCT	GC	ATT	CA	AA	6420
6421	AAG	TG	CT	ACT	GAG	TAC	TT	AC	TG	TG	GG	GT	TT	AG	TT	6480
6481	CAT	AGG	G	T	AA	TT	AT	CA	AA	AG	GG	CT	TA	AG	CA	6540
6541	GCC	CG	AC	CG	AT	CG	CC	TT	GG	GG	GG	GG	GG	GG	GG	6600
6601	TGG	TTT	CC	GG	CAC	CC	GG	GG	GG	GG	GG	GG	GG	GG	GG	6660
6661	GAT	AC	GG	TC	CG	TG	CC	CC	CC	GG	GG	GG	GG	GG	GG	6720
6721	AA	C	GT	AA	CC	AT	CC	CC	GG	GG	GG	GG	GG	GG	GG	6780
6781	TG	T	TG	ACT	CG	TG	CA	TT	GG	GG	GG	GG	GG	GG	GG	6840
6841	ATTT	TG	AT	GG	CG	TT	CCT	AT	GG	GG	GG	GG	GG	GG	GG	6900
6901	ATTT	TA	AC	AA	AA	AT	TA	AC	TT	GG	GG	GG	GG	GG	GG	6960
6961	TGG	GG	CT	TT	CT	GATT	AT	AC	TT	GG	GG	GG	GG	GG	GG	7020
7021	CGT	T	CAT	CG	TT	CT	TT	GG	GG	GG	GG	GG	GG	GG	GG	7080
7081	ATCT	CT	CAA	AA	AT	AG	CT	CC	GG	GG	GG	GG	GG	GG	GG	7140
7141	AT	TTG	GAT	GG	TG	TTT	GACT	GT	CT	CC	GG	GG	GG	GG	GG	7200
7201	ATT	ACT	CAG	G	CATT	GG	CA	TT	AA	AT	GG	GG	GG	GG	GG	7260
7261	AA	AT	AA	AG	GC	TT	CT	CC	CG	AA	AG	GT	TT	GG	GG	7320
7321	TAG	TTT	TAT	G	CT	GT	GAGG	TT	ATTG	CTT	AG	GG	GG	GG	GG	7380
7381	AT	TTT	ATT	GG	CG	TT	GG	GG	GG	GG	GG	GG	GG	GG	GG	7394

| 10 | 20 | 30 | 40 | 50 | 60

FIG. 10-2

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US93/10850

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) :C12N 15/00, 15/11, 15/62, 15/67, 15/70; C07H 21/04; C08G 69/02

US CL :Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : Please See Extra Sheet.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y,P	US, A, 5,185,147 (Papsidero) 09 February 1993, col. 2, 7, 8, 10.	1-46
Y	The Journal of Biological Chemistry, Volume 266, No. 33, issued 25 November 1991, B. M. Olivera et al, "Conotoxins", pages 22067-22070, see entire document.	1-46
Y	Proceedings of the National Academy of Science USA, Volume 87, issued August 1990, S. E. Cwirla et al, "Peptides on Phage: A Vast Library of Peptides for Identifying Ligands", pages 6378-6382, see entire document.	1-46

 Further documents are listed in the continuation of Box C. See patent family annex.

Special categories of cited documents:	
"A"	document defining the general state of the art which is not considered to be part of particular relevance
"E"	earlier document published on or after the international filing date
"L"	document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O"	document referring to an oral disclosure, use, exhibition or other means
"P"	document published prior to the international filing date but later than the priority date claimed
"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"Z"	document member of the same patent family

Date of the actual completion of the international search
04 FEBRUARY 1994

Date of mailing of the international search report

APR 06 1994

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231Authorized officer *Jill Warden for*
DOUGLAS GURIAN-SHERMAN
Telephone N. (703) 308-0196

Facsimile No. NOT APPLICABLE

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US93/10850

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Science, Volume 249, issued 27 July 1990, J. J. Devlin et al, "Random Peptide Libraries: a Source of Specific Protein Binding Molecules", pages 404-406, see entire document.	1-46
Y	European Journal of Immunology, Volume 20, issued March 1990, R. Jemmerson et al, "Fine Manipulation of Antibody Affinity for Synthetic Epitopes by Altering Peptide Structure: Antibody Binding to Looped Peptides", pages 579-585, see entire document.	1-46
Y	Gene, Volume 44, issued August 1986, A. R. Oliphant et al, "Cloning of Random-Sequence Oligodeoxynucleotides", pages 177-183, see entire document.	1-46
Y	Gene, Volume 73, issued 20 December 1988, S. F. Parmley et al, Antibody-Selectable Filamentous fd Phage Vectors: Affinity Purification of Target Genes", pages 305-318, see entire document.	7,17,19,20,21,36
Y	Proceedings of the National Academy of Sciences USA, Volume 89, issued May 1992, R. N. Zuckermann et al, "Identification of Highest-Affinity Ligands by Affinity Selection from Equimolar Peptides Mixtures Generated by Robotic Synthesis", pages 4505-4509, see entire document.	1-46
A	Proceedings of the National Academy of Sciences USA, Volume 84, issued December 1987, T. M. Fieser et al, "Influence of Protein Flexibility and Protein Conformation of Reactivity of Monoclonal Anti-Peptide Antibodies with a Protein Alpha Helix", pages 8568-8572, see entire document.	1-46
A	The EMBO Journal, Volume 9, No. 9, issued September 1990, A. Gallusser et al, "Initial Steps of Protein Membrane Insertion. Bacteriophage M13 Procoat Protein Binds to the Membrane Surface by Electrostatic Interaction", pages 2723-2729, see entire document.	7,17,19,20,21,36
A	European Journal of Biochemistry, Volume 177, issued November 1988, A. Kuhn, "Alterations in the Extracellular Domain of M13 Procoat Protein Make its Membrane Insertion Dependent on <u>secA</u> and <u>secY</u> ", pages 267-271, see entire document.	7,17,19,20,21,36

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US93/10850

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	The EMBO Journal, Volume 4, No. 7, issued July 1985, U. Schultz-Gahmen et al, "Towards Assignment of Secondary Structures by Anti-Peptide Antibodies. Specificity of the Immune Response to a Beta Turn", pages 1731-1737, see entire document.	1-46

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US93/10850

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

435/69.1, 69.7, 69.8, 172.3, 235.1, 320.1; 530/300; 536/22.1, 23.4, 23.72, 25.3

B. FIELDS SEARCHED

Minimum documentation searched

Classification System: U.S.

435/69.1, 69.7, 69.8, 172.3, 235.1, 320.1; 530/300; 536/22.1, 23.4, 23.72, 25.3

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, DIALOG, search terms: M13, geneVIII, gVIII, geneIII gIII, coat protein, secondary structure, conformation, affinity, antibody, synthetic, soluble, random peptide or oligonucleotide, unbiased or nonbiased, nondegenerate, disulfide, covalent bond